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Background: Heart failure is a common clinical syndrome associated with major adverse 
symptoms and poor outlook for patients, and high costs for healthcare systems globally. This 
thesis examines four aspects of the clinical pathway of patients with heart failure in primary 
care.  
Methods: Routinely collected GP records are used to estimate the number of newly 
diagnosed heart failure cases by year. A qualitative interview study explores the patient 
experience of the diagnostic pathway. Survival analysis is used to determine prognosis of 
patients following a first diagnostic label. Finally, a screening study examines who develops 
heart failure over time.  
Results: The incidence of heart failure has been static at 2.3 cases per 1,000 person-years 
since 2006. Patients initially normalise their symptoms so delay seeking help, GP access is 
challenging and communication in secondary care, particularly delivery of diagnosis, could 
be improved. Survival rates are 81.5%, 51.6% and 29.5% at 1, 5 and 10 years, respectively, 
and have not changed over time. Screening provides an alternative pathway to identify 
patients with heart failure.  
Conclusions: Strategies to reduce the number of new cases of heart failure, enhance patient 
experience, improve survival and explore new diagnostic pathways should be important 
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1. BACKGROUND AND AIMS OF THESIS 
 
1.1 Chapter Overview 
This chapter starts with an overview of this thesis, including the purpose and aims, to explain 
why examining the clinical pathway of patients with heart failure in primary care is 
important and justified. The rest of the chapter explores the relevant heart failure literature. 
First, the importance of heart failure, how it develops and how the definition has changed 
over time are explored. Next, the epidemiology of heart failure, in terms of incidence and 
the potential of general practice records as a source of epidemiological data are described. 
Then the experience of undergoing a diagnostic process from the patient’s perspective is 
examined. Evidence from heart failure prognosis research with a discussion of survival rate 
estimates is presented. Finally the role of screening in identifying patients with heart failure 
is considered. The chapter concludes with a detailed summary of the aims and objectives of 
this thesis. 
 
1.2 Overview of Thesis 
The overall aim of this thesis is to explore the clinical pathway for patients diagnosed with 
heart failure in primary care. The thesis comprises four elements, which are described in 
detail below but first, to set the scene, there is a brief description of my background and the 
circumstances that led to, and ultimately justify, this thesis.  
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1.2.1 My Background and Justification for this Thesis 
I am an academic GP in Birmingham practising in a deprived inner city surgery and 
conducting research and teaching at the university situated a mile away. The research 
questions in this thesis arose from encounters in both clinical and teaching situations where I 
realised that I did not have an evidence-based answer for either my patient or my student. 
The questions were relevant to different parts of the clinical pathway for patients with heart 
failure and, as in my clinical practice; I wanted my doctoral research to be ‘patient-centred’. 
 
From my perspective as a GP, heart failure is a common problem. Patients present with 
symptoms such as breathlessness along with a myriad of other, both physical and mental, 
health conditions and working out what is the main problem, and then a sensible 
investigation and management plan, is part of the challenge of being a generalist. I have 
always had an interest in cardiovascular disease and so I see a disproportionate number of 
patients with heart problems at the practice. I carry out the Quality and Outcomes 
Framework (QOF) coronary heart disease annual reviews and I am often the doctor who our 
respiratory nurse sends patients to if, despite optimisation of inhaler therapy, the patient 
with lung disease remains breathless.  
 
Perhaps due to my background, I consider heart failure as a differential diagnosis in any 
breathless patient, or those who have had previous cardiac events, so I’ve identified many 
cases over the years. But how many new cases of heart failure should we, as a practice, 
3 
 
expect to be diagnosing each year? And what is that initial part of the diagnostic pathway – 
starting to get symptoms and then deciding to see the doctor – like for the patient? 
 
I teach a Masters module on heart failure and in one of my teaching sessions I ask students 
to find a patient with heart failure and look back in their notes to see what happened leading 
up to, and following, a code of heart failure being entered into the record. The pathway my 
students describe is never uniform, as some guidelines might suggest it would be. Patients 
were seeing their doctor for several reasons, often having multiple health conditions and 
medications to manage. They had a variety of initial tests, sometimes, but not always, 
including investigations for heart failure, and were ultimately seen by the secondary care 
team to confirm the diagnosis. But what was that diagnostic process like from the patient’s 
perspective? 
 
In the practice, I regularly review patients with heart failure and I had one patient who, new 
to the area, attended to have his medication prescribed; however during the consultation, it 
became clear he did not realise that he had heart failure. Patients are seen and diagnosed in 
secondary care but often return to primary care afterwards. What are patients told about, 
and what do they understand by, a diagnosis of heart failure and what impact does it have 




I also teach medical students and I keep a record of the heart failure patients I see. I invite 
these patients to the surgery to speak to my students, or send the students out to see 
housebound patients. I noticed that, sadly, patients were dying and therefore dropping off 
my list after a year or two.  I started to wonder, what is the outlook for patients in general 
practice following their initial diagnosis of heart failure? The survival rates in the literature 
are from cohort studies in other countries or hospital populations where the patients are 
much more unwell than the people that I see with heart failure in general practice. If a 
patient wanted to discuss their prognosis following a diagnosis of heart failure, what survival 
figures are available that are relevant to them? And has the outlook improved in recent 
years, as it has for patients with cancer? 
 
Finally, I have been part of the Heart Failure team in my research department for several 
years and I have worked on a large heart failure screening study. I noticed that participants 
in the study who we found to have heart failure were then entering the healthcare system 
through an entirely different route, which did not rely on them presenting to their GP with 
symptoms. Also most of the patients we were screening were healthy volunteers and when 
assessed they did not have heart failure. I wondered if we were picking up sufficient heart 
failure cases as a result of screening a cohort of the general population and if this was 
something that may or may not be worthwhile on a larger scale. 
 
So I started to plan my doctoral work based on these areas of uncertainty. The aim was to 
provide answers to these fairly simple questions which were important to me as a practising 
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GP, the patients that I look after and the students that I teach. How many new cases of heart 
failure does the average GP practice see in a year and has this number gone up or down? 
What is it like for the patient going through the diagnostic process, from when they first 
notice some breathlessness or ankle swelling, through having tests, to receiving a diagnosis 
of heart failure? For the patient who is diagnosed through this route, rather than being 
diagnosed acutely in hospital, what is their outlook? And does screening actually pick up 
cases of heart failure in an otherwise healthy general population? In this thesis, I seek 
answers to all of these questions using four different methods which are described in more 
detail below; my contribution is detailed fully in Appendix 9.1. 
 
1.2.2 Aims of this Thesis 
The overall aim of this thesis is to examine four aspects of the clinical pathway for patients 
with heart failure in primary care as shown in Figure 1. 
 
 
Figure 1: Diagram of components of PhD thesis 






Symptoms Consult GP Diagnosis Outcome
Age Screened Diagnosis Outcome
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Firstly, the burden of disease will be determined by calculating the number of cases of heart 
failure recorded per year (incidence) in a general practice dataset. Heart failure is an 
important and costly condition so knowing how many patients are affected in a given 
population, how many new cases are emerging and if incidence is changing over time are all 
import considerations for clinicians and commissioners. Epidemiological data on the trends 
of heart failure in the population are available from a number of cohort studies from the 
United States and Europe but determining incidence of heart failure from routinely collected 
general practice data is a novel approach.1  
 
Secondly, the patient experience of the diagnostic pathway will be explored. Patients with 
heart failure may start to experience symptoms such as breathlessness, ankle swelling or 
fatigue and then consult their GP and undergo an investigative process to arrive at a 
definitive diagnosis. The patient experience of this process has not previously been 
researched.  
 
Thirdly, the outlook of patients diagnosed with heart failure will be explored also using data 
from general practice. Prognosis data for heart failure is usually derived from 
epidemiological studies or secondary care populations. The survival rates of patients in 





Finally, the role of screening in identifying patients with heart failure will be explored using 
data from a heart failure screening study. Screening provides an alternative diagnostic 
pathway where individuals are invited for assessment to determine whether they have a 
diagnosis of heart failure.  
 
The thesis concludes with a summary of the key findings from the four studies above, areas 
identified as requiring further research and recommendations for how the care of patients 
with heart failure in primary care could be changed or improved.  
 
Four different methodological approaches are used to accomplish each of the four aims 
above. The thesis is therefore presented in an ‘Alternative Format’ model according to the 
guidelines set out by the University of Birmingham.2 Chapter 1 describes the literature 
around the four areas of the clinical pathway for heart failure in detail. Then chapters 2, 6 
and 7 start with an abstract, introduction, methods, results and conclusion. Due to the 
volume of qualitative data from the interview study, the methods, findings and discussion 
have been presented in three chapters (Chapters 3-5), rather than one. The final discussion 
section (Chapter 8) summarises and synthesises the key findings and recommendations from 




1.3 Background on Heart Failure 
1.3.1 Why is Heart Failure Important? 
Heart failure is an important public health problem associated with significant morbidity and 
mortality for patients and high costs for healthcare systems.3 It occurs mainly in older people 
so may be predicted to increase as the population ages and more patients survive 
myocardial infarction but with a damaged heart.4  Accurate estimates of heart failure 
incidence and prognosis are vital to healthcare commissioners to allow appropriate 
allocation of resources for treatment and palliative care, to physicians in making 
management decisions and, perhaps most importantly, to patients to allow informed 
decisions about treatments and end of life care.5 6 
 
1.3.2 What is Heart Failure? 
Heart failure is a clinical syndrome characterised by an inability of the heart to pump blood 
effectively enough to meet the metabolic needs of the rest of the body. Patients experience 
symptoms such as breathlessness, fatigue and swollen ankles. Clinical signs including lung 
crepitations, a raised jugular venous pressure and pitting oedema of the ankles and calves 
may be found on examination. Investigations include blood tests and imaging with 
echocardiography or cardiac magnetic resonance imaging (MRI). According to the European 
Society of Cardiology, symptoms/signs and objective evidence are required in order to 




Heart failure is often an end result of considerable insult to the structure and function of the 
heart. Cardiovascular risk factors such as hypertension, high cholesterol, diabetes and 
subsequent coronary artery disease often predate the development of heart failure.8 
Treatments for coronary artery disease and heart failure may overlap but some may be 
contradictory, and novel therapies are emerging for both conditions.   
 
1.3.3 Types of Heart Failure 
In recent years the terms ‘heart failure with reduced ejection fraction’ (HFREF) and ‘heart 
failure with preserved ejection fraction’ (HFPEF) have evolved which recognise two distinct 
entities.9 HFREF occurs when there is left ventricular systolic dysfunction (LVSD) resulting in 
a reduction in ejection fraction. In developed economies, this is most commonly linked to 
coronary artery disease, particularly myocardial infarction, and is due to cell death followed 
by scarring and remodelling resulting in a reduction in the ability of the left ventricle to eject 
blood efficiently through the aortic valve and to the rest of the body.10 In developing 
economies, cardiomyopathies linked to aetiologies such as metabolic insult or infections, 
may be a more important driver of HFREF than coronary artery disease.11 
 
HFPEF appears to be a different clinical and pathological entity and is associated with left 
ventricular stiffness and reduced filling but a preserved ejection fraction.12 In HFPEF, the 
association with preceding coronary artery disease is less clear although risk factors such as 
hypertension or diabetes are often present.13 Other causes of heart failure include cardiac 
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arrhythmias and significant valvular disease which may be correctable with intervention. 
Angiography is usually performed prior to valve surgery to check for concomitant coronary 
disease which may be managed with bypass grafting during the procedure.  
 
1.3.4 How Does Heart Failure Develop Over Time? 
Heart failure is the end result of considerable pathological insult to the heart resulting in an 
inability to pump sufficient blood to meet the physiological needs of the body.7 The risk 
factors for, and precursors to, heart failure, such as hypertension, diabetes and high 
cholesterol, should be optimally managed as part of holistic primary prevention of 
cardiovascular disease.14 Where damage has occurred, such as following myocardial 
infarction or prolonged high blood pressure, patients may develop heart failure but have 
mild symptoms of shortness of breath, swollen ankles and fatigue for some time before 
presenting to their GP or being admitted to hospital. Detecting patients at an early stage 
may provide a valuable window of opportunity to intervene to slow further decline and 
improve prognosis.15  
 
1.3.5 Progression to Heart Failure 
The outcomes for patients with established coronary artery disease initially improved with 
the advent of thrombolysis in patients with ST elevation myocardial infarction (STEMI) and 
optimal secondary prevention strategies. Primary percutaneous coronary intervention (PCI) 
has further improved outcomes for patients with STEMI over and above the benefit derived 
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from thrombolysis.16 Timely access to a primary PCI service is now crucial in healthcare 
service planning in the developed world. As patients with coronary artery disease are living 
longer, the number with heart failure has increased. Hence, the prevalence of heart failure 
increases with age from around 1 to 1.5% in the general population overall to 10% in those 
over the age of 75.17 Patients may develop heart failure symptoms many years after the 
identification of risk factors.18 This provides a window of opportunity both for therapy to 
minimise the risk of progression to heart failure and early detection and treatment initiation 
if heart failure should develop. The prognosis of patients with heart failure is poor with 
survival rates for patients diagnosed after an acute admission for heart failure worse than 
most cancers 19 but early diagnosis and implementation of evidence based therapies could 
help to improve the outlook for patients.  
 
The risk factors for coronary artery disease and most types of heart failure are similar. 
Cardiovascular risk factors such as hypertension and diabetes promote the development of 
atherosclerosis which leads to coronary artery disease. Heart failure can occur as the result 
of coronary artery disease or as a direct result of a particular cardiovascular risk factor (e.g. 





Figure 2: Relationship between risk factors, coronary artery disease and heart failure 
 
1.3.6 Multimorbidity 
Atherosclerosis usually affects most major blood vessels so although coronary lesions may 
present acutely as a heart attack, blockage of other arteries can also lead to catastrophic 
events - cerebral vessel blockage causing stroke and limb vessel occlusion resulting in critical 
ischaemia. The renal vasculature is often also involved and can be a limitation in optimising 
heart failure treatments which act via the kidneys. 
 
Heart failure often occurs in the presence of other co-morbidities which share a common 
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obstructive pulmonary disease (COPD). The symptoms of heart failure can often overlap with 
those of COPD,21 resulting in heart failure being unrecognised, and therefore untreated, in 
patients with COPD. In a study of elderly patients with stable COPD, heart failure was not 
recognised in 80% of those with both conditions in routine healthcare.22 Similarly, chronic 
kidney disease is associated with common cardiovascular risk factors and may complicate 
and limit heart failure management options. 
 
Heart failure is largely a disease of the elderly and multimorbidity - the presence of more 
than one physical or mental health problem - is common in this particular age group; 
furthermore, as the number of physical health conditions increases, so does the risk of a 
concomitant mental health problem.23 Optimisation of both physical and mental wellbeing is 
therefore needed in these patients and primary care is well placed to offer holistic, person-
centred care in this way. 
 
1.3.7 Making a Diagnosis of Heart Failure 
There is significant evidence to support heart failure treatments but making the diagnosis 
can be challenging.24 Echocardiography is the most commonly used modality to identify 
objective evidence of cardiac dysfunction but resources are limited by cost and the number 
of trained echocardiographers. The symptoms and signs of heart failure are non-specific and 
the presence of co-morbidities and polypharmacy can complicate the diagnosis further. A 
recent systematic review showed that patients with symptoms such as shortness of breath, 
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fatigue and ankle swelling are significantly more likely to have heart failure if they have a 
history of myocardial infarction.25 As a result, some guidelines recommend referral directly 
for echocardiography in these patients.26  
 
Natriuretic peptides (NPs) are also increasingly being used to identify those patients with 
symptoms who have an increased likelihood of heart failure.27 NPs are released from the 
chambers of the heart in response to pressure or fluid overload, acting on the kidneys to 
induce a diuresis and on the vasculature to cause both arterial and venous dilatation, 
thereby reducing preload and afterload. Heart failure is associated with an increased NP 
level. A rising NP level can be an early sign of heart failure however other factors such as 
renal impairment and ACE inhibitors can influence the NP level so results need to be 
interpreted in light of these other factors.  
 
1.3.8 An Evolving Definition of Heart Failure 
Over time the definition of heart failure has changed leading to dysynchrony between 
epidemiological studies making comparison difficult and meaning a code of heart failure in 
the medical record may be based on different criteria depending on the accepted definition 
at the time of diagnosis. The original heart failure definition derived from the Framingham 
Heart study and this has been updated since the original publications in the 1970s.28 The 
European Society of Cardiology has also updated its definition of heart failure multiple times 
in the last two decades.7 29 30 The criteria used in the Framingham definition rely on the 
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presence of symptoms and signs to determine a diagnosis of heart failure as shown in Table 
1. A definitive diagnosis of heart failure requires the presence of two major or one major and 
two minor criteria concurrently.31  
 
Major Criteria Minor Criteria 
Paroxysmal nocturnal dyspnoea or 
orthopnoea 
Bilateral ankle oedema 
Distended neck veins Night cough 
Rales Dyspnoea on ordinary exertion 
Increased heart size by x-ray Hepatomegaly 
Acute pulmonary oedema on x-ray Pleural effusion on x-ray 
Ventricular (S3) gallop rhythm Decrease in vital capacity by one third from 
maximum record 
Increased venous pressure Tachycardia (120 beats per minute or more) 
Hepatojugular reflex Pulmonary vascular engorgement on chest 
x-ray 
Pulmonary oedema, visceral congestion, 
cardiomegaly shown on autopsy 
 
Weight loss on heart failure treatment 
(10lbs in 5 days) 
 
 
Table 1: Framingham criteria for diagnosis of heart failure 
 
The European Society of Cardiology definition of heart failure 2008 30 required the presence 
of objective evidence in addition to symptoms and signs as shown in Table 2.  
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Heart failure is a clinical syndrome in which patients have the following features: 
Symptoms typical of heart failure (breathlessness at rest or on exercise, tiredness, fatigue, 
ankle swelling). 
and 
Signs typical of heart failure (tachycardia, tachypnoea, pulmonary rales, pleural effusion, 
raised jugular venous pressure, hepatomegaly, peripheral oedema). 
and 
Objective evidence of a structural or functional abnormality of the heart at rest 
(cardiomegaly, third heart sound, cardiac murmurs, abnormality on echocardiogram, 
raised b type natriuretic peptides). 
 
Table 2: European Society of Cardiology heart failure definition 2008 
 
A more recent update of the guideline has recognised that signs may not always be present 
and has also delineated between two distinct heart failure types: HFREF and HFPEF as shown 
in Table 3.7 The emergence of this new type of heart failure has meant that the clinical 




The diagnosis of HF-REF requires three conditions to be satisfied: 
1. Symptoms typical of heart failure 
2. Signs typical of heart failure* 
3. Reduced left ventricular ejection fraction 
The diagnosis of HF-PEF requires four conditions to be satisfied: 
1. Symptoms typical of heart failure 
2. Signs typical of heart failure* 
3. Normal or only mildly reduced left ventricular ejection fraction and left ventricle not 
dilated 
4. Relevant structural heart disease (left ventricular hypertrophy/left atrial 
enlargement) and/or diastolic dysfunction. 
*Signs may not be present in the early stages of heart failure (especially in HF-PEF) and in 
patients treated with diuretics. 
 
Table 3: European Society of Cardiology guideline 2012: Diagnosis of heart failure 
 
1.4 Epidemiology of Heart Failure 
Most epidemiological data about heart failure comes from cohort studies or secondary care 
populations. This section provides a summary of the key data on incidence and prevalence 
from around the world. 
 
1.4.1 Incidence and Prevalence of Heart Failure in United States Cohorts 
The trend in incidence of heart failure over time was examined by Barker et al in a cohort of 
United States (US) patients over the age of 65 using the medical records of a large US 
healthcare provider. Framingham criteria were used to determine presence or absence of 
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heart failure.  The incidence of heart failure was found to have increased over time between 
the period of 1970-1974 and 1990-1994 from 11.7 to 12.7 per 1000 person-years in men and 
8.6 to 11.8 per 1000 person-years in women, respectively.4  
 
The Rochester Epidemiology Project in Olmsted County, Minnesota links patient records 
from the Mayo clinic, Olmsted Community Hospital and Olmsted Medical Centre allowing 
analysis of complete medical records for a defined geographical population.33 Roger et al 
examined the trends in the number of new cases of heart failure in this population to 
establish whether incidence was changing over time.34 4537 Olmsted County residents, 
average age of 74 years and 57% women, with a diagnosis of heart failure validated using 
Framingham criteria were included in the study. The incidence of heart failure in men was 
3.60, 3.90, 3.75 and 3.83 per 1000 person-years in the five year periods 1979-1984, 1985-
1990, 1991-1995 and 1996-2000 respectively. Incidence for women over the same time 
intervals was 2.84, 2.92, 2.60 and 3.15 per 1000 person-years. No statistically significant 
difference was found in incidence over time for either sex. 
 
Prevalence of heart failure has also been examined in the Olmsted County population. 
Redfield et al conducted a cross-sectional survey of 2042 Olmsted County residents over the 
age of 45.35 Framingham criteria were used to confirm a diagnosis of heart failure and 
Doppler echocardiography was also carried out to assess systolic and diastolic function. The 
overall prevalence of heart failure was 2.2% (95% CI 1.6% to 2.8%). Forty four per cent of 
participants with heart failure had an ejection fraction above 50%. Prevalence increased with 
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age from 0.7%, 1.3%, 1.5% and 8.4% in the age groups 45-54, 55-64, 65-74 and 75+ years, 
respectively. 
 
1.4.2 Incidence and Prevalence of Heart Failure in European Cohorts 
The Rotterdam study is a prospective population-based cohort study in the Netherlands 
recruiting 7983 patients over the age of 55.17 In a study of the cohort by Bleumink et al, 
baseline assessment was carried out from 1989 to 1993 and participants were followed up 
until 2000 through linkage of their general practice records and health authority data. Heart 
failure was defined according to the European Society of Cardiology 1995 definition. Point 
prevalence in 1999 was 7.0% (95%CI 6.4 to 7.7) with a mean age of 74.5 years in the study 
population. Incidence of heart failure was 14.4 per 1000 person-years (95%CI 13.4 to 15.5) 
overall with higher incidence in men (17.6 per 1000 person years, 95%CI 15.8 to 19.5) than 
women (12.5 per 1000 person-years, 95%CI 11.3 to 13.8). Incidence increased with age from 
1.4, 3.1, 5.4, 11.7, 17.0, 30.1, 41.9 and 47.4 in the 5 year age bands from 55-59 years through 
to 90+ years. 
 
The Echocardiographic Heart of England Screening (ECHOES) study in the UK screened 6162 
participants in the period 1995-1999 and found a heart failure prevalence of 2.3% in the 
general population group over the age of 45.18 The ECHOES-X study re-screened participants 
from the original cohort a decade later and found a prevalence of 5.5% in the now 55 years 
and over general population group who did not have heart failure or LVSD on assessment in 
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the original ECHOES study. Overall, 176 cases of heart failure were found in a total of 1618 
participants re-screened; 103 (58%) had an ejection fraction below 50% and were classified 
as HFREF and 73 (42%) had HFPEF. Multiple echocardiographic abnormalities were seen in 
participants with heart failure suggesting a complex and multifactorial disease. The full 
results of the ECHOES-X study are described in Chapter 7. 
 
1.4.3 Incidence and Prevalence of Heart Failure with Preserved Ejection Fraction 
Our understanding of the epidemiology of heart failure may be changing as HFPEF becomes 
increasingly recognised. Trends in prevalence of HFPEF were examined in the Olmsted 
County population over a 15 year period from 1987-2001 and reported in 2006.36 Patients 
discharged from the Mayo Clinic Hospitals with a diagnosis of heart failure were classified as 
HFPEF if they had an ejection fraction of 50% or higher on echocardiogram. 6076 patients 
were discharged with a code of heart failure over the time period and 4596 (76%) had an 
ejection fraction recorded, of which 53% had an ejection fraction above 50%. Over time the 
proportion of heart failure cases classified as HFPEF increased from 38% to 47% to 54% in 
the time periods 1987-1991, 1992-1996 and 1997-2001, respectively.  
 
1.5 General Practice Records as Sources of Epidemiological Data 
Most general practices in the UK have been computerised since the 1990s.37 Several 
providers have come into the market with software packages which allow GPs to record 
information in an electronic medical record. There has been considerable interest in using 
21 
 
routinely collected GP data since the start of computerisation but initially the quality of data 
was of concern to researchers.38 Sustained improvements in the way data are recorded by 
GPs and the implementation of quality assurance processes over the past two decades has 
made general practice records an increasingly attractive source of data.39 Several 
organisations have developed technology which can extract and store data anonymously in 
large databases and this has led to a significant and growing number of academic 
publications demonstrating the potential of record linkage to ultimately improve health 
outcomes.40 41  
 
1.5.1 General Practice Databases 
Routinely collected GP records provide a powerful source of data to answer important 
clinical questions.42 43 There are four large databases which collect data from NHS general 
practice records and store them securely for research purposes: Clinical Practice Research 
Datalink (CPRD), QResearch, ResearchOne and The Health Improvement Network (THIN).  
  
CPRD is owned and funded by the UK government through the National Institute for Health 
Research (NIHR) and the Medicine and Healthcare products Regulatory Agency (MHRA).44 
Currently, CPRD contains 11.3 million patient records; 4.4 million are active patients from 
674 practices contributing data.45 CPRD data are linked across the NHS from primary care, 
secondary care – through Hospital Episode Statistics (HES) – and to other organisations such 
as the Office for National Statistics (ONS) mortality database. CPRD is also developing 
22 
 
systems to allow clinical trial data to be extracted directly from the electronic health record 
and is pioneering innovative products including collection of patient reported outcomes and 
biosamples directly from patients.  
 
QResearch is a collaboration between the University of Nottingham and Egton Medical 
Information Systems (EMIS).46 The database holds data from 18 million electronic health 
records. There are currently 1,000 contributing practices through EMIS software systems. 
The QResearch database has been used to generate risk prediction tools including QRisk2 
which is recommended by NICE for estimation of cardiovascular risk in patients over the age 
of 35.47  
 
ResearchOne is also a database increasingly used for research purposes.48 Data are collected 
from over 4,500 healthcare settings using SystmOne including general practice, community 
care, acute hospitals, accident and emergency and out of hours services. Where providers 
are all using SystmOne the clinical data merges into one patient record avoiding the need for 
additional linkage.   
 
THIN is a database of anonymised patient records which has been widely used for 
epidemiological and drug safety research.49 It currently collects data from 570 practices, 
representing 6.05% of the UK population, and has a total of 11.7 million patients (3.7 million 
of these are currently active records).50  
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The data stored in these databases includes demographic details, diagnoses, prescribing 
data, additional health information such as test results, free text comments and 
socioeconomic status. Databases are also able to link patient records to other information 
sources such as HES which holds secondary care data. The data are anonymised to ensure 
individual patients cannot be identified. The demographics section includes general 
information such as year of birth, gender and dates the patient joined and left the practice 
but does not contain any identifiable information such as name, date of birth, postcode or 
NHS number. 
 
In this thesis, THIN database is used to explore the incidence of a first diagnostic code of 
heart failure in the GP record (Chapter 2) and the survival rates of people with a heart failure 
diagnosis (Chapter 6). The choice of THIN was, above all, a pragmatic one. For all databases, 
researchers must pay a fee to access the data. These charges may be one off payments or in 
the form of a license fee where institutions are granted access to the whole database for a 
fixed annual rate. For the duration of my PhD, the University of Birmingham had access to 




THIN provides a window into the day to day activity of general practice in the UK. Practices 
using Vision software provide data through a programme called ‘In Practice Systems’ which 
24 
 
runs in the background and does not disrupt routine recording of patient care. All patient 
identifiers are completely removed. Researchers can access the data by request through the 
THIN central registry. The database therefore provides a true reflection of what is happening 
every day in the NHS.  
 
THIN collects data from 570 practices which represents 6.05% of the UK population. Studies 
using THIN datasets are therefore likely to be generalizable to the general population.51 
Research using other methods, such as cohort studies, is unable to achieve this degree of 
representativeness.  
 
THIN contains a large volume of data with a total of over 80 million patient years of 
computerised data. Data are longitudinal, and continually updated, so changes in disease 
patterns and the effects of new treatments can be monitored over time.  This provides an 
incredibly powerful dataset for researchers. 
 
Weaknesses 
Research databases rely on the quality of data input at the time of the clinical consultation. 
The application and consistency of clinical coding is crucial for researchers to be able to 
reliably identify patterns in disease. The limitations of the use of clinical data for research 
are considered in the next section of this chapter.  
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Data may also be missing. For example, blood pressure or cholesterol measurements may 
not have been entered in a format where the data can be extracted. This can be dealt with 
by using the data which is present in the database to impute missing values for individuals. 
In addition, some data may simply not be captured. For example, over the counter 
medicines are not recorded in the electronic medical record and some fields, such as 
occupation, are often left incomplete.  
 
THIN is the smallest of the main database providers but the number of patient records is still 
very large. Cohort studies using THIN, such as the heart failure cohort used to examine 
incidence over time in Chapter 2, still have far greater numbers than any prospective cohort 
study might achieve.  
 
Linkage in THIN is less advanced than CPRD; while some practices in THIN link to HES data 
this is not universal. In addition, information such as cause of death from ONS mortality data 
has only recently been accessible. Innovative practice including integration of clinical trials, 
patient reported outcome measures and the possibility of biosamples from individual 
patients has been pioneered by CPRD rather than THIN.52 For the observational studies in 
this thesis, this functionality was not required and would therefore have been of no benefit.  
 
For all GP databases, to provide a reliable picture of activity in the NHS, particularly for 
observational studies, a database which includes all NHS records, in both primary and 
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secondary care, is needed but at present remains only an aspiration. Controversy around 
patient confidentiality and data security has stalled progress in this area.53  
 
1.5.2 Using Clinical Data for Research 
General practice databases have a wealth of data for use in research but, as for any study, 
the data collected and used to answer the research question must be of high quality. 
Research databases have evolved over the past two to three decades and there is increasing 
recognition of the need to assess the ‘readiness’ of data sources before embarking on 
research projects.54 De Lusignan et al argue that six key concepts should be considered, and 
reported, for all research studies involving routinely collected datasets so both the 
researchers themselves and the readers of the final paper are clear about the data source.55  
 
Firstly, they describe data quality as the overarching principle asking the fundamental 
question of ‘are these data fit for purpose? Secondly, the issue of data provenance - how the 
data were created – should be considered. In the case of the THIN database, this is 
dependent on clinical coding during routine consultations (considered in more detail in 
subsequent sections). Then data extraction and data processing must also be assessed. To 
extract data from THIN a list of clinical codes is used and the process of generating this list is 
described in Chapter 2. Finally, traceability – the degree to which reported results can be 
traced back to the original dataset – and curation which considers the importance of data 
storage to allow future researchers to replicate results or use the data source for new 
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projects. To achieve this level of data quality requires expertise in terms of clinical coding, 
data extraction and data analysis. Skills in some of these areas, particularly data extraction, 
are limited in the research community and, as a result, NHS data are currently underused for 
research purposes.56 
 
1.5.3 Clinical Coding in General Practice Records 
The information contained in GP clinical systems is a combination of free text and ‘coded’ 
data. During consultations, GPs input the clinical details of the encounter under a heading 
which broadly describes the problem. This may be a diagnosis or a symptom. Patients may 
consult with several different problems during one consultation and these are usually 
entered under separate problem headings. Each of the problem headings is a clinical code. 
The system of clinical coding used in practice is often referred to as ‘Read codes’ after their 
inventor Dr James Read. In the early 1980s, Dr Read, a practising GP, identified the need for 
a consistent set of clinical codes which were both intuitive and easy to use.57 He worked with 
a software manufacturer to develop a comprehensive thesaurus of clinical codes which were 
integrated into clinical systems. GPs have been using computerised record systems, and 
inputting coded data, since the early 1990s resulting in a large volume of clinical 
information, dating back over two decades, which can be used to analyse disease pattern 




1.5.4 The Impact of the Quality and Outcomes Framework on Clinical Coding 
There are a wide range of Read codes which can be used for a particular disease and GPs 
often vary in their choice of code.59 In 2004, the Quality and Outcomes Framework (QOF) 
was introduced as a payment incentive scheme in the NHS in England. The points-based 
system assesses clinical performance, particularly chronic disease management. Specific 
Read codes, recognised by QOF, are required for computer searches to allocate points. 
Multiple conditions such as diabetes mellitus, coronary artery disease, hypertension and 
heart failure are included in the QOF schemes with a limited range of Read codes. More 
broadly, the link to payment means that GPs have become much more aware of the need to 
accurately code diagnoses, investigations and treatments.  
 
1.5.5 Coding of Heart Failure in Primary Care Records 
The accuracy of clinical coding is a crucial consideration for researchers using primary care 
databases.60 The clinical codes extracted from the database for use in the research dataset 
should ideally be both valid and complete but in the real world of primary care data input 
this is rarely fully achieved. The concepts of validity and completeness, in the context of 
heart failure coding, are explored below. 
 
Validity 
For a heart failure code to be valid, the patient with that code in their medical record should 
have heart failure in real life. Heart failure is a clinical syndrome i.e. a collection of symptoms 
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and signs. The GP may initially code the symptoms with which the patient presents such as 
ankle swelling, breathlessness or lethargy, prior to a formal diagnosis being made. The 
diagnosis should be confirmed through further investigation, usually echocardiography. 
Once the severity and type of heart failure has been established, evidence-based treatments 
can be commenced and optimised to both relieve symptoms and improve outcomes for 
patients.  
 
Since 2006, the QOF has included a heart failure indicator, requiring practices to have a 
register of all patients with heart failure and ensure that the diagnosis of heart failure is 
validated either by the presence of an echocardiogram report or a letter from a consultant 
cardiologist confirming the diagnosis. Due to the requirement for objective testing, a 
diagnosis of heart failure in high performing QOF practices is likely to be validated.61 A 
clinical code of heart failure prior to this date may still though be valid. Heart failure is above 
all a clinical diagnosis and earlier definitions of heart failure did not require formal objective 
testing as described in the previous section.  
 
Completeness 
Researchers aspire to a complete data set to be confident in their research results and the 
conclusions they draw. Primary care research databases are reliant on the extent of coding 
at the time of consultation to ensure completeness. For example, if a diagnosis of heart 
failure is not coded according to a recognised system, this data cannot be extracted for 
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research purposes. This could result in an underestimation of prevalence or incidence of a 
particular disease.  
 
Recording in general practice databases may not be 100% accurate and the definition may 
have changed over time, but the data in GP records does reflect the real life situation of the 
healthcare system in which patients are managed each day in the UK. To provide clinicians 
with epidemiological information for patients in general practice it may be more appropriate 
to use data from general practice to calculate incidence and survival rates. If, for example, 
the prognosis of heart failure in epidemiological studies is different to the prognosis of 
‘diagnosed heart failure’ in general practice it implies that there may still be significant 
misclassification. A better understanding of the epidemiology of the condition within the 
general practice setting will be helpful in determining the healthcare burden posed by heart 
failure now and in the future. 
 
1.6 Patient Experiences of Heart Failure Diagnosis 
The evidence above illustrates that heart failure is a common, treatable and possibly 
preventable condition so making a diagnosis is important. Heart failure is a major cause of 
morbidity and mortality in our ageing population where survival from myocardial infarction 
has improved and effective treatments for cardiovascular disease have become available.4 18 
Healthcare costs in terms of hospital admissions and long term care remain high.3 19 62 Heart 
failure is a syndrome characterised by symptoms of shortness of breath, oedema and fatigue 
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but can overlap with other medical conditions making accurate diagnosis challenging.63 But if 
heart failure is diagnosed correctly and in a timely manner, evidence-based treatments exist 
to improve prognosis and quality of life.26 30 64 The patient experience of the diagnostic 
process and what the term ‘heart failure’ means to them is currently unknown. 
 
The diagnostic pathway for patients with heart failure in primary care is under-researched. 
The National Institute for Health and Care Excellence (NICE) guidance on Chronic Heart 
Failure 2010 provides an investigation algorithm (natriuretic peptide test or direct referral 
for echocardiogram) for patients once the diagnosis of heart failure is suspected but the 
patient experience and clinical decision-making prior to initiating investigation to confirm 
the diagnosis is unclear.26 The NICE guidance, and the evidence upon which it is based, does 
not address the grey area from when the patient first experiences symptoms to the time 
they seek medical attention and the diagnostic process prior to the GP considering heart 
failure and referring for an investigation to confirm the diagnosis. There has been some 
qualitative research around end of life care for patients with heart failure65 66 but the patient 
experience of the diagnostic pathway has not been critically evaluated. It is unclear what 
prompts patients to first seek medical attention, which symptoms are most common in 
primary care in patients who subsequently have a diagnosis of heart failure, and what 




1.6.1 Symptoms Onset and Seeking Medical Attention 
Symptom onset can vary according to disease. For example, patients with stroke may 
experience a sudden onset of symptoms with one-sided weakness, speech disturbance or 
facial asymmetry. Early intervention can lead to life-saving treatment yet there is often a 
delay in patients seeking emergency medical attention. Mackintosh et al conducted a 
qualitative interview study to understand what factors might be involved in the delay and 
found that help-seeking decisions by patients experiencing symptoms of stroke were 
complex.67 Some patients did not know the symptoms of stroke and others did not 
appreciate the importance of seeking medical help urgently. The role of primary care 
services in responding quickly in patients presenting with stroke symptoms was also 
variable. In addition to lack of knowledge, patients described fear of stroke or hospital 
admission and a subsequent denial which prevented them from seeking help immediately. 
Witnesses also played a key role in recognising stroke symptoms and taking action to access 
medical services.68  
 
Similarly, patients with acute myocardial infarction, or heart attack, often experience a 
sudden onset of symptoms namely crushing central chest pain. Henriksson et al conducted 
focus groups with patients and their relatives to explore their thought processes when 
symptoms of acute myocardial infarction occurred.69 Patients felt uncertain about the cause 
of their symptoms, often assuming they were caused by something less serious, and tried 
various methods to alleviate symptoms prior to seeking help. Relatives played a vital role 
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and were usually more concerned than the patient themselves, encouraging them to take 
further action such as calling for an ambulance.  
 
Unlike stroke or acute myocardial infarction, heart failure symptoms are often insidious in 
onset.7 Patients may experience a gradual onset of breathlessness on exertion over several 
months, mild ankle swelling or general tiredness. The patient experience of early symptoms 
and decision-making around seeking medical attention prior to a diagnosis of heart failure 
has not been evaluated. The first part of the qualitative study presented in Chapters 3-5 
explores the patient perspective from when they first noticed something wrong and what 
prompted them to seek medical help. 
 
1.6.2 Diagnostic Process from the Patient Perspective 
The process of heart failure diagnosis is complex and guidelines differ in the tests they 
suggest clinicians should use to assess the likelihood of the condition. For example, the NICE 
guidelines in England state that patients with symptoms suggestive of heart failure should be 
assessed using a natriuretic peptide test, unless they have a history of myocardial infarction 
where they should then be referred directly for echocardiogram.26 However the European 
Society of Cardiology still advocate the use of ECG and chest x-ray, as well as natriuretic 
peptide testing, in the diagnostic process.7 Echocardiogram is the most commonly used 
investigation to confirm the diagnosis but availability of echo machines and appropriately 
trained echo technicians, as well as cost, limits the availability to primary care.  
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Some studies have looked at the role of the clinician in the diagnostic process for heart 
failure. Fuat et al carried out focus groups with general practitioners to explore the barriers 
to accurate diagnosis, and management, of heart failure in primary care.70  Clinical 
knowledge, GP understanding of the investigative process, availability of local resources and 
a mistrust of the relevance of the evidence base to primary care were all factors affecting 
timely diagnosis and management. However, the process of visiting the GP, attending for 
diagnostic tests, waiting for results, and in some cases initiation of treatment, prior to 
receiving a formal diagnosis has not been explored from the patient perspective. Part of the 
qualitative study in Chapters 3-5 aims to find out what patients experienced in the pathway 
between first seeing their GP with symptoms to the point where they received a formal 
diagnosis of heart failure. 
 
1.6.3 Understanding of Heart Failure by Patients and Carers 
According to international guidelines, at the end of the diagnostic pathway in primary care, 
patients should receive a formal diagnosis of heart failure which is confirmed by 
echocardiogram and explained to them.7 However, some studies have identified that 
patients are not necessarily told, or do not retain, the diagnostic label of heart failure or may 
not understand what it means. Andersson et al interviewed patients with a label of heart 
failure in their medical records. Patients did not recall being given a diagnosis of heart failure 
and many put their symptoms down to advancing age rather than any underlying disease.71  
For those who are aware of their diagnosis of heart failure, understanding the term and 
adapting to living with the condition can be challenging and involve several stages. Stull et al 
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interviewed patients in Ohio to explore their experiences of being told they have heart 
failure and living with the disease.72 They found that the diagnosis was often made following 
a crisis event, rather than after a timely diagnostic process, and that patients and their 
families went through a process of role adaptation before finally coming to terms with the 
diagnosis and finding ways of moving on with their lives. 
 
1.7 Prognosis of Heart Failure 
Prognostic data are a vital part of the epidemiological information used by clinicians, public 
health experts and healthcare commissioners to inform the way care is provided at an 
individual and population level. Patients may want to discuss their outlook with their doctor 
and use this information to make informed decisions about their treatment options. Public 
health specialists monitor trends to see if the patterns of disease are changing and whether 
efforts to improve survival rates have been successful. In addition, commissioners need to 
understand the treatment and end of life care needs of the population for which they 
provide healthcare. Therefore accurate and contemporary epidemiological data from a 
directly relevant source is vital. 
 
The large epidemiological studies described above such as Framingham, Olmsted County, 
Rochester, ECHOES and other studies have examined survival rates in addition to incidence 
and prevalence rates. The study by Barker et al reported 30 day, 1 year and 5 year mortality 
rates in men and women in the Framingham Heart Study for the periods 1970-74 and 1990-
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94.4 In men, mortality rates fell from 14.2% (95%CI 9.1 to 19.3) to 9.8% (95%CI 7.6 to 12.0), 
46.8% (95%CI 39.7 to 53.0) to 32.5% (29.0 to 36.0) and 82.7% (95%CI 77.4 to 88.0) to 68.8% 
(95%CI 65.3 to 72.3) at 30 days, 1 year and 5 years, respectively between the two time 
periods. Mortality rates were less in women but did not reduce significantly between the 
two time periods (hazard ratio for mortality 1.01, 95%CI 0.77 to 1.30). 
 
Roger et al also reported mortality rates in those diagnosed with heart failure in the Olmsted 
County population between 1979 and 2000.34 In the 1996 to 2000 group, 30 day, 1 year and 
5 year mortality was 6% (95%CI 5 to 7), 21% (95%CI 18 to 24) and 50% (95%CI 45 to 54), 
respectively in men and 4% (95%CI 3 to 4), 17% (95%CI 14 to 19) and 46% (95%CI 42 to 51), 
respectively in women. Overall age-adjusted 5 year mortality declined over time from 57% in 
the 1979-1984 cohort to 48% in the 1996-2000 cohort. Survival gains were greatest for men 
and younger participants (below 75 years at time of heart failure diagnosis). A study by 
Redfield et al also in the Olmsted County population but looking at the burden of systolic 
and diastolic dysfunction found after controlling for age, sex and ejection fraction, the 
presence of moderate or severe diastolic dysfunction was predictive of all-cause mortality.35        
 
The Rotterdam study, which recruited participants over the age of 55 between 1989 and 
1993 and followed them up to the year 2000, reported survival, rather than mortality, rates. 
The median survival time following a diagnosis of heart failure was 2.1 years (range 1 day – 
9.0 years). Overall survival was 86% (95%CI 83 to 88) at 30 days, 63% (95% CI 59 to 66) at 1 
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year and 35% (95%CI 31 to 39) at 5 years. There was no statistically significant difference in 
survival between men and women (log rank test, p=0.15). 
 
The ECHOES study is one of the few studies to report 10 year, as well as 5 year, survival 
rates. All deaths in the cohort were collated from routinely collected mortality data. Five-
year survival rate was 53% in patients with heart failure and LVSD and 62% in patients with 
heart failure and no LVSD compared to 93% for the general population over the age of 45. 
Overall the mortality rate for all-cause heart failure was 9% per year.73 At ten years, survival 
was 27% for those with heart failure and LVSD and 27% for those with heart failure and no 
LVSD compared to 75% in those without heart failure.78 
 
1.8 The Role of Screening 
Currently in the UK there is no widespread screening programme to identify patients with 
heart failure. Instead, patients present with symptoms and undergo the diagnostic process 
outlined above. This may mean that patients have symptoms for some time and present 
later in the disease trajectory, although there is currently little evidence to suggest screening 
for heart failure in primary care is warranted. This final section explores the definition of 




1.8.1 Definition of Screening 
The aim of any screening intervention is to identify disease early to allow treatment which 
will improve outcome. The criteria used to determine if screening is a worthwhile process 
were developed by Wilson and Jungner.74 The UK National Screening Committee assesses 
any screening programme against a comprehensive set of criteria75, shown in Table 4. 
 
The NHS in England currently has three widespread screening programmes in operation: 
cervical cancer, breast cancer and bowel cancer screening.76 These programmes use 
screening tests to identify patients who require further investigation to confirm or rule out a 
diagnosis. Those found to have the disease are managed according to national guidelines. 
The aim of each programme is to diagnose and treat cancer sooner to improve the likelihood 
of cure but there is some controversy about whether screening on such a large scale may 




Criteria for appraising the viability, effectiveness and appropriateness of a screening 
programme 
Ideally all the following criteria should be met before screening for a condition is initiated: 
The Condition 
1. The condition should be an important health problem 
2. The epidemiology and natural history of the condition should be adequately 
understood.  
3. All the cost-effective primary prevention interventions should have been implemented. 
The Test 
4. There should be a simple, safe, precise and validated screening test. 
5. The distribution of test values in the target population should be known and a suitable 
cut-off level defined and agreed. 
6. The test should be acceptable to the population. 
7. There should be an agreed policy on the further diagnostic investigation. 
The Treatment 
8. There should be an effective treatment or intervention for patients identified through 
early detection, with evidence of early treatment leading to better outcomes. 
9. There should be agreed evidence based policies covering which individuals should be 
offered treatment and the appropriate treatment to be offered. 
10. Clinical management of the condition and patient outcomes should be optimised. 
The Screening Programme 
11. There should be high quality evidence that the screening programme is effective in 
reducing mortality or morbidity. 
12. There should be evidence that the complete screening programme is clinically, socially 
and ethically acceptable to health professionals and the public. 
13. The benefit from the screening programme should outweigh the physical and 
psychological harm (caused by the test, diagnostic procedures and treatment). 
14. The opportunity cost of the screening programme should be economically balanced in 
relation to expenditure on medical care as a whole (i.e. value for money). 
15. Adequate staffing and facilities for testing, diagnosis, treatment and programme 
management should be available. 
16. Evidence-based information, explaining the consequences of testing, investigation and 
treatment, should be made available to potential participants.  
 
Table 4: Adapted from the UK National Screening Committee criteria75 
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1.8.2 Heart Failure Screening Studies 
The Echocardiographic Heart of England Screening Study (ECHOES) recruited 16 general 
practices from the West Midlands region and invited over 10,000 patients to attend for 
screening. Patients were assessed by medical history-taking, clinical examination, ECG and 
echocardiogram. A cardiologist determined the diagnosis of heart failure. In the screened 
cohort, the overall prevalence of definite heart failure was 2.3% in the general population 
over the age of 45.18  
 
The mortality rates of all-cause, all-stage heart failure found at screening in the ECHOES 
population were around half those reported for patients diagnosed for the first time with 
heart failure during a hospital admission.78 Patients admitted to hospital present at a later 
stage in the disease process and have more severe heart failure with a consequently worse 
prognosis.79 However, these findings are subject to lead time bias where patients diagnosed 
earlier in the disease process show an increased survival simply because they had a label 
applied sooner than those presenting with symptoms to routine health services.  
 
The role of screening has also been examined for other chronic diseases, such as COPD, 
which are insidious in onset and are often diagnosed once symptoms become significant. 
Van Mourik et al examined the detection of heart failure and COPD in the frail elderly 
through a targeted screening method.80 Frail patients over the age of 65 years were sent a 
questionnaire asking about breathlessness and reduced exercise tolerance. Those with 
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either symptom were invited to attend a clinic appointment for further assessment which 
included clinical history and examination, blood test, spirometry, ECG and echocardiogram. 
Of 570 participants who responded to the questionnaire, 395 (69% of respondents) had 
reduced exercise tolerance and/or shortness of breath. 389 participants attended for 
screening and in this group, 127 patients (33.5% of the screened cohort) received a new 
diagnosis of heart failure and 65 patients (16.8% of the screened cohort) had a new 
diagnosis of COPD. The authors concluded that this was a simple and effective method of 
identifying patients with undiagnosed heart failure and/or COPD but the impact of detection 
on quality of life and survival is yet to be explored.  
 
In a follow-up of the COPD cohort, the authors examined the electronic medical records of 
patients with a new diagnosis of COPD at 6 and 12 months following the screening visit to 
identify any change in treatments, hospitalisations and survival.81 The management 
strategies seemed to change little despite a new diagnosis of COPD. However 32% of 
patients with a new diagnosis of COPD were hospitalised within a year of screening 
representing a significant healthcare burden. The reasons for lack of management changes 
were not explored but the authors speculate that the patients may not have complained 
about their symptoms if they were not severe compared to their other co-morbid 
conditions. Alternatively the clinician may have been reluctant to alter medications in 
patients with extensive polypharmacy for fear of adverse events although the inhaled nature 




Definitive evidence for widespread echo screening to detect heart failure is currently lacking 
and a large randomised controlled trial would be required to determine the clinical and cost-
effectiveness of screening prior to implementation of a population-wide programme. While 
screening programmes are still debated, all practitioners need to have a low index of 
suspicion for heart failure in patients with a history of coronary artery disease. Early referral 
for investigation is important to ensure optimal management and improve patient 
prognosis. 
 
1.9 Overview and Aims of Thesis 
1.9.1 Thesis Overview 
The overall aim of this thesis is to explore the clinical pathway for patients diagnosed with 
heart failure in primary care as illustrated in Figure 1. 
 
Firstly, the burden of disease will be determined by calculating the number of recorded 
cases of heart failure in a general practice dataset. Heart failure is an important and costly 
condition so knowing how many patients are affected in a given population, how many new 
cases are emerging and if survival rates are changing are all import considerations for 
healthcare providers. Epidemiological data on the trends of heart failure in the population 
are available from a number of cohort studies from the United States and Europe but 
determining incidence of heart failure from routinely collected general practice data is a 
novel approach.1  
43 
 
Secondly, the patient experience of the diagnostic pathway will be explored. Patients with 
heart failure may start to experience symptoms such as breathlessness, ankle swelling or 
fatigue and then consult their GP and undergo an investigative process to arrive at a 
definitive diagnosis. The patient experience of this process has not been previously 
researched.  
 
Thirdly, the outlook of patients diagnosed with heart failure will be explored also using data 
from general practice. Prognosis data for heart failure is usually derived from 
epidemiological studies or secondary care populations. The survival rates of patients in 
general practice using data from routinely collected records has not previously been 
determined. 
 
Finally, the role of screening in identifying patients with heart failure will be explored using 
data from a heart failure screening study. Screening provides an alternative diagnostic 
pathway where individuals are invited for assessment to determine whether they have a 
diagnosis of heart failure.  
 
1.9.2 Aims of Chapter 2 – Incidence of Heart Failure 
The aim of Chapter 2 is to determine the incidence of heart failure in the general practice 
population using routinely collected data. A cohort of patients with a diagnosis of heart 
failure was extracted from the THIN database to explore the number of new cases. The 
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clinical codes used to record a diagnosis were used to identify a first diagnostic label of heart 
failure. The objectives of Chapter 2 are: 
 To calculate the incidence of a first diagnostic label of heart failure in a general practice 
population by sex and age band. 
 To determine if the incidence of heart failure has changed over time. 
This epidemiological information is important to allow healthcare providers to plan services 
based on the number of patients with heart failure. It is also important to clinicians to 
understand if the pattern of the disease is changing, particularly whether new heart failure 
cases are being prevented by better primary and secondary prevention strategies for 
cardiovascular disease. 
 
1.9.3 Aims of Chapters 3, 4 and 5 – Patient Experience of Diagnosis 
The aim of Chapters 3-5 is to explore patient experiences of a diagnosis of heart failure, to 
develop an understanding of heart failure diagnosis from the perspective of the patient and 
to use this data to highlight behaviours and processes which could be modified to improve 
the patient experience and outcome. These aims are achieved by using semi-structured 
interviewing to gather data on participants experiences of heart failure diagnosis from when 
they first noticed symptoms to receiving a formal diagnosis of heart failure, and asking 
participants to reflect back on the experience to identify anything that could have been 
improved. Then a framework analysis of the data is carried out to describe key behaviours 
and processes in the participants’ journeys. The objectives of this study are: 
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 To explore how patients describe the onset of heart failure symptoms and the 
explanations they have for the symptoms initially.  
 To determine what prompts patients to seek medical attention for their symptoms. 
 To explore how patients describe the experience of seeing the GP and having tests 
carried out. 
 To examine what patients understand by a diagnosis of heart failure, what the term 
means to them and what impact the diagnosis has on their lives. 
 To gather patient’s views on their experience of the heart failure diagnostic pathway in 
hindsight and how they feel things might have been improved. 
The findings of the study provide a rich description of the patient experience of heart failure 
diagnosis from first symptoms to impact of the diagnosis on their everyday life. The data are 
used to identify what factors are important at key points in the diagnostic pathway (in 
particular, decision to initially consult, investigative processes and receiving a formal 
diagnosis) which could be modified to optimise patient experience. 
 
1.9.4 Aims of Chapter 6 – Survival of Patients with Heart Failure 
The aim of Chapter 6 is to explore the survival rates of patients with heart failure in the 
community. Routinely collected general practice data are used to determine the outlook for 
patients following a first diagnostic label of heart failure. The objectives of Chapter 6 are: 
 To determine the one, five and ten year survival rates of patients following a diagnosis of 
heart failure. 
 To explore whether survival of patients with heart failure has improved over time. 
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Up to date and relevant survival rates from a community population are important if 
patients wish to discuss outlook following a diagnosis of heart failure. Examination of trends 
in survival rates over time is also useful to determine if prognosis has improved with modern 
treatments and interventions.  
 
1.9.5 Aims of Chapter 7 – Role of Screening 
The aim of Chapter 7 is to explore the role of screening in diagnosing heart failure in the 
community. The ECHOES-X study procedure and findings are presented along with a 
discussion on the use of screening to identify heart failure patients in primary care. The 
original ECHOES study screened over 6,000 people to identify patients with heart failure. The 
aim of the follow-up study - ECHOES-X - was to estimate progression to heart failure within 
the previously screened cohort. Participants who were still alive from the original cohort 
were invited for re-screening. The objectives of Chapter 7 are:  
 To determine how many participants in a previously screened cohort have evidence of 
heart failure or left ventricular systolic dysfunction (LVSD) at re-screening. 
 To explore the outcome of those with heart failure or LVSD from the original ECHOES 
cohort. 
 To examine the role of natriuretic peptide testing in screening for heart failure in a 
community population. 
Screening can detect disease before symptoms become apparent. For some diseases, an 
earlier diagnosis can allow effective treatments to be started sooner and improve the 
subsequent outlook for patients, although the role of screening remains controversial. 
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Identifying patients with heart failure at re-screening from a previously screened cohort can 
provide vital insight into the natural history of heart failure. The role of natriuretic peptides 
in identifying those most likely to have a diagnosis of heart failure is also important.  
 
1.10 Summary of the Chapter 
This chapter started with an overview of this thesis which explores the clinical pathway for 
patients with heart failure in primary care. The background section began with a description 
of heart failure, including the definitions and classifications, the progression of disease, the 
importance and challenge of making the diagnosis and the role of multimorbidity. The 
literature related to the four aspects of the thesis was then explored. First, the epidemiology 
of heart failure, in terms of incidence and the potential of general practice records as a 
source of epidemiological data were described. Then what is known about the experience of 
undergoing a diagnostic process from the patient’s perspective was examined. Evidence 
from heart failure prognosis research with a discussion of survival rates estimates was 
presented. Finally the role of screening in identifying patients with heart failure was 
considered. The overall plan, and aims and objectives of the thesis, was set out in detail.  
 
In this thesis, by investigating the epidemiology of heart failure using general practice 
records, exploring the patient experience of the diagnostic process and considering the role 
of screening in identifying patients with heart failure earlier, the aim is to provide a better 
understanding of the clinical pathway for patients with heart failure in primary care.   
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2. INCIDENCE OF HEART FAILURE DIAGNOSIS IN GENERAL PRACTICE 
 
2.1 Chapter Overview 
This chapter aims to explore the incidence of heart failure in the community by examining a 
large database of general practice records. The background and aims of the study are 
described then the methodological approach to using general practice records for research 
purposes is explained. The results are presented then a discussion of the strengths and 
limitations of the study and the findings in relation to existing literature are explored. 
 
2.2 Abstract 
Background and Aims: Accurate and relevant epidemiological data are vital to monitor 
trends in chronic diseases to both inform clinical practice and plan healthcare services. The 
aim of this study was to determine the incidence of a first diagnostic label of heart failure in 
general practice records.  
Methods: This retrospective cohort study examined UK general practice records from The 
Health Improvement Network (THIN) between 1st January 1995 and 31st December 2012. All 
individuals over the age of 45 in the THIN dataset were included. Outcome was a label of 
heart failure by age, sex and year of diagnosis.  
Results: Of 2,730,738 patients in the cohort, 55,248 had a first diagnostic code of heart 
failure. Incidence fell from 5.36 (95%CI 5.17 to 5.55) per 1,000 person-years in year 2000 to 
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2.41 (95%CI 2.33 to 2.49) per 1,000 person-years in 2007 and remained around 2.3 per 1,000 
person-years until 2012. Overall, incidence of heart failure increased with age, and was more 
common in men than women in all age groups.  
Conclusions: The number of new cases of heart failure in general practice declined before 
2007 then remained stable. Further research is needed to explain these trends and to find 
strategies to reduce incidence. 
 
2.3 Background and Aims 
As set out in Chapter 1, heart failure is an important public health problem associated with 
significant morbidity and mortality for patients and high costs for healthcare systems.3 It is 
defined as a clinical syndrome requiring symptoms and objective evidence of a structural or 
functional cardiac abnormality to confirm the diagnosis.7 Accurate estimates of heart failure 
incidence are vital to healthcare commissioners to allow appropriate allocation of resources 
and to doctors and researchers to explore and understand patterns in the disease.5 6  
 
The incidence of heart failure has been well described by screening studies such as 
Framingham and Olmsted County in the United States82 and the Rotterdam and ECHOES 
studies in Europe.18 78 These populations represent well-phenotyped and distinct cohorts of 
patients who voluntarily took part in research and may not therefore be fully representative 
of the general community population.83 In recent years there has been increasing use of 
routinely collected datasets from general practice databases. This chapter explores the use 
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of one of these datasets to determine the incidence of heart failure in a primary care 
population. 
 
Hospital records and billing data can also be used to monitor trends in disease patterns but 
this approach has limitations. A Canadian study examined the incidence of heart failure in an 
administrative health dataset.84 The incidence varied according to the definition of heart 
failure used; when heart failure was defined as a record of one hospitalisation with a heart 
failure code in the billing record in a year, the incidence was 33% lower than if the definition 
was broadened to include hospitalisation or 2 physicians’ claims for heart failure in a year. 
This reflects the reality that most patients with heart failure will be managed within the 
community without necessarily requiring hospital admission. 
 
In many countries around the world, electronic primary care records are providing a valuable 
source of data directly relevant to community populations.39 85 86 87 88 Most general practices 
in the UK have been computerised since the 1990s thanks to software packages which 
allowed general practitioners (GPs) to record information in an electronic medical record.37 
38 Patient records contain diagnostic codes as well as demographic and treatment 
information.89 90 Large datasets of anonymised patient records have become an increasingly 




In the UK, at birth every individual is assigned an NHS number. Healthcare delivery 
throughout their lifetime is linked to this number which is unique to each patient. The NHS 
provides universal healthcare free at the point of access to all. General practice is the 
foundation of the NHS and almost the entire population of the UK are registered with a 
general practitioner; this structure for healthcare delivery provides a unique environment 
for research. THIN is one of the largest databases of general practice records in the world. It 
currently includes data from 587 practices in the UK, approximately 6% of the whole UK 
general practice population.50  
 
Heart failure can affect all age groups including children. The types of heart failure affecting 
children and younger people are pathologically distinct from heart failure found in older 
adults.91 The randomised controlled trials conducted in the 1990s to examine the 
effectiveness of drug treatment in patients with heart failure recruited participants who 
were from middle-age onwards.92 93 94 The ECHOES study recruited patients over the age of 
45 for this reason. To allow comparison with the ECHOES findings, an age group of 45 or 
older was also used for this cohort study. 
  
The aim of this study was to determine the incidence of heart failure in the general practice 
population using routinely collected data. A cohort of patients with a diagnosis of heart 
failure was extracted from the THIN database to explore the number of new cases. The 
clinical codes used to record a diagnosis were used to identify a first diagnostic label of heart 
failure. The objectives of the study were: 
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 To calculate the incidence of a first diagnostic label of heart failure in a general practice 
population by sex and age band. 
 To determine if the incidence of heart failure has changed over time. 
This epidemiological information is important to allow healthcare providers to plan services 
based on the number of patients with heart failure. It is also important to clinicians to 
understand if the pattern of disease is changing - particularly whether new heart failure 





An open matched retrospective cohort study was carried out using data from THIN database 
for the period between 1st January 1995 and 31st December 2012. 
 
2.4.2 Setting 
THIN is a primary care database containing electronic patient records from 587 general 
practices in the UK. At each consultation, the GP records details of the medical encounter. 
Symptoms or diagnoses are entered using a clinical coding system. Prescriptions and 
laboratory results/observations (e.g. blood pressure) are recorded electronically. 
Demographic details such as age, sex and linked deprivation scores also form part of the 
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record. Practices that contributed at least one year of clinical data were included in the 
study.95  
 
2.4.3 Study Population 
To determine incidence, a cohort was extracted from the database including all persons 
aged 45 years and over, registered at the practice for at least 12 months during the study 
period. Patients with a previous diagnosis of HF were excluded. Eligible cases were defined 
according to the following criteria: 
- A clinical code of heart failure from a list generated using the NHS terminology browser 
and the Quality and Outcomes Framework coding list.  
- Age 45 and over at the time of code recording. There was no upper age limit. 
- Confirmed cases were those with a hospital letter stating the diagnosis or abnormal 
echocardiogram recorded in the notes.  
- Unconfirmed cases were those with a clinical code of heart failure alone.  
- Index date was the first recorded heart failure diagnosis.  
- First diagnostic code was entered between 1st January 1995 and 31st December 2012.  
 
2.4.4 Clinical Codes 
Participants with a diagnosis of heart failure were identified using the clinical codes used by 
GPs to record new diagnoses in the medical record. The NHS Clinical Terminology Browser 
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and Quality and Outcomes Framework guidelines were used to generate a comprehensive 
list of terms used to code for a diagnosis of heart failure: 
1O1..00 Heart failure confirmed 
G1yz100 Rheumatic left ventricular failure 
G232.00 Hyperten heart&renal dis with (congestive) heart fail 
G234.00 Hyperten heart&renal dis+both (congestive)heart fail 
G58..00 Heart failure 
G58..11 Cardiac failure 
G580.00 Congestive heart failure 
G580.11 Congestive cardiac failure 
G580.14 Biventricular failure 
G580000 Acute congestive heart failure 
G580100 Chronic congestive heart failure 
G580200 Decompensated cardiac failure 
G580300 Compensated cardiac failure 
G580400 Congestive heart failure due to valvular disease 
G581.00 Left ventricular failure 
G581.12 Pulmonary oedema – acute 
G581000 Acute left ventricular failure 
G582.00 Acute heart failure 
G583.00 Heart failure with normal ejection fraction 
G583.11 HFNEF - heart failure with normal ejection fraction 
G58z.00 Heart failure NOS 
 
Heart failure is a clinical syndrome and the diagnosis requires the presence of symptoms and 
objective evidence of a structural or functional abnormality of the heart.7 Patients with a 
clinical code of heart failure and either an echocardiograph report or a hospital letter were 
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classified as being a confirmed case of heart failure and those with just a clinical code alone 
as unconfirmed cases.  
 
2.4.5 Baseline Variables 
Demographic variables including age, sex, ethnicity, area deprivation quintile (Townsend 96), 
cardiovascular risk factors and co-morbidities were extracted. The latest deprivation quintile 
prior to the index date was used or, if unavailable, the most recently recorded after the 
index date. Cardiovascular risk factors (smoking, blood pressure, cholesterol, body mass 
index (BMI)) were the most recent recorded prior to index date. Cardiovascular co-
morbidities (angina, myocardial infarction (MI), ischaemic heart disease, diabetes, 
hypertension, stroke, atrial fibrillation, valve disease), were defined by the presence of a 
clinical code at any time prior to the index date.  
 
2.4.6 Outcome Measures 
For the incidence calculations, outcome was presence of a first diagnostic code of heart 
failure.  
 
2.4.7 Statistical Analyses 
Data were extracted directly from THIN database using the list of clinical codes. Analysis was 
carried out using Stata versions 10 and 11. The number of practices, absolute numbers of 
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confirmed and unconfirmed heart failure cases and proportion of heart failure cases 
classified as confirmed was calculated. Age distribution of heart failure cases and 
participants characteristics for confirmed, unconfirmed and all heart failure cases were also 
summarised. 
 
Overall incidence of heart failure was calculated using the total number of new diagnoses of 
heart failure cases and the total number of patient years of observation in the THIN 
database between 1st January 1995 and 31st December 2012. Incidence was also calculated 
by sex and 10 year age bands from 45 years onwards. Incidence, by year of first diagnostic 
label of heart failure, was also calculated and adjusted for age using the mid-year population 




A total of 564 practices contributed at least one year of data between 1st January 1995 and 
31st December 2012. The number of contributing practices increased significantly over time 





Figure 3: Number of practices contributing to THIN dataset by year 
 
A total of 2,730,738 patient records were included in the incidence dataset. 55,248 
participants had a new clinical code of heart failure during the study period; 40,615 with a 
code of heart failure alone (unconfirmed case) and 14,633 with additional evidence to 
support the diagnosis such as hospital letter or echocardiogram result (confirmed case). 
 
The total number of new cases of heart failure per year in the dataset increased to nearly 
5,000 in 2003 then declined to around 3,500 in 2007 which remained stable until 2012 as 
shown in Figure 4. The number of confirmed cases increased during the first years of the 
study period then peaked in 2007 at 34% then declined year by year to just over 20% in the 








































Figure 4: Number of new cases of heart failure by year 
 
2.5.2 Study Population 
The age distribution of all heart failure patients is shown in Figure 5. It remains a disease 





































Figure 5: Age distribution of patients with a first diagnostic code of heart failure 
 
The characteristics of cases with confirmed and unconfirmed heart failure are shown in 
Table 5. Cases with confirmed heart failure were younger and 56% were male compared 
with 50% in the unconfirmed group. All five Townsend deprivation quintiles were similarly 
represented except for the most deprived group which had around one third fewer cases 
than the other four groups. The proportion of participants in each Townsend score group 
was similar for confirmed and unconfirmed cases. BMI was similar and there were 2% more 
smokers in the confirmed compared to the unconfirmed heart failure group. Ischaemic heart 
disease, angina and MI were all more common in the confirmed group. Cardiovascular co-











45-54 585 (4.0%) 1,182 (2.9%) 1,767 (3.2%) 
55-64 1,745 (11.9%) 3,598 (8.9%) 5,343 (9.7%) 
65-74 3,571 (24.4%) 8.807 (21.7%) 12,378 (22.4%) 
75-84 5,558 (38.0%) 15,750 (38.8%) 21,308 (38.6%) 
85-94 2,983 (20.4%) 10,238 (25.2%) 13,221 (23.9%) 
>=95 191 (1.3%) 1,040 (2.6%) 1,231 (2.2%) 
Male 8,204 (56.1%) 20,206 (49.7%) 28,410 (51.4%) 
Townsend score 
1 2,877 (19.7%) 8,233 (20.3%) 11,110 (20.1%) 
2 2,905 (19.9%) 8,449 (20.8%) 11,354 (20.6%) 
3 2,952 (20.2%) 8,346 (20.6%) 11,298 (20.5%) 
4 3,008 (20.6%) 8,068 (19.9%) 11,076 (20.1%) 
5 2,314 (15.8%) 5,733 (14.1%) 8,047 (14.6%) 
Not known 577 (3.9%) 1,786 (4.4%) 2,363 (4.3%) 
BMI 
Mean (SD) 27.9 (5.8) 27.8 (5.9) 27.9 (5.9) 
Missing 1,862 (12.7%) 7,181 (17.7%) 9,043 (16.4%) 
Smoking status 
Smoker 2,290 (17.7%) 5,502 (13.6%) 7,792 (14.1%) 
Not current smoker 11,731 (80.2%) 32,051 (78.9%) 43,782 (79.3%) 
Missing 612 (4.1%) 3062 (7.5%) 3674 (6.7%) 
Diabetes 2,971 (20.3% 7,878 (19.4%) 10,849 (19.6%) 
Hypertension 7,922 (54.1%) 21,247 (52.3%) 29,169 (52.8%) 
Angina 3,575 (24.4%) 9,201 (22.7%) 12,776 (23.1%) 
Myocardial infarction 3,919 (26.8%) 8,528 (21.0%) 12,447 (22.5%) 
Ischaemic heart disease 6,985 (47.7%) 16,694 (41.1%) 23,679 (42.9%) 
Stroke 1,270 (8.7%) 3,761 (9.3%) 5,031 (9.1%) 
Atrial fibrillation 4,732 (32.3%) 10,894 (26.8%) 15,626 (28.3%) 
Valvular disease 1,727 (11.8%) 3,841 (9.5%) 5,568 (10.1%) 
 
Table 5: Characteristics of patients with heart failure 
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2.5.3 Incidence of Heart Failure 
The incidence of heart failure overall for the entire study period was 3.02 (95%CI 2.99 to 
3.05) per 1,000 person-years and was higher amongst older individuals increasing from 0.29 
(95%CI 0.28 to 0.31) per 1,000 person-years in the 45-54 year age group to 18.60 (95%CI 
17.59 to 19.67) per 1,000 person-years in those aged over 95 (Table 6). The incidence of 
heart failure was higher in men than women in every age band. Overall incidence in the age 
group 65 and older was 6.83 (95% CI 6.77 to 6.89) per 1,000 person-years and in the age 
group 75 years and older was 10.93 (95%CI 10.82 to 11.04) per 1,000 person-years.   
 


























































































Table 6: Incidence of heart failure by age and sex (per 1000 person-years at risk) 
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The overall age-adjusted incidence of heart failure from 1995 to 2012 is shown in Figure 6. 
The incidence in 1995 was 7.44 per 1,000 person-years (95%CI 2.59 to 12.29) but just one 
practice contributed data in the first year of the study. The number of contributing practices 
increased rapidly in the first two years of the study period (Table 7). Incidence from 1997 
onwards is therefore likely to be most accurate. Incidence declined from 5.36 per 1,000 
person-years (95%CI 5.17 to 5.55) in 2000 to 2.41 per 1,000 person-years (95%CI 2.33 to 
2.49) in 2007, after which the rate stabilised at around 2.3 cases per 1,000 person-years.  
 
 




















































































































































2.6.1 Summary of Results 
This study confirmed the incidence of a first diagnostic label of heart failure is higher 
amongst older individuals and is more common in men than women. Incidence of a heart 
failure clinical code fell by more than half from 5.36 to 2.41 per 1,000 person-years between 
2000 and 2007. Since then incidence has remained stable at around 2.3 heart failure cases 
per 1,000 person-years.  
 
2.6.2 Strengths and Limitations 
This study reports incidence of heart failure from a large representative set of general 
practices and is therefore likely to be generalizable to the community population as a 
whole.97 The cohort included in this analysis is much larger than those used in 
epidemiological studies of heart failure. The large number of patients in each age and sex 
category improves the accuracy of the incidence estimates.  
 
The NHS has a strong primary care base and provides healthcare to the entire population, 
free at the point of access. This means nearly everyone in the population is registered at a 
general practice allowing a denominator – the number of people in the population – to be 
generated. General practice datasets like THIN are therefore able to generate a rich dataset 
which provides detailed information about routine care across a large number of 
participants from the general population. Unlike screening cohort studies, general practice 
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databases do not rely on participants volunteering to take part in the study rather they 
represent a cross-section of the entire population.  
 
The main limitation of the study is the reliability of GP coding. Heart failure is a chronic 
condition which is often insidious in onset and can masquerade as other conditions making 
early and accurate diagnosis difficult.21 The first recorded heart failure diagnosis in this 
dataset was in July 1995. Clinical coding improved significantly following the introduction of 
widespread computerisation and the use of Read codes. Previous authors have reported 
significant improvements in coding prior to the formal introduction of a QOF indicator.98 The 
heart failure QOF indicator, introduced in 2006, required robust evidence of heart failure. 
The number of heart failure cases fell prior to the introduction of QOF and has remained 
stable since then at around 2.3 cases per 1,000 person-years. so the fall between 2000 and 
2007 may partly reflect more robust clinical coding methods rather than a true fall in 
incidence.  
 
The number of confirmed heart failure cases – i.e. those without objective evidence - may 
reflect a lack of coding of echocardiogram or hospital letter rather than these elements 
being missing in the general practice record. This is another limitation of routinely collected 
datasets which rely on detailed coding of every piece of information for it to be retrievable 
for analysis. However, THIN provides a snap shot of real-life general practice which is 
complementary to detailed phenotyping by screening studies. 
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Over time the definition of heart failure has changed leading to dysynchrony between 
epidemiological studies, making comparison difficult, and the meaning of a code for heart 
failure in an individual’s medical record may be based on different criteria depending on the 
accepted definition at the time of diagnosis.7 29 30  A more recent update of the European 
Society of Cardiology guideline has also recognised two distinct heart failure types: heart 
failure with reduced ejection fraction (HFREF) and heart failure with preserved ejection 
fraction (HFPEF).7 The emergence of this new classification has meant that the clinical 
picture of heart failure is changing and, from a recent search we undertook for these codes 
in THIN database, coding in the general practice record has not, until very recently, started 
to capture this.  
 
All data extracted from the THIN dataset have been presented here for the purposes of this 
thesis, however, the first three years (1995-1997) of the dataset included data from less than 
100 practices. As shown in Figure 6, the confidence intervals for incidence are therefore 
wider than estimates for subsequent years. Previous research has suggested that THIN is 
similar to the UK general population51 but this may not be the case for the first three years 
of the study when the number of participants in the population was low.   
2.6.3 Comparison with Existing Literature 
There is a paucity of contemporary epidemiological information on heart failure from a 
primary care setting. In England, the QOF (a payment incentive scheme for general practice) 
report annual prevalence figures for heart failure which have been 0.8-0.9% per year since 
the introduction of the heart failure indicator in 2006.99 However the number of new cases 
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per year is not recorded. National heart statistics include heart failure incidence and 
mortality within an umbrella term of ‘cardiovascular disease’ so estimates for heart failure 
alone are lacking.100  
 
Incidence has therefore come from epidemiological studies such as the Framingham Heart 
study in the US or the ECHOES studies in the UK. The Framingham Heart study began in 1948 
and followed up the original cohort every 2 years.28 A study of the Framingham cohort 
examining the trends in incidence of heart failure between 1950 and 1999 found incidence 
was 5.54 per 1,000 person-years for men in 1999 and had remained unchanged in 50 years, 
however the incidence in women had fallen from 4.20 (95%CI 3.36 to 5.04) to 3.27 (95%CI 
2.66 to 3.88) per 1,000 person-years at risk over the same period.101 This is similar to the 
incidence in the THIN dataset pre-2006. However, the Framingham participants are largely 
white, middle class and voluntarily took part in research so are unlikely to be fully 
representative of the UK primary care population. The original criteria used in the 
Framingham definition also relied on the presence of symptoms and signs to determine a 
diagnosis of heart failure but more recent definitions emphasise the importance of objective 
evidence of a structural or functional abnormality of the heart, usually from imaging.31 
 
The Framingham Offspring Study follows up the children of the original Framingham 
participants and continues to explore cardiovascular disease patterns. Participants in the 
Offspring cohort were originally screened between 1995 and 1999 and are followed up every 
4 years. In a study to identify markers of new onset heart failure, Velagaleti et al examined 
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the cumulative incidence of heart failure following the original screening visit. There were 
2754 participants included in the sample with a mean age of 58 years and 54% female. Over 
a mean follow-up period of 9.4 years (maximum 12.8 years), there were 95 new cases of 
heart failure, providing a cumulative incidence of 3.4%. However the authors did not 
calculate the incidence by year or by person-years at risk so it is not possible to determine 
trends in incidence over time.102  
 
A screening study in the Netherlands also recently reported incidence of new onset heart 
failure in a screened cohort. The Prevention of Renal and Vascular End-stage Disease 
(PREVEND) study screened 8592 participants in 1997 and 1998. Age at recruitment was 28-
75 years and most participants were Caucasian. After 11.4 years follow-up, 374 participants 
had developed heart failure – a cumulative incidence of 4.4%. Participants were recruited 
due to a mildly raised urinary albumin excretion at baseline, a marker of possible 
cardiovascular risk, so the cohort is unlikely to be representative of the general 
population.103  
 
Sweden has well-developed, high-quality health registries which allow more detailed 
examination of the epidemiology of diseases. A cross-sectional study of 2.1 million residents 
of the Stockholm region was carried out by Zarrinkoub et al using an administrative health 
data register.104 The register contains records of both primary and secondary care 
consultations, as well as hospitalisations.  Between 2006 and 2010, the overall prevalence of 
heart failure was estimated to be 2.2% and incidence was 3.8 per 1,000 person-years. During 
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the study period there was a reduction in incidence of 0.9 per 1,000 person-years (a relative 
24% decrease, P<0.002) between 2006 and 2010 which was the same for both men and 
women. A similar decrease was not seen in the THIN dataset during this time period. 
2.6.4 Implications for Practice 
The data in GP records reflects the real life situation of the UK healthcare system in which a 
million patients are managed each day.105 In order to provide doctors and commissioners 
with accurate epidemiological information to inform patient care and plan health services, it 
is perhaps most appropriate to use data from general practice to calculate incidence. From 
our findings, a moderately sized GP practice with, for example, 5,000 patients over the age 
of 45 will have around 10 patients receiving a new heart failure diagnosis per year. This 
information is important when planning heart failure services at a local and regional level 
but also to individual GPs when considering the number of patients they are likely to see and 
treat within a year.  
 
The incidence of heart failure in this study has remained stable since 2007. The reasons for 
this are complex and require further research. Heart failure is a disease of the elderly and as 
the population ages the incidence would be likely to increase. However, awareness of the 
causes of heart disease, and more proactive treatment of risk factors at a population as well 
as individual patient level, are likely to improve cardiac health and push down incidence. 
Furthermore, improved survival for patients following acute myocardial infarction (MI) but 
with a damaged heart may be expected to increase incidence of heart failure however, 
prompt, more effective treatments at the time of MI may reduce the amount of muscle 
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damage and therefore the likelihood of developing heart failure in the future.106 The 
diagnostic criteria applied to determine a heart failure label can also influence the observed 
incidence. Further studies are required to examine the relative roles of risk factor 
management, MI treatment and the diagnostic pathway to highlight areas where 
intervention could ultimately help to reduce the incidence of heart failure over time.  
 
2.7 Summary of the Chapter 
This chapter presented a study using data from a general practice records database to 
determine the incidence of heart failure in the community population of the UK. The study 
included over 2.7 million patient records and found 55,248 patients with a first diagnostic 
label of heart failure in their GP record. The results were consistent with other studies which 
reported that the incidence of heart failure increases with age and is more common in men 
than women. The study found a reduction in heart failure incidence between 1995 and 2007, 
which may partly be explained by changes in clinical coding, but then a stable incidence of 
2.3 per 1,000 person-years since 2007 which coincides with more robust recording since the 
introduction of the heart failure QOF indicator in 2006. The literature on heart failure 
incidence was then presented which varies in methodology, quality and findings but with 
some studies reporting a reduction in incidence over time which differs from the results of 
this study. Possible reasons for the stable incidence were considered, along with the 




3. PATIENT EXPERIENCE OF HEART FAILURE DIAGNOSIS: METHODS 
 
3.1 Chapter Overview 
This chapter presents the methods of a qualitative study which explores the process of heart 
failure diagnosis in primary care from the patient’s perspective. Patients with a new 
diagnosis of heart failure were asked to describe key points in their journey from the time 
they first noticed symptoms to when they received a formal diagnosis. The methods and 




Background and Aims: Heart failure is a common and important disease which causes 
troublesome symptoms for patients. International guidelines suggest a simple diagnostic 
algorithm for patients presenting with symptoms suggestive of heart failure in primary care 
but it is unclear what the process entails from the patient’s viewpoint. The aim of this study 
was to explore the journey through the diagnostic process from the patient perspective and 
to highlight areas where care might be improved. 
Method: Qualitative interview study. Patients with a recent (<1 year) diagnosis of heart 
failure were invited for interview. Participants were asked to describe key points in their 
journey from the time they first noticed symptoms to when they received a formal diagnosis 
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of heart failure. Interviews were recorded and transcribed verbatim. Data were analysed 
using the Framework method. 
Results: Sixteen participants were interviewed. The findings are grouped into three key 
themes. 
Heart Failure Onset: Participants experienced shortness of breath, ankle swelling and fatigue 
but initially normalised their symptoms, attributing them to ageing, other co-morbidities, 
lack of physical fitness or a side effect of medications. Participants only sought medical help 
once symptoms affected their activities of daily living.   
Interactions with Healthcare: Participants entered the healthcare system through primary 
care and were referred for further testing in secondary care. Participants who were acutely 
unwell were admitted directly from their GP surgery. Participants valued the longitudinal 
relationship they had with their GP and practice. Interactions with secondary care 
professionals were less personal and felt rushed at times. Logistical frustrations such as GP 
access and hospital waiting times added to patient burden.  
Diagnosis and Impact: Participants’ understanding of the term ‘heart failure’ varied and the 
term itself caused anxiety. Delivery of the diagnosis by clinicians, and provision of 
information about the disease, could be improved in some cases. The impact of a heart 
failure diagnosis depended on participants’ adaptability and the presence of other 
conditions, which could cause more debilitating symptoms than heart failure itself.  
Discussion: The findings of this study on the diagnostic pathway for heart failure highlighted 
areas where the patient experience could be improved. Greater public awareness of heart 
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failure symptoms, improved access to primary care, a generalist patient-centred approach, 
better communication in secondary care and adequate explanation of ‘heart failure’ as a 
term are potential areas of service improvement.  
 
3.3 Background and Aims 
Heart failure is a common and important disease which causes troublesome symptoms and 
reduces life expectancy for patients.4 There are many treatments which improve quality of 
life, and survival, but making a diagnosis can be complex.26 30 63 64 Heart failure symptoms 
include shortness of breath, ankle swelling and fatigue but these can be present in many 
other conditions, or just a normal part of life.107 National and international guidelines 
provide investigation algorithms which lead the clinician through the appropriate testing and 
formal diagnostic criteria once the possibility of heart failure has been considered. However 
the patient experience and decision making prior to initiating investigation to confirm a 
diagnosis of heart failure is unclear.  
 
Guidelines do not address the grey area from when the patient first experiences symptoms 
to the time they seek medical attention and the subsequent diagnostic process from their 
perspective. It is unclear what prompts patients to first seek help, what patients experience 
at key points during the diagnostic pathway and what patients understand by the diagnostic 
label of ‘heart failure’. The existing literature in these areas was discussed in detail in Section 
1.6 of Chapter 1.  
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The aim of this study was to explore participant experiences of a diagnosis of heart failure to 
develop an understanding of the diagnostic pathway from the perspective of the patient and 
to use this data to highlight behaviours and processes which could be modified to improve 
both experience and outcome. The objectives of the study were: 
 To explore how patients describe the onset of heart failure symptoms and the 
explanations they have for the symptoms initially.  
 To determine what prompts patients to seek medical attention for their symptoms. 
 To explore how patients describe the experience of seeing the GP and having tests 
carried out. 
 To examine what patients understand by a diagnosis of heart failure, what the term 
means to them and what impact the diagnosis has on their lives. 
 To gather patient’s views on their experience of the heart failure diagnostic pathway in 
hindsight and how they feel things might have been improved. 
The findings of the study provide a rich description of the patient experience of heart failure 
diagnosis from first symptoms to impact of the diagnosis on their everyday life. The data are 
used to identify what factors are important at key points in the diagnostic pathway (in 
particular, decision to initially consult, investigative processes and receiving a formal 
diagnosis) which could be modified to optimise patient experience. The methods are 
described in detail in this chapter, the findings are presented in Chapter 4 and the 





3.4.1 Study Design 
A qualitative study, using semi-structured interviews with patients diagnosed with heart 
failure, was carried out between August 2014 and May 2015. Interviews were recorded, 
transcribed and analysed using the Framework method.108 Justification for the 
methodological approach is now briefly considered. 
 
The choice of research methodology depends on the phenomena being studied and question 
which needs to be addressed. The other three studies included in this PhD thesis use 
quantitative methods to answer the questions posed. The research paradigm – the beliefs 
and set of practices within which research is conducted – determines the approach to any 
study.109 Quantitative methods are usually associated with a positivist view of the world. 
Positivism assumes the nature of reality (or ontology) is fixed and discoverable.110 In 
epistemological terms, positivists believe knowledge exists to be found through 
methodologies which objectively measure phenomena and test hypotheses.111 This is 
important to explore numerically-based questions like how common is heart failure, how 
long do patients survive and how many new cases are found through screening?112  
 
The positivist approach, however, fails to effectively answer questions such as ‘what is it like 
to be a patient going through the heart failure diagnostic process’ or ‘what do patients 
understand by the term heart failure and how does it affect their lives’?113 These represent 
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issues particularly important to the patient and a better understanding of their experience is 
fundamental to improving healthcare services.114  To answer the questions of why and how, 
the alternative research paradigm of interpretivism, or social constructivism, is often used 
which rejects the existence of ‘one reality’ and instead argues that human beings are an 
integral part of the construction of their own reality and they are also a fundamental part of 
the knowledge about that reality. Qualitative methods used to gather data to support this 
ontological and epistemological viewpoint include interviewing, observation and document 
reviews.115  
 
The experiences of patients with heart failure are not only associated with how many tests 
are performed, where the tests are carried out or what drugs are started. Each person 
undergoing the process is unique with their own background and previous life events, 
current view of the world and influence from their wider social circumstance. Their view of 
the diagnostic pathway is likely to be different to the next patient with heart failure. For this 
reason, an interpretivist, or constructionist, view point was taken. I wanted to capture the 
‘story’ of each participant from the start of symptoms to the impact of diagnosis and this 
was most achievable using semi-structured interviews. 
 
Each patient story was unique but I wanted to explore the similarities and differences 
between each story to gain a better understanding of the heart failure diagnostic pathway as 
a whole. The Framework method, a type of thematic analysis, adopts a pragmatic approach 
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to analysing real world data using a clearly defined technique, described in more detail in 
Section 3.4.9 below, and so was chosen as the analysis method for this study. 
 
3.4.2 Recruitment 
To investigate the whole clinical pathway, participants needed to have a confirmed diagnosis 
of heart failure and be able to recall events easily. In addition, to capture the primary care 
part of the clinical pathway, participants needed to have presented to their GP and 
subsequently been referred to secondary care for objective testing and confirmation of a 
diagnosis of heart failure for the first time, rather than being admitted as an emergency or 
having a prior heart failure diagnosis.  
 
Participants were recruited from the heart failure clinic at the Queen Elizabeth Hospital 
Birmingham (QEHB). The clinical administrative team identified patients with a recent 
diagnosis (<1 year) of heart failure who had been referred from primary care. Patients with a 
heart failure diagnosis more than 12 months previously, who had not been diagnosed 
following referral to primary care, were not able to give written informed consent or who 





Birmingham is a large, socioeconomically diverse city in central England. The QEHB is part of 
the University Hospitals Birmingham NHS Foundation Trust and is located in the suburb of 
Edgbaston, close to the centre of the City. QEHB is the largest single site hospital in the 
UK.116 Local GPs can refer patients to QEHB through a primary care referral process. Patients 
with symptoms and signs suggestive of heart failure require a natriuretic peptide test to be 
performed by their GP. If the natriuretic peptide level is raised, patients can be referred to 
the heart failure clinic directly. The service is run by a consultant cardiologist at QEHB and 
the team includes heart failure specialist nurses, cardiology registrars, echocardiographers 
and administrative support staff. 
 
In the diagnostic heart failure clinic, patients are assessed through clinical history taking and 
physical examination. They have investigations which usually include an electrocardiogram 
(ECG) and echocardiogram (echo). Some patients may require more specialised tests such as 
cardiac magnetic resonance imaging (MRI). Patients are seen by a consultant cardiologist at 
the end of the assessment to explain whether they have a diagnosis of heart failure or not. 
Subsequently, the heart failure nursing team give the patient further information and 
provide follow-up at local community clinics to monitor physiological parameters such as 
pulse rate, blood pressure and weight and optimise heart failure medications. There are five 




The European Society of Cardiology definition of heart failure requires both symptoms and 
objective evidence to confirm the diagnosis. Participants were recruited from the QEHB 
heart failure clinic to ensure they had undergone a thorough diagnostic assessment so only 
those with a reliable diagnosis of heart failure were interviewed.  
 
This study aimed to explore the primary care aspect of the heart failure diagnostic pathway 
from when the patient first experienced symptoms to receiving a formal diagnosis. To 
ensure experiences were recent, and could be recalled easily, only patients who had 
received a diagnosis of heart failure within the last 12 months were invited to take part.  
 
3.4.4 Sampling 
Qualitative research aims to explore the experiences of individuals within their own context 
by collecting, analysing and interpreting data from interviews or observations.117 Unlike 
quantitative research, the aim is to achieve a depth of understanding of the experiences of a 
group of people in a particular time and place. The number of participants included in 
qualitative studies cannot therefore be determined by a power calculation – the method 
used in quantitative studies such as clinical trials to ensure the number of participants in the 
study is large enough to detect a difference between two groups.118 Instead, the number of 
participants required for a study is determined by the aims of the study, the quality of data 
collected from the interviews and the findings at the analysis stage, including the concept of 
saturation. 119  
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At the planning stage of the study, my supervisor (an experienced qualitative researcher) 
and I discussed the number of participants required. The concept of ‘sample specificity’ as 
described by Malterud et al 120, examines the extent to which the participants to be 
recruited to a study are similar and how this related to the overall study aims. In studies 
where ‘sample specificity’ is high, participants are recruited from a narrow group of 
individuals often with several criteria in place. The aim of this study, set out above, was to 
explore participant experiences of a diagnosis of heart failure to develop an understanding 
of the diagnostic pathway from the perspective of the patient. The study was to recruit 
patients over the age of 55 from a single outpatient heart failure clinic at the local hospital 
who had been diagnosed with heart failure within the last year following referral from 
primary care. While variation of experience within this group was expected, and necessary 
for the study, these detailed criteria meant the number of participants required to achieve 
saturation would be less than if the sample specificity was broader. From my supervisor’s 
experience, interviews with between 12 and 20 participants were usually adequate to 
achieve the study aims in this context. We agreed an initial aim of 20 participants, but to 
review this in light of the interview data and subsequent analysis. 
 
Heart failure usually occurs in older age groups, typically over the age of 55, and can affect 
men and women of different ethnic groups. Purposive sampling was planned in order to 
achieve demographic variation. The aim was to recruit a total of 20 patients over the age of 
55 years with at least 2 participants from each age group of 55-65, 65-75, 75-85 and 85+ 
years old to be included. A mix of men and women in each age group and patients of White, 
81 
 
Asian and Black ethnicity were also sought. Arrangements for an interpreter to be used 
where needed were put in place to prevent exclusion of non-English speaking patients. 
Unfortunately, due to challenges in the recruitment process, detailed below, purposive 
sampling according to the criteria above was difficult to achieve fully. Participants were a 
range of ages and a mix of gender but ethnic mix was not achieved. All but one participant 
was White and all participants spoke English as their first language. This has implications for 
the application of the findings and is discussed in detail in Chapter 5.  
 
During the interviews, participants provided rich and detailed descriptions of their 
experiences of the diagnostic process. After each interview, audio data were transcribed and 
coded. The Framework method, described in more detail below, was used to analyse data. 
This method requires systematic coding and sorting of data into an analytical framework 
which allows data from each participant to be compared easily. Following 12 interviews, no 
new themes were emerging. We agreed to carry out the remaining 4 scheduled interviews 
and once all 16 interviews had been completed we found no new or emerging themes and 
felt saturation had been achieved.             
 
3.4.5 Recruitment Process 
The study aim was to recruit 20 participants within a four month period between September 
and December 2013. Prior to the start of the recruitment phase, a meeting was held with the 
QEHB heart failure clinic team, which included the heart failure nurse specialists and 
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consultant cardiologist, to discuss the logistics of the recruitment process. The clinical team 
were enthusiastic about the project and, after discussion, felt that handing out patient 
information leaflets in the clinic would be acceptable to patients and minimally disruptive to 
the usual running of the clinic.  
 
The research documents (Appendices 2-3) received ethical approval on 28th August 2013 
from the Hampshire A Research Ethics Committee (reference 13/SC/0475). The Head of 
Research and Development (R&D) at QEHB gave authorisation for the Heart Failure clinic to 
be a Participant Identification Centre. The patient information sheet (Appendix 9.2) was 
given to all patients receiving a new diagnosis of heart failure between November 2013 and 
January 2014.  
 
Ethics and R&D requirements meant that as a researcher I was unable to approach patients 
directly for the study because I was outside of their usual clinical team. The patient 
information sheet, handed out by the heart failure specialist nurses, contained details of the 
research project and contact information for those who wished to take part in the study. 
Unfortunately this prospective recruitment strategy did not yield any participants. The 
reasons why recruitment was unsuccessful were not entirely clear but may have included 
factors such as time pressures within the clinic meaning heart failure nurse specialists did 
not have the opportunity to discuss the study in detail or that patients who had just received 




Following consultation with my PhD supervisors, the heart failure clinical team and the head 
of R&D at QEHB, a new recruitment strategy was agreed which involved letters being sent 
directly to patients who had received a diagnosis of heart failure in the last 12 months. A 
substantial amendment was sought from the ethics committee and the revised protocol was 
approved on 16th June 2014. The conditions of the ethics and R&D approval meant that the 
clinical team needed to identify patients who met the eligibility criteria: 55 years and over 
with a recent (<1 year) diagnosis of heart failure following referral from primary care. 
Initially this was challenging as clinical time was very limited and this cost had not been 
factored in to my original PhD Fellowship application. Following further discussions, it was 
agreed that the clinic administrative staff would identify patients for the study and send out 
the invitation letters and patient information sheets.  
 
Letters were sent out to a total of 100 eligible participants in August and September 2014. 
Patients were invited to contact me by phone to discuss any aspect of the study and to 
volunteer to take part if they wished by returning the reply slip which was enclosed along 
with a prepaid envelope addressed to the clinical team. The clinical administrators collated 
reply slips and sent a spreadsheet with the name, address and phone number of all those 
who had responded and were willing to take part. In total, 21 participants responded to the 
invitation letter and were contacted by phone to arrange a time and location to carry out the 
interview. The location of interview was decided by the patient. I offered to travel to the 
patient’s own home or to arrange another quiet and private location that was convenient to 
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them. A convenient date and time was also agreed. No payment was available for 
participants taking part in the study but travel expenses were offered.  
 
From the list of 21 participants who returned the reply slip, 16 participants agreed to take 
part. One participant had changed her mind when contacted, one participant had recently 
been admitted to hospital so was no longer available to be interviewed and three 
participants were not contactable through the details given on the reply slip. 
 
3.4.6 Data Collection 
Interviews took place between October and December 2014. Fifteen interviews took place in 
the participants’ home and one interview was conducted by telephone. I conducted all 
interviews myself. All 16 interviews were recorded using a digital voice recorder. For each 
participant, I explained the aims of the study, as outlined in the patient information sheet, 
and invited questions. Once all questions had been addressed, written informed consent was 
obtained using the consent form (Appendix 9.3).  
 
Semi-structured interviews were carried out with an originally estimated duration of 
between 30 - 60 minutes. An interview topic guide (Appendix 9.4) was used to ensure key 
areas were covered to achieve the aims and objectives of the study.  The topic guide 
included questions on symptom onset and seeking medical attention, the investigative 
process and understanding a diagnosis of heart failure. 
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I carried out all of the interviews and the subsequent analysis. I therefore was integral to the 
research process and could not be truly independent so I needed to be aware of how I might 
influence and inform the research, a process known as reflexivity. This process is vital to 
reduce researcher bias and ensure results are credible.121  
 
The behaviour of study participants can be influenced by the researcher – the ‘observer 
effect’ – and the professional role of the interviewer can influence interview interactions.122 I 
am a female general practitioner and researcher. I have worked in the NHS for 12 years and 
subspecialised in academic general practice 8 years ago. I work in a busy inner city practice 
which serves a largely socially-deprived population. Several steps were taken during the 
research process to reduce the effect of researcher bias and observer effect.  
 
Firstly, I introduced myself by my first name and emphasised to participants that I was 
interviewing them as a researcher from the university rather than as a GP to reduce the 
observer effect of participants feeling they could not perhaps be open and honest about 
their experiences when talking to a doctor.  
 
I had not carried out any qualitative interviewing before but I have had extensive training in 
interview technique through my medical and particularly general practice training. This 
included the importance of asking open questions (rather than closed or leading questions), 
listening and encouraging participant contribution. However, I am aware that qualitative 
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interviewing requires a technique dissimilar from the doctor-patient consultation.123 
Qualitative interviewing aims to encourage participants to share their experiences, meanings 
they attach to events and views of the world with the interviewer in an uninhibited way. In 
the doctor-patient relationship, listening is key to a successful consultation but the outcome 
is often to arrive at a diagnosis or treatment choice with the patient.  
 
I had no previous experience of analysing qualitative data so I attended a Health Experiences 
Research Group course in Oxford on Qualitative Data Analysis. To ensure the style of 
interviewing and data analysis was appropriate, I conducted and transcribed my first two 
interviews under the close supervision of my PhD supervisor (NG), an experienced 
qualitative researcher. We met and discussed my interview technique and repeated this 
process for the next 2 interviews. NG was happy with my technique and the quality of the 
interview data so the remaining interviews were carried out independently. 
 
Finally, I have considerable experience of diagnosing and managing patients in primary care 
so had some ideas of what the study may find but tried to suspend these expectations 
during the interview process. I used well-recognised qualitative methods for producing novel 





3.4.7 Data Management 
Digital audio recording equipment was used during the interviews to collect data. The digital 
files were downloaded to a designated folder on the University of Birmingham secure 
network. I transcribed the first two interviews which helped me to become familiar with the 
data and also to reflect on my interview technique. I transcribed the words only and did not 
include details about conversational style, tone or interruptions. I met with my supervisor 
(NG) to discuss the interview method, transcription technique and to consider refining the 
topic guide. In the first two interviews, the participant descriptions of their understanding of 
a heart failure diagnosis, and the meaning they associated with the term, was not explored 
in great detail. To achieve a depth of understanding of the patient experience, my supervisor 
suggested I spend more time on this part of their diagnostic journey before terminating the 
interview. The structure of the topic guide remained unchanged but I ensured that during 
subsequent interviews I allowed more time and space for patients to talk about the term 
heart failure and what it meant to them in the context of their individual circumstances. I 
carried out two further interviews which I also transcribed and discussed with my supervisor. 
Both interviewees gave an insightful and detailed account of heart failure as a term, the 
mechanisms they felt underpinned the condition, the impact on their lives and subsequent 
adaptation they and their family had experienced. The interview technique, and topic guide, 
was therefore not adjusted further. I then completed the remaining 12 interviews. A 
professional transcription service was used for these interviews so I read and re-read the 
transcripts to familiarise myself with the data. Audio-recordings and transcripts will continue 




Formal ethical approval for the study was sought from the National Research Ethics Service 
(NRES) using their online application system and the University of Birmingham Ethics 
Committee. The first ethics application was approved through a process called 
‘Proportionate review’. This is a new fast-track process which aims to deal with simple 
studies where the patient is exposed to minimal risk. The next available ethics committee 
reviews the application without the need for the researcher to attend. The study received a 
favourable ethical opinion from the Hampshire A Research Ethics Committee (13/SC/0475) 
in August 2013. As described above, due to problems with recruitment a substantial ethical 
amendment was required which was approved in June 2014. Confirmation of full ethical 
approval was received prior to commencement of the study which was sponsored by the 
University of Birmingham.   
 
3.4.9 Data Analysis 
Data were analysed using the Framework method.124 This is a systematic approach carried 
out in 7 stages: transcription, familiarisation with the interview, coding, developing an 
analytical framework, applying the analytical framework, charting data into the framework 







All interviews were digitally recorded and transcribed verbatim. Data were anonymised by 
removing any information which would make the patient identifiable. I carried out the 
transcription for the first four interviews then the remaining 12 interviews were transcribed 
by a professional transcription service. All participants available for and willing to take part 
were interviewed.  
 
Familiarisation and initial coding 
I read and re-read all transcripts to ensure I was familiar with the data. The first two 
transcripts were then coded by hand to generate a list of codes. The coding was reviewed by 
my supervisor (NG) to ensure the types and range of codes applied was appropriate. A 
further three transcripts were coded by hand which generated further coding lists. An 
iterative process, with constant comparison, was used during the interviews and analysis to 
ensure that the key areas identified in the objectives were addressed along with any new 
and emerging themes.125 
 
Developing and applying the analytical framework 
The coding lists were used to develop an analytical framework which finally contained 150 
codes organised into 17 categories (Appendix 9.5). The framework was reviewed by two of 
my supervisors (NG and TM). An experienced qualitative researcher (SS), independent of the 
project team, also coded an interview and commented on the analytical framework leading 
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to further modifications. I then coded all of the interview transcripts, according to the 
agreed codes and categories, using the software package NVivo10. I attended a course on 
using qualitative data analysis software packages to ensure I was able to use NVivo 
effectively to code, categorise and export the data.  
 
Charting data into the Framework matrix 
Coded data were exported from NVivo according to individual code and saved as separate 
documents. The data for each code was read, re-read then summarised for each of the 16 
participants in the study. Microsoft Excel was used to manage the summarised data. A new 
worksheet was used for each of the 17 categories. The name of the relevant code was 
inserted at the top of a column and the participants 1 to 16 were numbered down the left 
hand side. This process was repeated for each of the 17 categories (including all 150 codes). 
An example of charted data is presented in Appendix 9.6. 
 
Interpreting data 
Each category was then interpreted using an analytical memo (Appendix 9.7) to explore 
emerging themes and concepts. At this stage the key findings of the study began to surface 
and my supervisor (NG) and I had several meetings to discuss the main themes in detail. As 
part of this process, ‘deviant cases’, also called ‘disconfirming cases’, were considered. For 
example, as in Appendix 9.7, one participant had been to the heart failure clinic and had 
volunteered to be part of the research study but the participant, and his wife, did not appear 
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to realise or acknowledge he had heart failure. This was an isolated case and all of the other 
participants were aware they had the condition and were willing to discuss it openly. As part 
of the Framework Analysis this type of disconfirming case was acknowledged and described 
in the findings section (Chapter 4) but, as only observed in a single participant, did not 
contribute to an emerging theme. The literature, both sociological and clinical, was also 
explored to further examine the place and importance of the findings, and to consider 
implications for policy and practice.  
 
3.5 Summary of the Chapter 
This chapter summarised the background and aims of this qualitative study to explore the 
experiences of patients who have recently received a diagnosis of heart failure. The methods 
including sampling, recruitment strategy, interview technique and analysis using the 





4. PATIENT EXPERIENCE OF HEART FAILURE DIAGNOSIS: FINDINGS 
 
4.1 Chapter Overview 
This chapter presents the findings of the qualitative study described in Chapter 3. The 
interviews were transcribed and analysed, using the Framework method, to develop a better 
understanding of the heart failure diagnostic process from the patients’ point of view. The 
key characteristics of participants are summarised then the three key themes which 
emerged from the data are presented along with illustrative quotes. A discussion of the 
findings in relation to the literature, and key recommendations, follows in Chapter 5.  
 
4.2 Participants 
Sixteen participants identified by the heart failure clinic to have a diagnosis of heart failure 
within the previous 12 months were interviewed. Interview duration was an average of 42 
minutes with a range of between 21 minutes and 74 minutes.  
 
The demographic characteristics of the study participants are shown in Table 8. Five women 
and 11 men agreed to take part. Participants were in their 50s, 60s, 70s and 80s with a 
median age of 78.5 years; the youngest participant was 52 years old and the oldest was 87 
years old. The final ethnic make-up of the sample was not as diverse as originally intended 
with all but one participant being White British. Ten of the 16 interviewees were 
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accompanied by a relative during the interview. The interviews were primarily with study 
participants but the contribution of relatives present was welcomed throughout. 
 
Participant Age Sex Ethnicity Relative present 
P1 76 Male White British Spouse 
P2 75 Female White British  
P3 79 Female Black  
P4 80 Male White British Spouse 
P5 84 Male White British Spouse 
P6 87 Male White British Spouse 
P7 81 Male White British Spouse 
P8 71 Male White British  
P9 78 Male White British Spouse 
P10 70 Male White British Spouse 
P11 80 Female White British Spouse 
P12 67 Male White British  
P13 52 Female White British Daughter 
P14 67 Female White British Spouse 
P15 85 Male White British  
P16 87 Male White British  
 
Table 8: Demographic characteristics of study participants 
 
4.3 Overview of Themes 
Three key themes emerged from the data. The first theme was Heart Failure Onset which 
included symptom onset, progression and the decision to seek medical attention. The 
second theme was ‘Interacting with Healthcare’ which included contact with both primary 
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and secondary care during the diagnostic process. The third theme was Heart Failure 
Diagnosis - Delivery and Impact which included both the delivery of the diagnosis and the 
subsequent impact and adaptation process which followed. Each theme, and associated 
categories, will now be discussed along with illustrative quotes. 
 
4.4 Heart Failure Onset Theme 
The Heart Failure Onset theme incorporated participants’ recollections of the time prior to 
developing heart failure, the symptoms they first noticed, when these occurred and the 




This category included the symptoms participants experienced during the onset and 
progression of their disease.  
 Shortness of breath 
Shortness of breath featured in all participant stories. It was often gradual in onset and was 
only noticed as a problem when it interfered with usual daily activities such as going for the 
bus, gardening or going to the toilet. Initially shortness of breath was put down to being a 
normal part of ageing, trying to ‘do too much’, going up a steep incline, weather, bringing it 
on self by ‘panicking’ or due to another co-morbidity. Participants initially coped with 
symptoms by resting or ‘calming down’ to resolve the breathlessness. 
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"I used to panic and I just couldn’t get any breath…When I sat up, it was okay after a short 
time. I just have to calm myself down because I felt like, am I bringing this on myself by 
getting in a state?" (P5) 
 
Respiratory disorders were blamed for shortness of breath but increases in treatment for 
these conditions didn’t improve symptoms. The degree of breathlessness could be 
significant before the participant thought it was a problem e.g. shortness of breath on 
walking to the toilet a few yards down the hallway or waking up gasping for breath. 
Participants carried on with usual activities despite significant limiting symptoms. 
 
"I was going up the hill at the golf course and I can’t breathe. I couldn’t breathe. It was really 
bad. I should have stopped, but no. I stood there for a while and got myself up again, hit the 
ball again. Out of breath again. I should have stopped, but I didn’t. I kept on going all the 
way around, but I was really getting out of breath." (P7) 
 
 Swollen ankles 
Some participants had swollen ankles while others did not. For those with swollen ankles it 
was or still is a visible persistent reminder that something is wrong.  
 
"...swelling of the feet. Which is still going on as you can see there, I end up like a hobbit by 
the evening." (P4) 
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Ankle swelling caused significant discomfort and morbidity for some while others did not 
have these symptoms and wonder why they were always asked about it. 
 
"I’m suffering badly with very, very swollen feet. If I don’t put them up here all day long, they 
are just horrendous. I can’t get shoes on in the evening." (P11) 
 
For some participants, the swelling was initially put down to vein problems and remained 
untreated while for others medication was used to ‘get rid of fluid’ which meant the ankles 
became less swollen. For those on treatment, slim ankles as an effect of the medication 
became a marker of health.  
 
 Tiredness 
Four participants described tiredness, lethargy or a decrease in energy levels which could 
result in the need for an afternoon nap. For one participant, tiredness was the main 
symptom but was initially put down to being busy. 
 
"I kept feeling really tired and my feet kept swelling an awful lot throughout the day." (P13) 
 
 Lack of symptoms 
Two participants reported a lack of any initial symptoms – one participant had an arrhythmia 
picked up incidentally on ECG while in hospital for another condition and another participant 
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had evidence of a previous heart attack also found on ECG. Cough or mild shortness of 
breath was noticed in retrospect but not thought to be a significant symptom initially. 
 
 Other symptoms 
Two participants recalled episodes of severe chest pain due to heart attack or angina and 
dizziness, occurring in warm weather on holiday or being related to blood pressure 
medication. Pain elsewhere was not a reported feature. 
 
 Symptom improvement 
Several participants reported improvement or resolution of symptoms following diagnosis 
and treatment – this was not a direct part of the interview remit but came up as participants 
told their story.  
 
"They say to me, “Do you sit up in bed at night? Or do you wake up gasping?” I don’t. I’m 
really well, really well; I think they’ve done a marvellous job on me." (P11) 
 
4.4.2 Explanation of Symptoms 
Participants had a variety of explanations for their symptoms including that they were just a 
normal part of life rather than indicative of underlying disease. Participants who normalised 
98 
 
their symptoms often put them down to being a normal part of ageing or blamed 
themselves for over-exertion or ‘doing too much’. 
 
"I just put it down to the fact that [er] I over stretched myself you know. Yeah I was trying to 
do too much. Simple simple as that." (P4) 
 
"I just thought it was probably my age. I don’t think I thought it was the heart to start with, 
no. I just thought that it was because I was walking a long distance and I needed to stop." 
(P6) 
 
Participants also thought symptom onset had occurred, or was perhaps noticed more, when 
they were outside of their usual environment such as away from home staying with family or 
on holiday and this was used as an explanation for the symptoms. Others thought that 
symptoms could be due to their other medications or that they were bringing the symptoms 
on themselves. A stoical approach sometimes prevented participants from taking action to 
deal with their symptoms. 
 
"I thought that’s what it was. I was telling myself, “Well I’ve got to put up with this. It’s the 




One participant just felt ill and didn’t have a particular explanation for why they felt that way 
but assumed that the symptoms would probably resolve with time. 
  
"I didn’t know really, I was mystified, I thought that’s unusual and why is this and it probably 
went on for a couple of months before I went to see the doctor. I thought it would probably 
pass." (P16) 
 
Participant background influenced the explanation and conclusions they came to. One 
participant had a nursing background. Being a retired nurse she thought swollen ankles were 
due to problems with the heart or kidney – if the swelling could be pressed in with a finger 
then it was due to the heart. She did not know exactly what heart problem it was but went 
to the GP several times as she was worried. Her professional background drove her to feel 
there was something wrong. 
 
Participants had comorbidities and sometimes thought their symptoms were due to their 
other medical conditions. One participant with chronic obstructive pulmonary disease 
(COPD) thought his breathlessness was because he needed stronger inhalers. 
 
"I think perhaps my lungs, COPD. I mean this is what I attach to myself, to thinking, I suppose, 
for decades now...So I think I must have concentrated and focused on the COPD when it could 




Most participants had retired but many maintained active social lives which were disrupted 
by the symptoms. One younger participant was working age and thought that tiredness was 
a normal part of her busy lifestyle and job. 
 
"Just tiredness, just my job which is physical really running round wards and stuff." (P13) 
 
4.4.3 Multimorbidity 
Multimorbidity is the presence of more than one chronic disease.23 Heart failure is a disease 
of the elderly and patients often have several medical conditions. The presence, type and 
impact of multimorbidity influenced the participant’s perception of ‘heart failure onset’. 
 
 Cardiovascular co-morbidities 
The presence of other cardiovascular diseases, such as heart attacks and arrhythmias, pre-
dating heart failure onset, was found in some participant stories. Cardiovascular problems 
often spanned decades – for example, P4 (male, age 80) had high blood pressure in the 
1980s, a stroke in 2004 then severe chest pain more recently which was diagnosed as 
angina. Some participants were found to have pre-existing heart problems during 
investigations for heart failure e.g. evidence of a previous heart attack found on ECG of 






The age of participants in the study meant arthritis was common and one participant felt 
arthritis was ‘blamed for everything’. For three participants their main limitation was 
arthritis not heart failure e.g. painful walking, difficulty getting dressed. 
  
"Yeah, maybe slower because of your knees, but not because of your heart." (P14 spouse) 
 
The pain of arthritis was so severe it dominated life for these participants and the resulting 
disability limited daily activities more than any other disease. 
 
"Oh God, I’d never have believed what arthritis is like. You have to have it, to know it. I never 
paid any attention to things like this until now." (P11) 
 
"I mean, my hand, I don't know what will happen when… I hope I’m gone before that hand 
goes like this one because… I mean even when my grandkids were little, opening a bottle of 
pop, they’d say, “I’ll do it granddad,” I couldn’t, absolutely no strength at all." (P16) 
 
For these participants, the presence of arthritis limited their ability to self-manage their 
multiple conditions. For example, one participant needed to lose weight in order to have a 
knee operation, to help with her arthritis, but could not exercise due to pain in her knee. The 
treatment of heart failure also limited the use of arthritis medications. 
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"I suffer from arthritis, but because of this medication they’ve put me on, I can’t have my 
arthritis tablets." (P7) 
 
Participants were also reluctant to push for arthritis treatment due to heart problems. 
 
"No cartilage in this shoulder at all, that’s a bone rubbing job. And I’m taking paracetamol 
for that. And my left hip is a a little bit dodgy. Can’t sleep on it occasionally. I haven’t pressed 
the issue because of [erm] the heart condition." (P3) 
 
Arthritis is a painful and debilitating condition but many participants took a stoical approach 
to their symptoms and had a real determination to ‘get on with it’. 
 
"I mean the arthritis comes and goes and I get a lot of back ache, but you learn to 
accommodate pain. I think you really do, I mean I know it’s going to be painful when I walk, 
and I just try not to think about it and think of other things."(P16) 
 
 Mental Health 
The presence of cardiovascular disease was perceived to have a direct effect on the mental 
health of some participants. One participant described being irritable and short tempered 
following his heart attack but that this gradually improved. There was a determination to 
stay mentally strong despite the physical symptoms and disability caused by heart failure 
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and other medical conditions. But for one participant, his mental health problems were 
more difficult to cope with than his physical health conditions. 
 
"I had my other doctor, before I left to come up to this area, she was, she said, “Oh, I’m really 
impressed how you’ve got over that testicular cancer, you’re marvellous”… I said, “Love, it’s 
nothing compared with mental illness.”" (P8) 
 
He was also concerned that his mental health problems could have impacted on his physical 
health e.g. chronic alcohol use affecting the heart. 
  
 Other conditions 
Chest infections often complicated heart problems and were a source of significant suffering 
for two participants. Amongst those interviewed, many had also experienced multiple other 
conditions from cataracts to testicular cancer, anaemia, oesophageal tear, diverticulitis, 
restless leg syndrome, prostate problems and macular degeneration. Some co-morbidities 
had been unmasked by starting heart medications, for example one participant had an upper 
gastrointestinal bleed after starting anti-platelet therapy for her heart condition. In addition, 
co-existing diseases were sometimes found incidentally during tests for heart problems.  
 
The presence of previously diagnosed conditions sometimes limited treatment options for 
heart problems. One participant (P2) had a significant cerebral haemorrhage in 2002 which 
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led to concerns over the safety of prescribing warfarin following diagnosis of an arrhythmia 
for which anticoagulation was otherwise indicated.  
 
"They were thinning my blood down and they didn’t know whether it was a good thing to do, 
to do that or not but the blood specialist eventually said yes you know, there’s no reason why 
she shouldn’t, shouldn’t have it so that was the deciding factor. Yeah. But I’m awkward 
aren’t I. It’s not just one thing wrong, its several things wrong." (P2) 
 
Some participants experienced severe and life-threatening illness which was not related to 
their cardiovascular disease. 
 
"I still survived having had two brushes with death, I had two years ago pancreatitis which 




The Time category explored participants’ descriptions of the onset of symptoms and how 
they progressed over time, when participants sought medical advice and what prompted 
them to do so. Participants varied in their ability to recall events and the temporal sequence 




 Symptom onset and progression 
Symptom onset timing ranged from gradual onset over a number of years to a sudden event 
which required immediate action. Shortness of breath, ankle swelling and tiredness were 
often described. Participants took symptoms seriously only once they started to affect 
activities of daily living e.g. getting shortness of breath when going for the bus. Symptoms 
were initially put down to other conditions as described above.  
 
"Anyway we lived on a hill and of course I was starting getting breathless, going up this hill to 
the shops or whatever, I started getting breathless and I thought, well this is never right, so it 
went on for a few weeks, and I just went and seen the doctor and he said, “Well I’m going to 
send you for a test...” (P10) 
 
Symptoms often progressed over time. For example, participants noticed their shortness of 
breath gradually impinging on activities of daily living up to quite severe levels where they 
were ‘gasping for breath’ and unable to sleep. One participant called an ambulance after 
realising he had become so unwell. 
 
"I was getting more and more ill…I hadn’t realised it because you have a steady decline…You 





 Decision to seek medical advice 
Most participants were quick to seek medical advice from their GP as soon as they realised 
something was wrong. Initially some did not realise there was anything wrong and hoped 
symptoms would pass, whilst others, with the benefit of hindsight, wished they had gone to 
their doctor sooner and reflected that they had known something was wrong but had not 
sought medical advice, instead wanting to carry on as normal. 
 
"I should have gone to see him. I should have stopped straight away. Knowing what I know 
now, what I’ve been told, I should have stopped and gone straight to see the doctor, but I 
didn’t". (P7) 
 
The prompt to seek medical advice was either symptom severity and/or when there was a 
direct impact on daily life e.g. breathless walking to the bathroom or around the golf course, 
or unable to sleep at night. Others waited until they were seeing their doctor for another 
complaint to raise the issue of their recent symptoms. 
 
 Recall and temporal sequence of events 
In recalling events, participants used time of year – particularly seasons and Christmas – to 
place when things happened. The exact dates of sudden, serious events were recalled most 
easily. Some participants could not recall events particularly when lots of appointments and 
tests occurred over a short time period. The participant’s spouse or partner was often 
helpful in recalling events that they could not remember. 
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Some participants had a complex temporal sequence of events and experienced multiple 
pathologies e.g. heart attack, stroke then developed heart failure. Multiple events often 
occurred over years or even decades and there was usually a significant time lag between an 
initial cardiac event and development of heart failure, with participants experiencing a good 
quality of life in the intervening period. 
 
 “I had about another two heart attacks while I was in hospital… I came back and I went to 
see the heart specialist whatever they said ‘Righto [P1], you can go back to work provided 
you have a light job’ which was no problem and  going back to work and within two days I’d 
had another heart attack. So I was off again then for another few months. And that was 
different, only a mild one. I had another couple of months off and then after that I went back. 
I don’t think I had another day off from work from 1982 right up until 1998” (P1) 
 
Family played an important role within the sequence of events including in decision-making 
such as taking patients to the GP practice or calling an ambulance, as described in the next 
section.  
 
4.5 Interacting with Healthcare Theme 
The second theme of Interacting with Healthcare explores the patient experience from their 
first contact with the health system through the investigative process to the point of 




The logistics category considers the logistical arrangements in the patient journey through 
the diagnostic pathway, including medical interactions in both primary and secondary care.  
 
 Access to General Practice 
GP access was an issue raised by several participants; some had positive experiences of 
accessing healthcare whilst others found access difficult. 
 
"Our surgery is excellent, he really is up there, like we’ve been up here 30 odd years and only 
once have I ever failed to get an appointment on the day I wanted one and they really are 
good. And now you can phone and talk to them if you have a problem. The doctor will talk to 
you…They’re brilliant up there. When my wife was ill, they were absolutely fantastic. I could 
ring up any time and they would be down and I couldn’t have had better service if we were 
paying. They were really fantastic." (P16) 
 
There was an awareness of ‘how the system worked’, e.g. one spouse knew to call just 
before 8.30am to get a same day GP appointment, however this sometimes led to 





Participants were keen to see the same GP. Some identified with a doctor that was ‘their’ 
GP. There was an idea that seeing the same GP meant they did not have to ‘start from the 
beginning’. Many participants spoke favourably of their GP, despite not always being able to 
see them. 
 
"She’s supposed to be my doctor but I can never get to see her because she’s always booked 
up months in advance literally. She’s, she’s always booked up. You never get to see her so [er] 
that’s, that’s disheartening to think that she can’t see, and and I mean she is very good." (P2) 
 
However, in some cases seeing a different GP led to the diagnosis of heart failure being 
considered when it hadn’t been previously. One participant (P3) saw three doctors and only 
on the third occasion was she examined thoroughly and referred for further investigations. 
Another participant was frustrated when treatment was initiated by one GP but she was 
unable to get an appointment to see the same GP for follow-up.  
 
In circumstances where an urgent appointment was needed, participants had usually been 
‘fitted in’ but often with a GP they didn’t know. In one case, the GP queried why the patient 
hadn’t come sooner as they were acutely unwell and the patient said ‘not my fault’ as she 





 Assessment in primary care 
GPs were quick to spot the possibility of heart failure for most participants and arranged for 
further tests (e.g. ECG or blood test) or direct referral to cardiology at the first appointment. 
Two participants were admitted directly from the GP surgery. Delays occurred in two cases 
where the patient was initially treated for an alternative diagnosis e.g. chest infection with 
antibiotics and ankle swelling put down to venous insufficiency. In retrospect both these 
patients felt the diagnosis could have been quicker.  
 
"Well, I mean I could be treated earlier. They had noticed, they had taken notice what I was 
showing them. You know I, I could be treated earlier. Then I think I could have gone into 
cardiac arrest and nearly die because they take so long." (P3)  
 
 Emergency care 
Many participants praised the speed of response of ambulance services to emergencies in 
the past – heart attack or stroke – and to more recent acute onset symptoms of heart 
failure. The spouse or partner, rather than the patient themselves, often called the 
ambulance and were comforted by their response. Most participants had needed to use an 




"I phoned the paramedics. I said he couldn’t breathe, he couldn’t get his breath properly and 
they said, “We’ll come along.” This was on a Sunday morning and they were extremely 
good…they were so kind". (P6 spouse) 
 
 Assessment in secondary care 
Participants in the study were all under the care of one heart failure service. Initial diagnostic 
appointments took place in the main hospital heart failure clinic and follow-up was at 
community heart failure clinics located either at the main hospital or at peripheral sites.  
 
Some participants felt that outpatient appointments in secondary care were rushed and 
impersonal. Specialists did not introduce themselves and their directness was difficult to 
manage for some patients.  
 
"I think appointments telling you more about your particular problem. I realise their hurry 
and it seems like they want to get you out because the next person’s waiting to come in…” 
(P2) 
 
"Just how impersonal the personnel were when I went in for my heart examination. That 
could be improved immensely. It wouldn’t have hurt them to have become a little human and 
thought a little bit about the... just the diagnosis and “There you are.”.  There’s a better way 
of dealing with somebody than that. Not difficult to do." (P6) 
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The systems in secondary care also seemed illogical to participants at times e.g. long waits 
for x-ray due to inpatients taking priority. The burden of the number of appointments 
participants needed to attend and different locations was confusing and meant it was 
difficult to plan life. There were also some good experiences with one example where the 
participant had been seen, had a heart scan done and was then reviewed by the specialist all 
within one appointment. 
 
 Waiting and consequences 
Two participants with ischaemic heart disease and valve disease had long waits for 
operations. One of these participants had become more acutely unwell and was advised to 
call an ambulance but he did not want to be seen as ‘jumping the queue’. He was admitted 
as an emergency and subsequently had surgery at a different hospital with a successful 
outcome. 
 
The other participant (P10) had a coronary artery bypass graft (CABG) operation cancelled 
four times, with no cardiac medications commenced in the interim, then the surgeon said he 
was unable to do the procedure as the patient had developed heart failure and become too 
unwell. This was an unusual case with poor patient experience throughout. The participant’s 
wife was concerned about the perceived poor care her husband had received and felt there 
should be other options and had heard about ‘stenting the artery’ being a possibility when 
bypass surgery was not feasible. She spoke to the surgeon’s secretary to ask if this was an 
option and the secretary arranged an appointment for a second opinion from a cardiologist. 
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The patient subsequently had 5 stents inserted by the cardiologist and made a good 
recovery.  
 
"Now this took 12 months for all this to come out. Why didn’t they pick that up straight 
away? Why didn’t they treat him on some sort of medication to stop anything happening? I 
mean, his heart is damaged..." (P10) 
 
For some participants, once they were in hospital and the surgery had been performed, 
there was a further delay in discharge. One participant suggested a possible solution for his 
own discharge was a step-down bed in the local community hospital where he had been 
previously and this was subsequently arranged by the ward. 
 
 Follow-up 
Participants were often followed up in heart failure clinics after receiving a diagnosis of heart 
failure or a hospital admission and found locations of the clinics were closer to home which 
made appointments easier to attend. Participants described the process during the clinic, 
including pulse and blood pressure checks, but the purpose of the clinic visits wasn’t always 






This category considered decision-making along the diagnostic pathway, including the 
decision to seek help and medical interactions in both primary and secondary care.  
 
 Decision by patient to see GP 
As described in the Heart Failure Onset theme, participants often had symptoms that had 
been present for weeks, months or longer, and had sometimes become severe before they 
made the decision to see their GP. Patients sometimes found it difficult to recall the exact 
timeframe between symptom onset and seeking help. The decision to seek help was often 
based on symptoms having an impact on activities of daily living. Once participants realised 
there was a problem, most made contact with the GP as soon as possible.  
 
 Initial GP appointment 
Two participants were on holiday or staying with family when symptoms first occurred. One 
participant got in touch with the GP as soon as they got back home. The other participant 
became suddenly breathless while staying with his daughter in Australia. His daughter took 
him to her own GP the same day and, following an ECG at the practice, he was admitted 




Participants perceived that GPs realised there was something wrong, including the possibility 
of heart failure, in the first consultation in most cases and arranged tests or admitted the 
patient directly to hospital. For one participant, the GP expressed concern that she had not 
sought medical help sooner.  
 
"We’re going back two and a half years. I had a bad coughing fit, so I went to the doctor. She 
put me onto the hospital and everything started from there...Yes, I went for the cough. She 
was a new doctor then. She’d just come into general practice...Yeah, she looked at me, 
listened to me, sounded me out and said, “You’re going to hospital.”" (P9) 
 
Two participants were initially treated for other conditions before heart failure was 
considered a possibility. Both of these participants felt they should have been assessed more 
thoroughly and diagnosed sooner, and felt let down by the first doctors they had seen.  
 
"The lady that, at my own practice, the lady she was very thorough. She, she sort of, she did 
blood tests and so on [erm] but she [erm] as I say she examined me you know with a 
stethoscope for a long time and she must have noticed that there was something wrong. But 
other doctors had, had, had, had examined me on, on very few occasions ‘cause they don’t 





 Referral to Secondary Care 
Participants were referred promptly to secondary care by their GP in most cases. Some 
patients were admitted directly to hospital but in less acute cases, tests such as ECG or blood 
tests were done at the GP surgery prior to referral. This process was usually carried out 
quickly, for one participant in less than a week. Even in cases where the patient felt there 
had been a delay, referral to a cardiologist was usually done by the third or fourth 
appointment for those who could recall the consultations in detail, and often followed a 
blood test. Delays did not occur over months for any of the participants in this study.  
 
One GP diagnosed heart failure based on the blood test result alone and informed the 
patient of the diagnosis at the time of referral. Other GPs did not offer a possible diagnosis 
but used more vague language of ‘sending to a cardiologist’ or ‘I think we’ll get some 
cardiology checks’. 
 
"It came back, I mean it came back didn’t it and then he told us that he had got heart failure. 
I’ll refer you to heart failure clinic at Hospital X. Then you had an appointment come through 
then quite quickly." (P1 spouse) 
 
GPs generally stayed within their competence and remit and did not offer a definitive 
diagnosis or prognosis estimates until the patient had been seen by a specialist and the 
diagnosis of heart failure had been confirmed.  
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"You wonder how long you’ve got to live really. You know, and like I said to the GP who 
came, I said, “Is it very severe?” “Well, all heart problems are severe,” he said, “To a lesser or 
greater degree, but I’ll refer you to the hospital and see your heart specialist in the hospital,” 
and that’s when I met Dr X (cardiologist)." (P16) 
 
 Experience of secondary care 
The patient experience of secondary care was a mix of positive and negative accounts. Some 
participants had a very positive experience of having an appointment and scan done quickly 
and the process explained. There was particular affection and admiration for consultants 
involved in key events such as performing heart bypass operations. However, some 
participants felt appointments were rushed and their expectation was that this would always 
be the case. One participant was surprised when the consultant listened and answered her 
queries. 
 
"…because sometimes with Dr X he is a bit quick too… because he’s so busy to get you out the 
door and then I’ll come out and think, oh I wish I had asked that… 
…No but I thought he was just going to sort of laugh me out the door almost but he really did 
take a lot of time to go through everything with me which was really nice I thought. I thought 




Several participants described an impersonal approach in cardiology clinic with no-one 
introducing themselves and a general lack of empathy.  
 
"He didn’t give a name. He didn’t say, “I’m a so and so”. All he said was that I’ve got a weak 
heart. I said, “What would happen if something... I needed to come in, what treatments?” He 
said none. There’d be no treatment if I came in. So I thought “Well, what a happy day!” (P6) 
 
Some participants expressed a desire for more information, tailored to their particular case 
and often felt they did not receive adequate information during the consultation. 
Participants also felt they were not involved in clinical decision-making and there was a lack 
of time to ask questions. There were also examples of good patient experience where a 
direct approach to risk had helped informed decision making. 
 
"I said, “Well my attitude is if it’s wrong, fix it if it’s at all possible”…I saw Mr X early in 
February and he said he would do it, warned me I could die but that’s standard practice but 
he said 90% survive so I thought it was worth going ahead so did he." (P15) 
 
 The Role of Heart Failure Nurses 
Heart failure nurses played an important ongoing role in the care of heart failure patients. 
One participant was seen prior to discharge and given an explanation of ongoing care 
arrangements. Some appointments with the heart failure nurse were for initiation or 
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uptitration of heart failure medications whereas others were for monitoring of pulse, weight 
and blood pressure only. A blood test was often taken for monitoring the effect of 
medication e.g. the impact of ACE inhibitors on renal function. 
 
"I have seen a heart failure nurse, I was under the heart failure nurses till all my medication 
was sorted out and I can ring them at any point I want as well, chat to them.” (P13) 
 
Some participants seemed less clear on the purpose of these routine appointments, one 
participant questioning why this could not be done at their local surgery. 
 
"…they’ve monitored my weight. That was about it really. It was [er] one way [pause] just my 
pure thoughts here, it was a bit of a waste of time going there when I could have gone to my 
own doctor just to check my blood pressure sort of thing but they were only doing their best 
for me so I take it as it comes in that situation." (P4) 
 
The heart failure clinics are situated in different geographical locations around the area and 
participants generally preferred those closer to home for convenience.  
 
 Ongoing GP relationship 
Participants identified with their GP and described a familiarity with their doctor and the 
practice, often over a period of time. Their main frustration was being able to get an 
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appointment with their ‘usual doctor’ as they were often booked up for months in advance 
although some participants were pleasantly surprised by the performance of the doctor they 
knew less well.  
 
GPs played a role in co-ordinating care and providing a stable longitudinal relationship with 
the participants who often went in and out of the secondary care system. GPs had a role in 
prescribing and adjusting heart failure medications, on the advice of the cardiologists. In one 
case, target medication doses suggested by the specialist were not achievable in reality as 
the patient could not tolerate the higher dose which led to low blood pressure. His GP wrote 
back to the cardiologist as part of an ongoing dialogue to ensure coordinated care. 
 
"So that’s where I’ve been going backwards and forwards from the GP to Dr X and that’s 
when they started talking about having something because it was getting dangerous with 
the low blood pressure." (P13) 
 
The GP had knowledge of the patients overall health and their past medical history. The 
cardiologist suggested addition of an ACE inhibitor for one participant (P15) but his GP 
reviewed his notes first and found cough on ramipril in the past so initiated an alternative 




4.6 Heart Failure Diagnosis – Delivery and Impact Theme 
4.6.1 Explanation of Diagnosis and Cause 
This category examined the explanation of heart failure diagnosis from the participant’s own 
perspective and what they recall being told by their GP and specialists. It also explores the 
causes of heart failure. 
 
 Patient own explanation 
Patient explanations were varied in complexity and depth. Some simply described having a 
‘weak heart’ or ‘not getting enough oxygen in my blood to have the energy to push myself’ 
while others had a detailed description in their mind. Participant education and background 
influenced their understanding and sense-making of the diagnosis.  
 
One participant had seen a cardiologist, attended the nurse-led heart failure clinic and had 
responded to take part in the heart failure study but, even on direct questioning during the 
interview, did not realise that he had heart failure. Conversely, two participants were 
engineers by background and appeared to have a detailed understanding of the disease 
process by thinking of heart failure in mechanical terms. 
 
"…it’s a pump system isn’t it that’s all it is, it’s a pump system. You’ve got the power of the 
pump, you’ve got the pipework going round, and the various sizes of the pipework. And if you 
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increase the size of the pipework, the pump will bang it round very easily but if the pipework 
gets constricted in any way then the pressure will go up. There [is] an easy hydraulic 
relationship with that…” (P4) 
 
Some participants actively sought extra knowledge about the diagnosis by looking online or 
in textbooks whilst others preferred to avoid knowing too much. 
 
"I didn’t bother to go too deeply into it, you know knowledge can kill you, the wrong kind of 
knowledge, or half knowledge" (P8) 
 
One participant was still working and found she needed an explanation for her condition 
which she could tell work colleagues to account for why she gets so tired. 
 
 “I just tell them it’s a heredity thing, I’ve got a bit of heart failure and I get more tired than 
what you do. As I said it’s probably being twice as tired and working twice as hard as what 
they do". (P13) 
 
There was considerable fear associated with the term heart failure for many participants. An 





"Well I mean heart failure means, when they [say] heart failure it means your heart’s going 
to, it’s wearing out or whatever, it’s going to stop. It could stop. It’s failing. And I know 
you’ve only got one so I mean let’s face it that’s not a good thing." (P2) 
 
"I’d been told that the valves were not operating properly and they told me the result was a 
reflux and I was… I would often wake up very conscious of this going on in my chest. Knowing 
what it was I could imagine blood not just going through and then shutting off but coming 
back again and sort of regurgitating inside the heart." (P15) 
 
 Medical professional explanation 
Secondary care specialists, usually cardiologists, were responsible for giving the diagnosis to 
most participants. GPs were involved in initial investigation of the problem and referral for a 
definitive diagnosis but did not explain in detail what heart failure was as the diagnosis was 
not confirmed. Breaking bad news was not handled well in some cases with a lack of 
ascertainment of what they already knew, signposting or empathic delivery described by 
several participants. There were examples of participants being left shocked by the mode of 
delivery of the bad news as well as the diagnosis itself. There was a need for more time and 
space to explore and understand the problem.  
 
"Just how impersonal the personnel were when I went in for my heart examination. That 
could be improved immensely. It wouldn’t have hurt them to have become a little human and 
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thought a little bit about the... just the diagnosis and “There you are”.  There’s a better way 
of dealing with somebody than that. Not difficult to do." (P6) 
 
For some participants the explanation was proportionate and appropriate, delivering the 
news of heart failure gradually and initially avoiding use of the term. 
 
P13: "It was very good, I mean he says, it’s just a degree of heart failure. They actually didn’t 
use those words for a long time to me, he just said… he told me it was a left valve that wasn’t 
pumping properly. It should pump at so much percentage and it was pumping at a lesser 
percentage and that’s why you’re feeling tired because it’s having to work harder. You’re 
working twice as hard as you should be, he says, that’s why you feel tired. He explained to 
me quite well..." (P13) 
 
"No it was all explained to me very well and I had visions of valves going like this so I got a 
clear picture of what was going on inside my heart". (P15) 
 
The explanations of the term ‘heart failure’ offered by medical professionals were 
sometimes clear as described above but in some cases medical jargon led to a lack of 
understanding although some participants preferred to take a stance of ‘not wanting to 




"They tried, but they used so much jargon, I didn’t understand. I didn’t want to know too 
much, anyway. But I saw what was written down and was able to translate that…They say 
my left ventricle is not working fully. They don’t say why...The last thing I do is worry. There’s 
a hospital full of doctors. Let them do it." (P9) 
 
 Causation 
None of the participants had thought that previous cardiac events had led to heart failure 
prior to receiving their diagnosis. However, when they were told they had heart failure some 
participants suggested their own reasons for why they had developed the condition whilst 
others recalled being given a particular explanation by the specialists.  
 
"But a part of my heart is damaged, he says, which is caused by a heart attack I suppose". 
(P10) 
 
One participant blamed himself for ‘over doing it’ and was convinced his heart failure had 
been brought on by his own behaviour. 
 
"I think this is one of the reasons I’ve, over the years, probably just wore myself out...I’m just 




 Heart failure terminology 
Many different ways to describe heart failure were used by participants and specialists. The 
term itself was often associated with fear and a concern that the heart may stop or that 
outlook was poor. Participants developed strategies to cope with this as time went on. 
 
"It was worrying I mean you know when they tell you that your heart’s not working properly 
and they call it ‘heart failure’, whatever’s wrong with your heart they call it heart failure 
don’t they which I think is horrible because failure means it could stop you know. That’s 
worrying but the longer you live with it, the more you get used to it". (P2) 
 
There was some confusion over ejection fraction terminology and what that meant – if 
ejection fraction was 20%, for example, one participant assumed that meant only 20% of 
their heart was working and were not aware that a normal ejection fraction is 50% or above.  
 
4.6.2 Impact on Life and Current Health State 
These categories captured participant views of the impact that a heart failure diagnosis had 






 Activities of daily living/physical activity 
Symptoms which affected activities of daily living were often the reason participants first 
sought medical advice. Until then, symptoms had often been ignored until they had a 
significant impact on day to day life such as shortness of breath on walking to the bathroom 
or being unable to mow the whole lawn as usual. Once the diagnosis had been confirmed, 
participants adapted to cope with the limitations of their illness e.g. wife cuts the grass or 
have carer to help. Some participants and their spouses reflected on the comparative 
difference in activity levels between themselves since the participant had become unwell. 
 
“So you do some exercise because we’re out shopping. But you’re not out and about all the 
time like I am. You go so far, and then as I say, by lunchtime, that’s it. It’s enough, really." (P9 
spouse) 
 
For some participants, the limitation of their symptoms meant they had to stop and rest 
when necessary. Although others found diagnosis and treatment had meant they were able 
to ‘get back to normal’ and were sometimes fitter than their peers. 
 
"All my mates say the same. They go play golf this morning, they go home and they won’t do 





Some participants described remarkable recoveries following episodes of severe or life-
threatening illness. 
 
"I was able to tell him [surgeon] that the weekend before I’d walked a couple of miles again. 
He expressed surprise...so he said I don’t need to see you again which was music to my ears." 
(P15)  
 
The provision of cardiac rehabilitation at the hospital following surgery helped some 
participants in their recovery. 
 
"the [hospital] do a good thing they invited me to go for exercises for a period of eight 
sessions and I’ve got my last one next week." (P15) 
 
 Patient adaptability 
At the time of recruitment, participants had been diagnosed with heart failure within the 
past 12 months. During interview participants talked about how they were coping and 
adapting to their new diagnosis. 
 
"I’ve been all right. I’ve been coping quite well. You know, you take one day. Sometimes 
you’re better than others. You feel more spritely some days than others. Oh, well, we are all 
right. We’re survivors, aren’t we?" (P6) 
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Participants had generally learnt to cope with their new circumstances. But doing activities 
at the edge of their limits could be a reminder that they were not completely back to their 
previous self e.g. one participant planned to start line dancing classes run by the hospital, 
but recently walked up a steep hill in town and needed to sit down when he got to the top 
so acknowledged he was 'still not 100%'. The determination to ‘get out every day’, despite 
some limitation, was important to one participant. 
 
"The bus is… we go through a gully we call it there, but I just get through that gully and turn 
the corner and then I start… my breath starts to go…I just keep taking the medication and, as 
I say, it enables me to get out every day…” (P16) 
 
Participants described the ‘work’ and routine of attending frequent hospital appointments 
became ‘the norm’ after a while. 
 
"It’s a strange sort of thing, you almost get used to this way of life, as you say, going from 
nothing, from no tablets and nothing really, to all of a sudden this took off. You hit this wall, 
don’t you, of medication and tablets and everything." (P9) 
 




"I think since I’ve realised what it was you see I can address it more because I think it was 
there before for a few years but I didn’t know what it was, I didn’t know what was happening 
really." (P13) 
 
Adaptations were physical as well as psychological and included physical alterations to the 
home, stopping driving, getting help from a carer or limiting travel.  
 
4.6.3 Outlook 
This category explored participant views on outlook following their diagnosis of heart failure. 
Participants were very aware of their own mortality and many described episodes of acute 
illness where they had ‘brushes with death’. There were also amazing stories of recovery, 
sometimes following major surgery or a long hospital stay, with participants able to get back 
to a good quality of life.  
 
"How I survived that heaven knows. I didn’t realise at the time but my wife stayed overnight 
because mostly it was touch and go whether I would make it through the night." (P12) 
 
Participants reflected on the death of peers and the age that other family members passed 
away. Operative risk meant some participants were refused surgery and risk of death had 
been discussed in detail. A fear of death was often present when participants were acutely 
unwell or didn’t know what was causing their symptoms. Prognosis, in terms of survival 
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rates, was not discussed in any great detail. Some participants questioned the value of 
knowing information of this type. 
 
"I mean how bad does it get before you, is it a good thing to know [laughs] is it a good thing 
to know that that your heart is getting worse or, you know, or improving a bit, I don’t know. 
[pause] I really don’t know." (P2)  
 
Discussions about survival rates, long term planning and Do Not Attempt Resuscitation 
(DNAR) were overall lacking and had not been addressed during medical interactions. 
 
"I think it’s always in the back of your mind that you worrying that you’re going to get worse 
as well…I just think well there’s no cure, there’s no actual cure for heart failure, there’s no 
cure. It’s one of those things but there’s a lot of preventions and stuff but is that going to be 
[my] downfall? You do think that but there you go." (P13) 
 
4.7 Summary of the Chapter 
This chapter presented the key findings of the qualitative study of patient experiences of the 
diagnostic pathway for heart failure in primary care. Three key themes emerged – Heart 
Failure Onset, Interacting with Healthcare and Diagnosis Delivery and Impact – and were 
explored along with verbatim quotes from interviews. The next chapter summarises the 
findings, discusses them in relation to the literature and makes some key recommendations.  
132 
 
5. PATIENT EXPERIENCE OF HEART FAILURE DIAGNOSIS: DISCUSSION 
 
5.1 Chapter Overview 
The findings of the study in Chapter 4 highlight important behaviours and processes which 
could be modified to improve the experience of patients with heart failure. This chapter 
explores emerging concepts from the key findings, compares with the existing literature and 
gives key recommendations, policy implications and suggestions for further research.  
 
5.2 Heart Failure Onset Theme  
5.2.1 Emerging Concepts and Comparison with Existing Literature 
The emerging concepts from the Heart Failure Onset theme include symptom explanation 
and normalisation, symptom type and onset, symptom awareness, complexity and 
multimorbidity and facilitators of help-seeking. These concepts are discussed in relation to 
the existing literature and theories.  
 
Symptom explanation and normalisation 
Participants in the study did not realise initially that the symptoms of breathlessness, ankle 
swelling or tiredness were due to heart failure. Instead they thought their symptoms were 
due to normal ageing, ‘doing too much’, other medical conditions and medications or just 
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assumed that they would pass. Studies looking into decision-making at the onset of other 
chronic medical conditions have also found a similar phenomenon. McCabe et al interviewed 
patients with a recent diagnosis of atrial fibrillation (AF) to explore their experience of 
symptom onset; most participants had initially ‘misinterpreted’ their AF symptoms and had 
attributed them to ageing, excess work demands, physical deconditioning or stress and had 
dismissed them as ‘not important’.126  
 
Normalisation of symptoms is a common sociological phenomenon and a barrier to diagnosis 
in other medical conditions, such as dementia where ‘forgetfulness’ is initially seen as a 
normal part of ageing.127 The presence of symptoms in the general population is common 
which might explain why ‘normalising’ prevalent symptoms such as fatigue or breathlessness 
is so widespread. A study by Petrie et al examined the prevalence of symptoms in a 
randomly selected sample of 1,000 participants from the general population.107 Researchers 
asked participants if they had experienced any of a list of 46 symptoms in the previous 7 
days. Thirteen percent had experienced shortness of breath and 36% had experienced 
fatigue. The challenge therefore is to enable patients to identify symptoms which are 







Symptom type and onset 
Participants experienced symptoms including shortness of breath, ankle swelling, fatigue 
and dizziness which were gradual in onset. Symptoms were often severe, and had an impact 
on activities of daily living, before participants sought medical help.  
 
A narrative review by Gravely-Witte et al explored the length of delay in seeking medical 
care for heart failure patients - admitted to hospital rather than presenting to primary care - 
according to symptom type and onset.128 Participants who suddenly developed shortness of 
breath were less likely to delay seeking help than those with symptoms of more gradual 
onset such as ankle swelling or fatigue. In this review most patients already had a diagnosis 
of heart failure and the delay was the time between symptom onset and admission to 
hospital which ranged from 2 hours to 7 days. This differs from the current study which 
examined the diagnostic pathway for patients referred from primary care. The community 
population with new onset chronic heart failure is likely to differ from the population with 
existing heart failure experiencing an exacerbation which requires hospital admission, 
however the impact of symptom type on delay in seeking medical help within primary care is 
worthy of further consideration in future research.  
 
The concept of ‘biographical disruption’ was first described by Bury in the 1980s. He 
interviewed patients with a new diagnosis of rheumatoid arthritis and found that the 
symptoms, and ultimately label of disease, had a profound effect on the patient’s social 
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world and their sense of self.129 In the interviews with heart failure patients, participants 
reflected that their whole world changed at the point where they realised something was 
wrong and sought medical help.  
 
Symptom awareness 
A delay in seeking help has also been found for other cardiovascular conditions like stroke 
and heart attack. Patients with an acute stroke most commonly experience a sudden onset 
of symptoms with one-sided weakness, speech disturbance or facial asymmetry; early 
intervention can be lifesaving but patients do not always seek immediate medical attention. 
Mackintosh et al conducted a qualitative interview study to try to understand what factors 
might be involved in the delay and found that some patients did not know the symptoms of 
stroke and others did not appreciate the importance of seeking medical help urgently.67 In 
addition to lack of knowledge, patients described a fear of stroke or hospital admission and a 
subsequent denial which prevented them from seeking help immediately. Witnesses, who 
were most often family, played a key role in recognising stroke symptoms and taking action 
to access medical services.68  
 
Similarly, patients with acute myocardial infarction, or heart attack, often experience a 
sudden onset of symptoms - usually crushing central chest pain - but may delay getting help. 
Henriksson et al conducted focus groups with patients and their relatives to explore their 
thought processes when symptoms of acute myocardial infarction occurred.69 Patients felt 
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uncertain about the cause of their symptoms, often assuming they were due to something 
less serious, and tried various methods to alleviate symptoms prior to seeking help. Relatives 
played a vital role and were usually more concerned than the patient themselves, 
encouraging them to take further action such as calling an ambulance.  
 
Complexity and multimorbidity 
Many participants in this heart failure study had a history of previous cardiovascular disease 
and had multiple past contacts with healthcare. Epidemiological evidence shows that 
patients who have had a previous myocardial infarction are more likely to develop heart 
failure than those who have not had a previous event.25 Yet participants were initially 
unaware that their symptoms could be due to heart failure.  
 
Multimorbidity increases with age and the participants in this study were in the older age 
group (median age 78.5 years). Conditions such as arthritis were common and contributed to 
poor quality of life; indeed symptoms from other diseases in some cases overshadowed 
those due to heart failure. Participants also attributed their symptoms to side effects of 
medications which added to complexity and influenced their help-seeking behaviour. The 
management of chronic conditions, often according to single disease guidelines, can result in 
older patients taking a large number of medicines, but with a lower likelihood of receiving 
optimal therapy for specific conditions such as heart failure.130 More research is required to 
examine the impact on patient outcomes including those with a heart failure diagnosis.131   
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Facilitators of help-seeking 
Symptom worsening, effect on activities of daily living and family concern were all reasons 
for participants in the study to see their GP. A qualitative synthesis by Smith et al, exploring 
patients’ help-seeking experiences and delay in cancer presentation, found remarkable 
similarities in their list of triggers to recognition of illness which included “symptoms worsen 
or do not go away”, “symptoms affect everyday life” and “discussion of symptoms with 
friends and family”.132 Other triggers which were not found in the current study were 
“specific well-known symptoms (e.g. lump)” and “knowledge of cancer symptoms and 
awareness of risk”. These concepts were notably absent from all of the interviews in the 
heart failure study suggesting awareness of heart failure symptoms is much less than for 
cancer symptoms in the general population. 
 
5.2.2 Recommendations, Policy Implications and Further Research 
Participants developed plausible explanations for their symptoms which delayed their 
presentation to primary care. Increased awareness of heart failure symptoms is vital for 
patients, carers and the public to recognise the condition. Campaigns by government and 
charities have raised awareness of the symptoms of several different cancers with the 
prospect of earlier diagnosis leading to better outcomes.133 A similar campaign at a national 
level, or a more targeted campaign aimed at those with a previous history of myocardial 




Participants who had previous cardiac events were unaware of the possibility of developing 
heart failure and therefore did not recognise the onset of symptoms yet they interacted with 
medical services frequently through cardiac rehabilitation and primary care follow-up. 
Tailored education, perhaps during cardiac rehabilitation following a heart attack, could help 
to raise awareness in this particularly at risk population.134 In addition, patients with a 
history of coronary artery disease are reviewed annually as part of the QOF. This provides an 
opportunity to assess these at risk patients for evidence of heart failure by asking a 
screening question such as ‘do you feel breathless, tired or do your ankles swell?’ and/or 
carry out a blood test for elevated natriuretic peptides. Further research is required to 
determine if these approaches would be cost-effective. 
 
Alternatively, as participants did not recognise their symptoms as important, so did not 
present to medical services for some time after symptom onset, screening may help to 
identify heart failure in the non-presenting community population; this potential approach is 
considered in more detail in Chapter 7. 
 
Heart failure is a syndrome that results from acute and/or sustained insults to the heart. 
Primary and secondary prevention strategies are important to stop or slow progression to 
heart failure. Increasing patient awareness of cardiovascular risk factors and prompt action 
in the event of a myocardial infarction could help limit cardiac damage and prevent the 
development of heart failure.135 
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5.3 Interactions with Healthcare Theme 
5.3.1 Emerging Concepts and Comparison with Existing Literature 
The emerging concepts in the healthcare interactions theme included access to healthcare, 
diagnostic uncertainty, continuity of care in general practice, communication in secondary 
care and the role of generalism. 
 
Access to Healthcare 
GP access and continuity was a source of frustration for patients in the study, although 
examples of good access arrangements were also described. The difficulties in GP access 
have been documented for some years and have been more widely recognised recently.136 
The Royal College of General Practitioners (RCGP) has described general practice as 
underfunded and overstretched meaning patients can struggle to get a GP appointment.137 
General practice undertakes 90% of healthcare interactions but has less than 10% of the NHS 
budget.138 Some patients in the study were affected by lack of GP appointments and this 
represented a delay in their diagnostic pathway. 
 
The first contact with the GP often initiated a cascade of tests, appointments and 
treatments. Realising something was wrong and attending the GP surgery, then hospital 
clinics, participants adopted the ‘sick role’ originally identified by Talcott Parsons.139 
Participants were often off work and spouse and family became more involved in daily 
activities. There were several examples where a close relative was instrumental in initially 
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accessing healthcare – in one case, for example, the spouse of the participant had called an 
ambulance after realising he had become so unwell.  
 
Diagnostic uncertainty 
When seen by the GP, care was usually thorough and prompt with further tests or referral 
arranged within 1-2 appointments. In cases where the diagnosis of heart failure was 
‘delayed’, a differential diagnosis (e.g. chest infection) was considered first. All patients in 
this study who could recall their diagnostic pathway in detail were usually referred by their 
third or fourth GP appointment and delays did not occur over months. 
 
The symptoms of heart failure can overlap with other medical conditions which can make 
the diagnosis challenging.140 Symptoms such as shortness of breath may be caused by a wide 
range of conditions other than heart failure such as COPD, chest infection, anxiety and 
muscle disorders.21 Point of care testing can help to differentiate the causes of shortness of 
breath. Natriuretic peptides are significantly elevated in patients with heart failure and can 
be measured through a blood test to support clinicians in deciding which patients require 






Continuity of care in general practice 
Patients wanted to see the same GP, ideally the person they identified as ‘their GP’, over 
time. The value of continuity of care has been previously described; seeing the same doctor 
and forming a ‘therapeutic relationship’ can improve both patient safety and outcomes.142  
However, in two cases, being seen by a different GP led to the alternative diagnosis of heart 
failure being considered, tests arranged and referral to secondary care.  
 
Whilst the literature strongly supports the ideology that continuity of care remains valuable 
in the care of patients with chronic conditions, some recent evidence has suggested that 
seeing a different doctor during the early stages of the disease can be beneficial in some 
circumstances. The effect of continuity of care in the diagnostic pathway for cancer was 
investigated by Ridd et al using electronic medical records.143 Continuity – seeing the same 
doctor at each consultation – in the 12 months prior to the index consultation was found to 
be associated with later diagnosis for colorectal and lung cancer. The authors suggest that 
familiarity could mean that symptoms are put down to pre-existing diagnoses rather than a 
new disease process.  
 
Communication in secondary care 
Participants tended to spend more time in, and have more contact with, secondary care 
during the diagnostic process and their experiences were mixed. The approach of some 
secondary care staff was impersonal and led to poor patient satisfaction. Participants felt 
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less connection with the secondary care team compared with their general practice. The role 
of heart failure nurses was unclear to some patients.  
 
Secondary care interventions were also associated with long waiting times. Some patients 
required cardiac surgery or interventional cardiology procedures and in one case, the 
surgery was cancelled four times, with little communication in the interim; and the patient 
subsequently became too unwell to have the procedure. The issue of safe and 
compassionate care was highlighted in the public enquiry into the Mid Staffordshire NHS 
Foundation Trust where hundreds of patients died unnecessarily due to poor quality care. 
The report found failings in communication and compassion in all areas and made 
recommendations to prevent this situation reoccurring within the NHS.144 The importance of 
communication skills remains a priority in NHS Trusts and specialty training programmes.  
 
The role of generalism 
 The place of generalism was explored by the Commission on Generalism in their report 
‘Guiding Patients Through Complexity: Modern Medical Generalism’ which was published in 
October 2011.145  The Commission reflected on the rise of specialisation within healthcare 
services whilst the population they serve is becoming older with multiple co-existing 
conditions. The report highlighted the need for generalists – clinicians who deal with the 
whole person, including multiple conditions and within their social context, presenting with 
often undifferentiated illness. 
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5.3.2 Recommendations, Policy Implications and Further Research 
The healthcare system is under considerable strain and general practice was a key entry 
point to the diagnostic pathway for most patients. Improved access to general practice 
through increasing the number of GP appointments would facilitate patients being seen 
more easily and quickly but would require recruitment and retention of more GPs. The RCGP 
have estimated that 8,000 more GPs are needed in England by 2020146 to meet the current 
patient demand and in response, the government have committed to work towards 
increasing GP numbers through increasing training numbers, recruitment campaigns and 
initiatives to improve retention of the existing workforce.147 
 
When the participant was able to see the GP, the care was usually good but in two cases, a 
different diagnosis was considered before heart failure. Availability of point of care testing to 
measure natriuretic peptide level within the practice may help differentiate the cause of 
symptoms for some patients. Further research is required to prove the cost-effectiveness of 
this option.148 
 
There is a need for a compassionate, patient-centred approach in secondary care. The 
‘Hellomynameis…’ campaign in hospitals is helping to improve communication skills of 
secondary care staff and help patients feel more at ease by knowing the name of the person 
responsible for their care.149 Clinicians should explain key parts of the diagnostic pathway, 
including what tests are required and why, and patients should have time and opportunity to 
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ask questions. The need for generalist care within general practice and hospitals is crucial for 
patients with multiple co-morbidities including heart failure. More emphasis on generalism, 
and training in generalist skills, within secondary care would improve the holistic care of 
these complex patients. 
 
5.4 Heart Failure Diagnosis - Delivery and Impact Theme 
5.4.1 Emerging Concepts and Comparison with Existing Literature 
The emerging concepts in the Heart Failure Diagnosis theme included ‘heart failure’ as a 
term, diagnostic delivery and understanding, and adaptation and optimising function. 
  
‘Heart Failure’ as a term 
Participants understanding of ‘heart failure’ as a term varied. Some participants could 
describe the mechanisms of heart failure, in terms of a failing pump system, and relate this 
to previous heart damage whereas other participants chose not to consider the diagnosis in 
considerable detail. One participant in the study did not even know that he had heart failure. 
 
The nomenclature used around heart failure is complex and does not perhaps accurately 
describe the pathological processes involved in deterioration of cardiac function.150 In recent 
years the emergence of a new type of heart failure where the ejection fraction is within 
normal limits – heart failure with preserved ejection (HFPEF) – has led to debate about the 
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classification which should be used by specialists for consistency.151 In guidelines, there has 
been an emphasis on publishing precise definitions required for heart failure diagnosis and 
there has also been a suggestion by some authors to ‘stage’ the disease in a similar way to 
cancer.152 But for patients the term ‘heart failure’ itself is associated with fear and 
uncertainty. There is little research on the impact of the terminology used in heart failure 
and a change in the name to a less frightening and better descriptive term may be helpful for 
patients and clinicians. 
 
Diagnostic delivery and understanding 
In this study, 15 out of the 16 participants were told they had a diagnosis of heart failure 
within secondary care. Across Europe the place of diagnosis varies between countries. Hobbs 
et al interviewed 1363 primary care physicians from 14 European countries and reviewed 
11,062 patient notes and found that overall 50% of heart failure diagnoses were made in 
primary care.153  
 
Some participants were satisfied with the explanations they had received but for others the 
appointment where they had been told they had a diagnosis of heart failure had felt rushed 
and uncaring. Breaking bad news is a key communication skill for clinicians delivering any life 
changing diagnosis.154 Discussions need to be tailored to the individual and based on pre-
existing knowledge and understanding as well as their wishes for what they want to be told 
about their diagnosis. The current evidence base focuses on interventions for practitioners 
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to enhance their communication skills but more research is required to establish how 
breaking bad news impacts on patient reported outcomes, and how this can be improved.155  
 
Rodriquez et al interviewed American patients about their knowledge and understanding of 
a heart failure diagnosis.156 Patients reported a need for more information about heart 
failure and greater opportunity to discuss their condition in detail with their physician. 
Patients also expressed a desire to discuss prognosis but reported this was lacking during 
medical consultations. 
 
Most participants in the current study had not been given any written information so some 
went online to find out more about their condition. However, participants would have 
preferred information tailored to their own particular condition and circumstance and would 
have welcomed more time to discuss the diagnosis with the secondary care team, perhaps at 
a further appointment. In a review by Davidson examining tools for conversations about 
treatment decisions and outlook in patients with heart failure, the ‘receptivity’ of the patient 
to information about their conditions was not uniform.157 Patients valued honesty in general 
but the depth and type of information they required was highly variable. An individualised 






Adaptation and optimising function 
The impact of the diagnosis was different for each participant. A heart failure diagnosis had 
led to effective treatment for some which had meant they were able to get back to a good 
quality of life. For others, adjusting to the diagnosis was difficult and took time. Some 
participants worried about the future although few spoke explicitly about prognosis or 
advanced care planning.  
 
As described previously, Bury introduced the concept of biographical disruption which 
accompanied a new diagnosis of rheumatoid arthritis but the concept has been found to 
apply to many chronic illnesses including COPD and cancer.158 Heart failure has a poorer 
prognosis than many cancers. A recent study exploring the ‘disruption’ of a cancer diagnosis 
with a poor outlook found that participants acknowledged that a full recovery was 
impossible, with their self-identity and social world already changed forever, and instead 
aimed to achieve a ‘new normal’ within the limits of what their disease allowed.159   
 
Previous qualitative studies have examined the impact of a heart failure diagnosis on 
patients’ everyday lives. Jeon et al undertook a systematic narrative review of qualitative 
studies examining the experiences of patients living with heart failure.160 The main impact 
was living in fear, a sense of loss of control and social isolation. Knowledge and 
understanding of their disease trajectory, along with easy access and continuity of care 
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within healthcare services which were high quality, enabled patients to adapt and improve 
their quality of life through regaining control and self-management.  
 
Pihl et al examined the impact of heart failure on daily physical activities in a 
phenomenographic analysis. Patients were limited by their heart failure symptoms but 
found ways of adapting and changing their daily activities to accommodate this. They felt it 
was important to maintain a degree of physical activity for as long as possible to maintain 
independence and prevent social isolation. However, interviewees described a fear of 
increasing physical activities as they associated this with possibly putting their cardiac health 
at risk.161  
 
Many participants in the current study described multiple medical conditions which 
impacted on their life, sometimes more than their heart failure symptoms. The presence of 
more than one chronic disease, including mental illness, is common in patients with heart 
failure due to their age and common risk factors. Murad et al examined the prevalence of 
comorbidities in a subgroup of the Cardiovascular Health Study cohort with incident heart 
failure.162 Sixty percent of participants with incident heart failure had three or more 
comorbidities, and 17% had cognitive impairment. It is therefore vital that patients are 
managed in a holistic way by practitioners who are able to consider the whole person with 
all of their diseases, within their social context. As discussed previously, the role of 
generalists therefore is crucial in heart failure management. 
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5.4.2 Recommendations, Policy Implications and Further Research  
The term ‘heart failure’ may be unhelpful but there is little research of the impact this has on 
patients. Further work is required to establish what terminology patients might find helpful 
and the feasibility of changing the terms routinely used in healthcare. Any change in 
terminology would require a global consensus. Further consideration of this important area 
could occur through discussion with international organisations such as the European 
Society of Cardiology and American Heart Association, perhaps at their annual conferences. 
 
Delivery of the diagnosis is important and patients remember if this is not done well. 
Clinicians delivering a heart failure diagnosis should be appropriately trained in ‘breaking 
bad news’ and this should include regular updates to ensure their technique and knowledge 
remains adequate throughout their career. Further research is required to understand the 
impact of diagnostic delivery on the long term outcome of patients with heart failure.  
 
Appropriate written information should be available to all patients following a diagnosis of 
heart failure. Further opportunities to discuss the diagnosis, its implications, and to ask any 
questions, should be agreed for a future date a short time after the initial diagnosis is given. 
Facilitating physical and psychological adaptation following the diagnosis should be an 




Multimorbidity is common in patients with heart failure and can mean it is not always their 
main problem. A generalist approach in both primary and secondary care should be used to 
optimally manage patients with multiple diseases and polypharmacy. Complex decisions on 
the balance of benefit versus harm of treatments may be required rather than following 
single disease guidelines. There is also a need to consider what is most important to patients 
through patient-centred care and shared decision-making. 
 
The issue of prognosis was not covered in detail by this study. There may be risks and 
benefits of discussing survival rates and outlook at the time of diagnosis. Further research 
into patient wishes for prognostic information and the way in which this could be delivered 
is needed. 
  
5.5 Limitations of the Study 
This study examined the experiences of a group of 16 people with a recent diagnosis of heart 
failure recruited from a single centre. Throughout the research process every effort was 
made to minimise bias to ensure the results were both valid and trustworthy. There are 







Qualitative research in general does not attempt to be representative of the whole 
population but seeks to explore the experiences of a particular group of people to gain a 
deeper understanding of the complex thoughts, actions and underlying sociological 
processes in a particular time and context.163 In this study, the original intention was to use 
purposive sampling to ensure participants were from a range of ages, gender and ethnic 
groups. The challenges in recruitment described in Chapter 3 limited the number of 
participants available for the study. There were participants from each decile from 50 years 
to 90 years and a mix of men and women however only one of the 16 participants was from 
a minority ethnic group. All participants also spoke English as their primary language. The 
experiences of patients from different ethnic groups and non-English speakers were not 
captured in this study. The findings are therefore less likely to be relevant to this group.        
 
Participants were recruited from a single outpatient clinic at a large tertiary referral hospital 
close to the centre of Birmingham. This means that the findings are particularly relevant to 




The researcher is an integral part of the qualitative research process but can introduce bias if 
their influence and pre-existing ideas are not recognised and acknowledged throughout the 
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conduct of any study.164 As an academic GP, I encounter patients with heart failure during 
my clinical work in general practice and I have also worked within acute hospital settings 
within a cardiology team. I therefore had my own preconceived ideas of where there may be 
issues within the patient diagnostic pathway. However, I have not worked in the hospital in 
Birmingham and fortunately, do not have any personal or family experience of undergoing 
the diagnostic process for heart failure.  
 
At the start of the study I clearly described the sampling, data collection and analysis 
techniques in the study protocol which received ethical approval. I also explored the issue of 
reflexivity in detail in Chapter 3 to highlight and therefore attempt to minimise any bias I 
may unintentionally introduce.  
 
Data Collection - Interviews 
Participants were aware that I was a GP from the participant information leaflet but during 
interviews, I emphasised that my role in the study was as a researcher (rather than a GP) and 
my intention was to understand the experience of the diagnostic pathway for heart failure 
from the patients’ perspective. I also made sure participants were aware that I was not part 
of their clinical team and no identifiable information would be available to their own 
cardiologist or GP. Interviews were conducted in participants own homes, at a time 
convenient to them. Participants spoke openly about their experiences, both positive and 
negative, and did not appear to be holding back or tailoring their story for my benefit 
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although it is difficult to say for certain that this did not occur at all.122 Interviews were 
recorded and transcribed verbatim to ensure all data were included in the final analysis. 
Data analysis and interpretation 
Several researchers were involved during the analysis and interpretation process to offer 
specialist expertise in qualitative methods and highlight any areas where my perspective as 
the main researcher appeared biased. Data were analysed using the Framework method. A 
detailed coding framework was generated then reviewed by an experienced qualitative 
researcher (NG). A sample transcript was then coded using the draft framework by another 
experienced researcher (SS), who was independent of the research team, and further 
modifications were made to the framework as a result of her feedback. During the 
interpretation phase, findings were discussed with NG and another researcher (TM) to 
explore emerging themes and consider how these fitted within existing sociological theories 
and literature. This thorough approach ensured findings were credible and trustworthy as 
well as relevant to the original research question.165 
 
Generalisability and transferability of findings 
Generalisability describes the extent to which research findings can be applied to the non-
study population and is a common goal of quantitative research.166 This study recruited 11 
male and 5 female participants age 52 years to 87 years, all white British except one Black 
female participant, from a single heart failure clinic based at a large teaching hospital in 
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inner city Birmingham. Qualitative research aims to understand both the experiences of a 
defined group of people and explore the meaning they attach to these events.167  
 
The findings of this study are therefore relevant to the group of participants interviewed but 
the emerging themes and concepts are likely to be relevant and transferable to the wider 
NHS. It is unlikely that the interviewees are unique in not recognising their symptoms as 
heart failure until a late stage as this has been described for other disease processes. The 
interactions with healthcare may be more specific to the clinic from which participants were 
recruited and engagement with the leading clinician to agree and implement changes to 
improve the patient experience is planned. Primary and secondary care doctors are trained 
according to national standards so the issues of communication and compassion highlighted 
in the analysis are likely to be of national significance. Further research is required to explore 
how the points of delay or poor patient experience in the heart failure diagnostic pathway 
identified by this study can be improved for future patients.       
 
5.6 Summary of the Chapter 
This chapter provided a summary of emerging concepts for the key emerging themes: Heart 
Failure Onset, Interacting with Healthcare and Heart Failure Diagnosis – Delivery and Impact 
and integrated these with the existing literature. For each theme, recommendations were 
presented which, if implemented, could impact on policy and improve the experience of the 
diagnostic pathway for patients with heart failure. Areas for further research were also 
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highlighted. Finally the limitations of the study, including biases and transferability of the 




6. SURVIVAL OF PATIENTS WITH A HEART FAILURE DIAGNOSIS IN GENERAL 
PRACTICE 
 
6.1 Chapter Overview 
This chapter explores the survival of patients with heart failure in the community population. 
The prognosis of patients with heart failure has previously been estimating in secondary care 
populations following discharge from hospital with a heart failure related problem, or from 
longitudinal cohort studies where patients were followed up over time.18 78 These 
populations do not represent the general practice population so survival data relevant to 
this group is currently lacking.83 General practice records collated in routinely collected 
datasets can be used to explore disease patterns, including prognosis, for patients in the 
community.  
 
The study in this chapter uses THIN dataset to describe the prognosis of patients with heart 
failure in a primary care population. The background and aims of the study are described 
then the methodological approach to using general practice records for prognostic research 
is explained. The results are presented, the strengths and limitations of the study are 





Background and Aims: Survival estimates are useful to monitor the outlook of patients with 
chronic diseases and to understand the impact of treatments and plan healthcare services. 
The aim of this study was to determine the overall survival rates for patients with heart 
failure from the time of diagnosis.  
Methods: Retrospective cohort study of UK general practice records from The Health 
Improvement Network (THIN) database between 1st January 1995 and 31st December 2012. 
For the survival analysis, patients aged 45 or over with a first diagnostic label of heart failure, 
were matched by age, sex and practice to people without heart failure. Outcome was death 
in the heart failure and non-heart failure comparator cohorts.  
Results: Overall survival rates for cases with a first diagnostic label of heart failure were 
81.5%, 51.6% and 29.5% at one, five and ten years respectively. Survival has changed little 
between 2000 and the most recently available data.  
Conclusions: The survival rates for patients diagnosed with heart failure have not improved 
over time. Further research is needed to explain these trends and to find strategies to 
improve prognosis. 
  
6.3 Background and Aims 
Heart failure is a common condition with an estimated 1-2 in every 100 people (of all ages) 
in Western populations living with heart failure.168 The costs of heart failure to the NHS in 
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the UK are second highest for any disease after stroke.3 Accurate estimates of heart failure 
prognosis are vital to healthcare commissioners to allow appropriate allocation of resources, 
to physicians in making management decisions and, perhaps most importantly, to patients 
to allow informed choices about treatments and end of life care.5 6  
 
The prognosis of patients with heart failure has been established from hospital data and 
from following up participants of screening studies. Recent analysis of Medicare billing data 
in the US found that following an admission with heart failure, 67.4% of patients were 
readmitted to hospital within a year and 35.8% died within the same period. 169 Heart failure 
requiring hospital admission therefore has a poor outcome for patients and is also 
associated with significant healthcare costs arising from multiple admissions. 
 
The outlook for participants in community screening studies is less bleak. In the Olmstead 
County population, 1 year mortality was 21% for men and 17% for women and at 5 years 
was 50% and 46% for men and women, respectively.35 The ECHOES study, which screened a 
general population cohort over the age of 45, found a 5 year survival rate of 53% in 
participants with heart failure due to LVSD, compared with 93% in the group without heart 
failure.73  
 
Hospital data and screening studies however fail to explore the survival rates of patients 
who are diagnosed in a community setting and are not admitted to hospital nor actively 
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involved with screening for research purposes. As described in Chapter 2, electronic primary 
care records provide a valuable source of data directly relevant to community populations.39 
85 86 87 88 The computerisation of general practice in the UK and increasingly robust coding of 
medical information has led to large datasets which, following anonymization, can be used 
to explore epidemiological trends, including survival rates. 37 38 39 89 90 THIN is one of the 
largest databases of general practice records in the world; it currently includes data from 
587 practices in the UK, approximately 6% of the whole general practice population.50  
 
The aim of this survival analysis was to determine the one, five and ten year survival rates of 
patients with heart failure in a general practice population and examine whether prognosis 




An open matched retrospective cohort study was carried out using data from THIN database 
for the period between 1st January 1995 and 31st December 2012. 
 
6.4.2 Setting 
THIN is a primary care database containing electronic patient records from 587 general 
practices in the UK. At each consultation, the GP records details of the medical encounter 
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and symptoms or diagnoses are entered using a clinical coding system. Prescriptions and 
laboratory results/observations (e.g. blood pressure) are also recorded electronically. 
Demographic details such as age, sex and linked deprivation scores also form part of the 
record.  
 
Practices that contributed at least one year of clinical data were included in the study.95 Only 
data after the practice acceptable mortality reporting date (the date on which the practice 




The incidence cohort, described in Chapter 2, was also used for the survival analysis. The 
incidence cohort was extracted from THIN database and included all persons aged 45 years 
and over, registered at the practice for at least 12 months between 1st January 1995 and 31st 
December 2012 and after the date of acceptable mortality reporting. Patients with a 
previous diagnosis of HF were excluded. 
  
To determine survival, a matched cohort was extracted from the incidence cohort. Cases had 
a clinical code indicating heart failure. The index date was the first date of a recorded heart 
failure code. Cases were matched with up to five comparators who were registered in the 
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same practice on the index date but did not have a diagnosis of heart failure on that date 
(but could become a case later). Comparators were also matched on sex and age +/- 5 years. 
 
To allow comparison with the ECHOES findings, an age group of 45 or older was also used for 
this survival analysis. The types of heart failure affecting children and younger people are 
pathologically distinct from heart failure found in older adults91 and the randomised 
controlled trials conducted in the 1990s to examine the effectiveness of drug treatment in 
patients with heart failure recruited participants who were from middle-age onwards.92 93 94 
The ECHOES study recruited patients over the age of 45 for this reason.  
 
6.4.4 Clinical Codes 
Participants with a diagnosis of heart failure were identified using clinical codes, also known 
as Read codes, diagnostic codes used by GPs to record new diagnoses in the medical record. 
The NHS Clinical Terminology Browser and Quality and Outcomes Framework guidelines 
were used to generate a comprehensive list of terms used to code for a diagnosis of heart 
failure. Heart failure is a clinical syndrome and the diagnosis requires the presence of 
symptoms and objective evidence of a structural or functional abnormality of the heart.7 
Patients with a clinical code of heart failure and either an echocardiograph report or a 
hospital letter were classified as being a confirmed case of heart failure and those with just a 




6.4.5 Baseline Variables 
Demographic variables including age, sex, ethnicity, area deprivation quintile (Townsend96), 
cardiovascular risk factors and co-morbidities were extracted for each case and control. The 
earliest deprivation quintile prior to the index date was used or, if unavailable, the most 
recently recorded after the index date. Cardiovascular risk factors (smoking, blood pressure, 
cholesterol, body mass index (BMI)) were the most recent recorded prior to index date. 
Cardiovascular co-morbidities (angina, myocardial infarction (MI), ischaemic heart disease, 
diabetes, hypertension, stroke, atrial fibrillation, valve disease), were defined by the 
presence of a clinical code at any time prior to the index date.  
 
6.4.6 Outcome Measure 
The outcome measure was time to death (all-cause mortality).  
 
6.4.7 Statistical Analyses 
Data were extracted directly from THIN database using the list of clinical codes. Analysis was 
carried out using Stata versions 10 and 11. The number of practices, absolute numbers of 
confirmed and unconfirmed heart failure cases and proportion of heart failure cases 
classified as confirmed was calculated. Age distribution of heart failure cases and 
participants characteristics for confirmed, unconfirmed, all heart failure cases and 




Practice patients included in the survival analyses were followed until the earliest of the 
following dates: patient died, patient left (de-registered from) their practice, the practice 
ceased contributing data to THIN, or the study ended.  
 
Kaplan-Meier curves were used to compare survival in participants with and without heart 
failure and by age group and Townsend quintile. Log rank tests were used to compare 
survival between groups. One, five and ten year survival rates for cases were calculated for 
each 10 year age band over the age of 45. For comparison, survival rates of patients over the 
age of 45 without a diagnosis of heart failure were also determined. Survival rates were 
calculated by year of diagnosis to examine trends over time. Survival within the confirmed 




A total of 564 practices contributed at least one year of data between 1st January 1995 and 
31st December 2012. The number of contributing practices increased significantly over time 
from just 9 in 1995 to over 500 by 2008. A total of 55,248 participants had a new clinical 
code of heart failure during the study period; 40,615 with a code of heart failure alone 
(unconfirmed case) and 14,633 with additional evidence to support the diagnosis such as 




6.5.2 Population – Confirmed and Unconfirmed Heart Failure 
The characteristics of people with confirmed and unconfirmed heart failure, and 
comparators without heart failure, are shown in Table 9. Cases with confirmed heart failure 
were younger and 56% were male compared to 50% in the unconfirmed group. All five 
Townsend deprivation quintiles were similarly represented except for the most deprived 
group which had around one third less cases than the other four groups. The proportion of 
participants in each Townsend score group was similar for confirmed and unconfirmed 
cases. BMI was similar and there were 2% more smokers in the confirmed compared to the 
unconfirmed heart failure group. Ischaemic heart disease, angina and MI were all more 
common in the confirmed group. Cardiovascular co-morbidities such as AF and stroke were 
common in both heart failure groups. 
 
6.5.3 Population – Heart Failure and Comparator Cohorts 
A total of 55,248 participants had a first-ever clinical code of heart failure during the study 
period and were matched with up to 5 comparators by age, sex and practice. The 
characteristics of cases and comparators are shown in Table 9. All five Townsend deprivation 
quintiles were similarly represented except for the most deprived group which had around 
one third less cases than the other four groups. BMI was similar in cases and comparators, 
but there were 1.2% more smokers in the heart failure group. Cardiovascular co-morbidities, 
particularly ischaemic heart disease, AF and valvular disease were more common in cases 














Age (years)  
45-54 585 (4.0%) 1,182 (2.9%) 1,767 (3.2%) 8,830 (3.4%) 
55-64 1,745 (11.9%) 3,598 (8.9%) 5,343 (9.7%) 26,693 (10.2%) 
65-74 3,571 (24.4%) 8.807 (21.7%) 12,378 (22.4%) 61,554 (23.7%) 
75-84 5,558 (38.0%) 15,750 (38.8%) 21,308 (38.6%) 101.955 (39.3%) 
85-94 2,983 (20.4%) 10,238 (25.2%) 13,221 (23.9%) 56,250 (21.7%) 
>=95 191 (1.3%) 1,040 (2.6%) 1,231 (2.2%) 4,040 (1.6%) 
Male 8,204 (56.1%) 20,206 (49.7%) 28,410 (51.4%) 132,478 (51.1%) 
Townsend score  
1 2,877 (19.7%) 8,233 (20.3%) 11,110 (20.1%) 59,941 (23.1%) 
2 2,905 (19.9%) 8,449 (20.8%) 11,354 (20.6%) 57,030 (22.0%) 
3 2,952 (20.2%) 8,346 (20.6%) 11,298 (20.5%) 51,777 (20.0%) 
4 3,008 (20.6%) 8,068 (19.9%) 11,076 (20.1%) 46,827 (18.1%) 
5 2,314 (15.8%) 5,733 (14.1%) 8,047 (14.6%) 32,531 (12.5%) 
Not known 577 (3.9%) 1,786 (4.4%) 2,363 (4.3%) 11,216 (4.3%) 
BMI  
Mean (SD) 27.9 (5.8) 27.8 (5.9) 27.9 (5.9) 26.4 (4.7) 
Missing 1,862 (12.7%) 7,181 (17.7%) 9,043 (16.4%) 53,694 (20.7%) 
Smoking status  
Smoker 2,290 (17.7%) 5,502 (13.6%) 7,792 (14.1%) 33,414 (12.9%) 
Not current 
smoker 
11,731 (80.2%) 32,051 (78.9%) 43,782 (79.3%) 199,001 (76.7%) 
Missing 612 (4.1%) 3062 (7.5%) 3674 (6.7%) 26,907 (10.4%) 
Diabetes 2,971 (20.3%) 7,878 (19.4%) 10,849 (19.6%) 27,790 (10.7%) 
Hypertension 7,922 (54.1%) 21,247 (52.3%) 29,169 (52.8%) 107,878 (41.6%) 
Angina 3,575 (24.4%) 9,201 (22.7%) 12,776 (23.1%) 29,151 (11.2%) 
Myocardial 
infarction 
3,919 (26.8%) 8,528 (21.0%) 12,447 (22.5%) 16,579 (6.4%) 
Ischaemic 
heart disease 
6,985 (47.7%) 16,694 (41.1%) 23,679 (42.9%) 44,508 (17.2%) 
Stroke 1,270 (8.7%) 3,761 (9.3%) 5,031 (9.1%) 15,183 (5.9%) 
Atrial 
fibrillation 
4,732 (32.3%) 10,894 (26.8%) 15,626 (28.3%) 18,149 (7.0%) 
Valvular 
disease 
1,727 (11.8%) 3,841 (9.5%) 5,568 (10.1%) 6,326 (2.4%) 
Table 9: Characteristics of confirmed, unconfirmed heart failure cohorts and non-heart 
failure comparator cohort 
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6.5.4 Survival in the Cohort 
The pattern of survival of patients with and without a diagnostic label of heart failure in their 
medical record is shown in Figure 7. Patients with heart failure had a significantly worse 
prognosis than those without heart failure (log rank test, χ2 (1) 12,817.30, 1, P<0.0001). 
 
  
Figure 7: Kaplan-Meier curve showing survival of people with and without heart failure 
 
Survival of heart failure cases was also related to age group with risk of death increasing with 





Figure 8: Kaplan-Meier curve showing survival of people with heart failure by age band 
 
The survival of patients with heart failure by Townsend Score is shown in Figure 9. There was 





Figure 9: Kaplan-Meier curve showing survival of people with heart failure by Townsend 
Score quintile 
 
The survival rates for all patients diagnosed with heart failure during the study period are 
shown in Table 10. Overall survival rates were 81.5% at one year from date of diagnosis, 
51.6% at five years and 29.5% at ten years. The survival rates of age, sex and practice 














































































































Table 11: One, five and ten year survival rates of people without heart failure by age 
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6.5.5 Survival Over Time 
The survival rates of all people with heart failure by year of diagnosis are shown in Figure 10. 
One and five year survival rates have remained stable since 2000 at around 80% and 50% 
respectively. Ten year survival rates from 1997 to 2002 were stable at 28%.  
 
 
Figure 10: One, five and ten year survival rates for all people with heart failure by year of 
diagnosis 
 
6.5.6 Survival by Case Definition 
The number of confirmed cases (14,663) made up just over a quarter (26.5%) of the total 
number of heart failure cases (55,248) in the dataset. The overall survival rates were worse 















Year of first diagnostic label of heart failure 
1 year survival 5 year survival 10 year survival
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test, χ2 (1) 170.37, 1, P<0.0001) as shown in Figure 11. Table 12 shows overall around a 5% 
difference in one, five and ten year survival rates between the confirmed and unconfirmed 
heart failure groups. 
 
Figure 11: Kaplan-Meier curve showing survival of people with confirmed and unconfirmed 




Years since first diagnostic 
label of HF 
Survival (%) 
Confirmed HF Case 
(95% CI) 
Unconfirmed HF Case 
(95% CI) 













Table 12: One, five and ten year survival rates of people with confirmed and unconfirmed 
heart failure 
 
The number of confirmed and unconfirmed cases with a recording of a first diagnostic label 
of heart failure by year is shown in Table 13. The number of contributing practices rose 
sharply in the first five years of the study period meaning the number of patients with a first 
diagnostic label of heart failure also increased. The number of contributing practices, and 
therefore heart failure cases stabilised from 2000 onwards to between 3,000 and 4,000 per 
year. The proportion of confirmed cases in this time varied between 20 and 30% with an 





Year 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Total cases 
(n=55,248) 
















45 477 3991 8501 11346 14591 19105 21671 22353 19880 18642 17341 16044 16720 17094 17084 17452 16998 
Number of 
practices 
1 16 73 115 148 207 272 358 409 422 460 473 472 503 508 497 487 477 
 
Table 13: Number of people in confirmed and unconfirmed heart failure cohorts, and non-heart failure comparator cohort, by year 
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Survival rates for people with confirmed and unconfirmed heart failure by year of diagnosis 
are illustrated in Figure 12 and the absolute numbers are shown in Table 14. The one year 
survival rates for those diagnosed from 1995 to 2011 were around 85%. The five year for 
those diagnosed from 1995 to 2007 were around 50% and ten year survival rates, for those 
diagnosed 1995 to 2002 were around 30%. There was a difference in survival rates between 
confirmed and confirmed cases; the unconfirmed heart failure group had worse survival 





















Year of first diagnostic label of heart failure 
1 year confirmed 5 year confirmed 10 year confirmed




 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 
Total cases 
(n=55,248) 
9 101 825 1758 2378 3102 4085 4619 4771 4233 3979 3712 3449 3582 3689 3654 3705 3597 
One year 
survival (%) 
100 92.1 92.9 85.9 82.6 81.5 81.6 80.8 80.2 79.9 79.7 80.3 79.9 81.5 82.7 81.6 81.6 - 
Five year 
survival (%) 
37.5 42.8 58.5 54.0 50.4 48.2 50.8 49.4 51.2 50.5 50.1 52.0 53.0 - - - - - 
Ten year 
survival (%) 




0 11 104 277 441 588 894 955 1216 1359 1268 1258 1185 1188 1123 1062 959 747 
One year 
survival (%) 
- 100 92.2 86.7 83.0 80.6 84.6 82.4 86.6 83.7 83.4 86.0 77.6 79.6 85.9 85.6 86.3 - 
Five year 
survival (%) 
- 56.3 59.4 56.3 50.1 49.0 54.5 55.2 57.7 53.3 54.1 56.5 50.2 - - - - - 
Ten year 
survival (%) 








9 90 721 1481 1937 2514 3191 3664 3555 2874 2711 2455 2265 2395 2567 2592 2746 2853 
One year 
survival (%) 
100 91.1 93.0 85.7 82.5 81.7 80.7 80.3 78.0 78.0 78.0 77.3 77.6 79.6 81.3 80.0 79.9 86.3 
Five year 
survival (%) 
37.5 41.2 58.3 53.6 50.4 48.0 49.7 47.8 49.0 49.0 48.2 49.6 50.2 - - - - - 
Ten year 
survival (%) 









45 477 3991 8501 11346 14591 19105 21671 22353 19880 18642 17341 16044 16720 17094 17084 17452 16998 
 




This study found overall survival rates for cases with a first diagnostic label of heart failure 
were 81.5%, 51.6% and 29.5% at one, five and ten years, respectively. Survival changed little 
between 2000 and the most recently available data. Confirmed evidence of heart failure was 
associated with improved survival. 
 
6.6.1 Strengths and Limitations 
The results provide survival rates for heart failure patients from a large representative set of 
general practices and are therefore likely to be generalizable to the community population 
as a whole.97 Unlike screening cohort studies, general practice databases do not rely on 
participants volunteering to take part in the study rather they represent a cross-section of 
the entire population. The cohort included in this analysis is much larger than those used in 
epidemiological studies of heart failure and the follow-up was over 15 years for some 
patients. The large number of patients in each age and sex category also improves the 
accuracy of the survival rate estimates.  
 
Research using general practice databases is reliant on the accuracy of clinical coding input 
by GPs during the consultation and this can be a limitation of this type of study.21 The first 
recorded heart failure diagnosis in THIN was in July 1995 and clinical coding has improved 
significantly since then. The introduction of the heart failure QOF indicator in 2006 required 
robust evidence of heart failure and evidence of significant improvements in coding prior to 
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the formal introduction of a QOF indicator have previously been observed.98 The benefit of 
THIN and similar general practice databases are that they provide an insight into real-life 
general practice and the survival rates of patients with a clinical code of heart failure in their 
record is likely to be an important statistic for practising GPs.  
 
There have also been changes to the definition of heart failure with the emergence of two 
distinct heart failure types: heart failure with reduced ejection fraction (HFREF) and heart 
failure with preserved ejection fraction (HFPEF) which have only been coded very recently in 
GP records so estimates of survival by heart failure type was not possible in this study. 7 29 30  
32 
 
6.6.2 Comparison with Existing Literature 
The ECHOES study is one of the few studies to report 10 year survival rates. All deaths in the 
cohort were collated from routinely collected mortality data. In ECHOES, the five-year 
survival rate was 53% in patients with heart failure due to left ventricular systolic 
dysfunction compared to 93% for the general population over the age of 45. Overall the 
mortality rate for all-cause heart failure was 9% per year.73 At ten years, survival was 27% for 
those with heart failure due to LVSD compared to 75% in those without heart failure.  
 
The overall 10 year survival rate of 29.5% for the heart failure group in the present study is 
therefore remarkably similar to the screened population in ECHOES. However, the survival 
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rates for the general population were significantly less in the THIN cohort than ECHOES. This 
may reflect selection bias which affects most prospective epidemiological studies in that 
those likely to participate in research are often more healthy from the start. The participants 
of ECHOES without heart failure were younger and had less cardiovascular co-morbidities 
then the non-heart failure comparator cohort in this study. The comparators derived from 
the THIN dataset are more likely to represent the full spectrum of patients found in 
community populations. 
 
The Framingham Heart study began in 1948 and followed up the original cohort every 2 
years.28 A study of the Framingham cohort examining the trends in survival rates for heart 
failure between 1950 and 1999 found an overall improvement in survival of 12% per decade 
between 1950 and 2000.101 However, the Framingham participants were largely white, 
middle class and voluntarily took part in research so are unlikely to be fully representative of 
the UK primary care population. The original criteria used in the Framingham definition also 
relied on the presence of symptoms and signs to determine a diagnosis of heart failure but 
more recent definitions emphasise the importance of objective evidence of a structural or 
functional abnormality of the heart, usually from imaging.31 Therefore patients diagnosed 
with heart failure in the earlier decades of the study may have had more advanced heart 
failure at the time of diagnosis.  
 
The Rotterdam study, which recruited participants over the age of 55 between 1989 and 
1993 and followed them up to the year 2000, reported overall survival was 86% (95%CI 83-
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88) at 30 days, 63% (95% CI 59-66) at 1 year and 35% (95%CI 31-39) at 5 years. There was no 
statistically significant difference in survival between men and women (log rank test, 
p=0.15). 
 
A cross-sectional study using an administrative health data register in Sweden which 
included 2.1 million people examined survival rates for patients with heart failure over the 
age of 40. The overall 5 year survival rate was 48%, similar to the THIN study results, 
however between 2006 and 2010 there was a 19% decrease in mortality in both men and 
women (P<0.001).104  
 
Previous epidemiological research has shown a strong correlation between socioeconomic 
status and longevity; people in lower socioeconomic groups live shorter, and less healthy, 
lives than those from more privileged parts of society.170 The Kaplan-Meier curve comparing 
survival of patients with heart failure from all Townsend quintiles (Figure 9) however showed 
no difference in mortality between socioeconomic groups. This may be due to immortal time 
bias which occurs when participants do not have an opportunity to be exposed to the 
disease, or drug, of interest.171 In this case, people from the lowest socioeconomic groups 
may have died before having an opportunity to enter the cohort and the number of people 
in the THIN dataset from the lowest Townsend quintile was one third less than in the other 
Townsend groups. However, there is evidence to suggest that the mortality gradient related 
to socioeconomic status is diminishing for people with heart failure. A study by Hawkins et 
al, using a primary care dataset found that outcomes of patients with heart failure were 
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similar regardless of socioeconomic status. In particular, the use of evidence based 
medicines known to improve prognosis in patients with heart failure was equitable across 
socioeconomic groups.172 Further research is required to explore the relationship between 
the socioeconomic status and prognosis of patients with heart failure in more detail.  
 
6.6.3 Implications for Practice and Further Research 
From our findings in Chapter 2, a moderately sized GP practice with, for example, 5,000 
patients over the age of 45 will have around 10 patients receiving a new heart failure 
diagnosis per year. From the results presented in this chapter, at least two of these patients 
are likely to die within a year, half will still be alive at 5 years but perhaps only two of these 
patients will still be alive at 10 years. This information is important for practising GPs if 
patients want to discuss their outlook following a diagnosis of heart failure. 
 
The overall one, five and ten year survival rates for patients with a first diagnostic label of 
heart failure have not improved over time which differs from the findings in other European 
and North American populations. More research is needed into the disease trajectory and 
management of heart failure in order to explain the lack of improvement in survival over 
time found in this study despite the availability of evidence-based therapies shown to 
improve outcomes in clinical trials.  
The results of this study are estimates at a population level but discussions with the 
individual patient require tailored statistics and information in a form that they can 
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understand. Prognostic estimates will vary depending on age and sex but also other co-
morbidities, treatments and variables such as blood pressure and ejection fraction. An 
analysis by Pocock et al pooled 30 prognostic studies to derive a survival risk calculator 
which is available online at www.heartfailurerisk.org and calculates predicted one and three 
year survival.173 174 Prognostic modelling to include other variables from the THIN database 
to more accurately predict survival for individual patients is an area where further research 
is planned. 
 
6.7 Summary of the Chapter 
This chapter presented a study examining survival of 55,248 patients with heart failure in a 
general practice population. One, five and ten years survival rates were presented along 
with survival rates by year which do not appear to have improved over time. The reasons for 
this are not clear and require further research to explore trends and identify strategies 
which can improve outlook for heart failure patients following diagnosis. More individualised 




7. THE ROLE OF SCREENING FOR HEART FAILURE IN THE COMMUNITY 
 
7.1 Chapter Overview 
This chapter explores the role of screening in identifying patients with heart failure. In 
Chapters 3 to 5, interviews with participants revealed that they did not seek help for some 
time following symptom onset only when symptoms were severe enough to significantly 
affect their daily activities did participants seek medical help. In Chapter 6, a survival analysis 
of over 55,000 patients with heart failure found prognosis had not improved over time. 
Strategies to identify and treat patients earlier in their disease process may be a method to 
improve outcomes. The effectiveness of screening patients for heart failure remains 
uncertain, but theoretically has the potential to identify those patients who do not present 
to medical services prior to the onset of severe symptoms.  
 
The Echocardiographic Heart of England Screening Extension (ECHOES-X) study was a 
longitudinal cohort study to examine progression to heart failure in a screened population. 
This chapter describes the background and aims of the study, detailed methods and results 
and a discussion of the findings in the wider context of heart failure screening. The results of 
this study have been published (Taylor et al, BMJ Open 2014) and my contribution to this 




Background and Aims: Heart failure is a clinical syndrome which develops over time as a 
result of deterioration in cardiac function. The aim of the Echocardiographic Heart of 
England Screening Extension (ECHOES-X) study was to determine progression to heart failure 
in a screened community population.  
Methods: Observational longitudinal cohort study to re-screen a large community 
population to assess progression to heart failure over time and the role of natriuretic 
peptide testing in screening. The setting was 16 socioeconomically diverse practices in 
central England. Participants from the original Echocardiographic Heart of England Screening 
(ECHOES) study were invited to attend for re-screening. Outcome was prevalence of heart 
failure at re-screening (overall and for each original ECHOES subgroup) and test performance 
of N-Terminal pro-B type natriuretic peptide (NT-proBNP) levels at different thresholds for 
screening.  
Results: 1618 of 3408 participants underwent screening which represented 47% of survivors 
and 26% of the original ECHOES cohort. A total of 176 (11%, 95% CI 9.4% to 12.5%) 
participants were classified as having heart failure at re-screening; 103 had heart failure with 
reduced ejection fraction (HFREF) and 73 had heart failure with preserved ejection fraction 
(HFPEF). 68 out of 1232 (5.5%, 95% CI 4.3% to 6.9%) participants who were recruited from 
the general population over the age of 45 did not have heart failure in the original study, but 
had developed heart failure on re-screening. An NT-proBNP cut-off of 400pg/ml had 
sensitivity of 79.5% (95% CI 72.4% to 85.5%) and specificity of 87% (95% CI 85.1% to 88.8%) 
for the diagnosis of heart failure. 
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Conclusions: Re-screening identified new cases of both HFREF and HFPEF. Progression to 
heart failure poses a significant threat over time. The natriuretic peptide cut-off level for 
ruling out heart failure must be low enough to ensure that cases are not missed at screening. 
 
7.3 Background and Aims 
Chronic heart failure is a clinical syndrome which occurs following significant pathological 
insult to the heart over a period of time and is associated with poor outcomes for patients.79 
Symptoms are often insidious in onset and overlap with other conditions meaning diagnosis 
can be difficult.21 Epidemiological studies have focused on the point prevalence of heart 
failure, which is around 1 - 1.5% in the general population rising with age to 10% in those 
over 75 years in some studies17, and in particular on the development of heart failure 
following myocardial infarction8, yet the progression to heart failure in the general 
population over time is less well understood. Natriuretic peptides can be used both in the 
diagnosis of heart failure and in determining disease trajectory although debate about 
diagnostic and prognostic threshold levels remains.175 176 
 
The Echocardiographic Heart of England Screening (ECHOES) study was one of the largest 
and most well-phenotyped community cohorts for heart failure in the world and identified 
an overall prevalence of 2.3% in participants over the age of 45 in the general population. 
The ECHOES-X study started 10 years after the ECHOES study completed and aimed to re-
screen participants still alive and contactable from the original cohort.  
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7.3.1 The Original ECHOES Study 
The original ECHOES study screened 6162 participants from 16 general practices in central 
England between March 1995 and February 1999.18 A full clinical assessment, combined with 
echocardiography and electrocardiogram, was used to determine the presence of heart 
failure or left ventricular systolic dysfunction (LVSD), defined as an ejection fraction less than 
40%. The European Society of Cardiology (ESC) criteria published in 1995, shown in Table 15, 
were used to determine a diagnosis of heart failure.29 A subgroup of the study population 
also had a natriuretic peptide level recorded. 
 
1. Symptoms of heart failure (at rest or during exercise) 
and 
2. Objective evidence of cardiac dysfunction (at rest) 
and 
3. Response to treatment directed towards heart failure (in cases where the diagnosis is 
in doubt) 
Criteria 1 and 2 should be fulfilled in all cases 
 
Table 15: European Society of Cardiology criteria for diagnosis of heart failure 1995 
 
The ECHOES study comprised four subgroups; general population over age 45, participants 
with risk factors (hypertension, history of myocardial infarction, angina and diabetes), 
participants with a prior diagnosis of heart failure, and a group prescribed diuretics. The 
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results of the ECHOES study provided a contemporary estimate of the prevalence of heart 
failure in these four groups as shown in Table 16.18   
 








Risk factors (hypertension, history of 













Total 6162 449 328 
 
Table 16: Prevalence of heart failure and LVSD in the original ECHOES cohort by subgroup18 
 
7.3.2 The ECHOES-X Study 
The ECHOES-X study aimed to follow up the ECHOES cohort to determine the rate of 
progression to heart failure or LVSD, calculate an estimate of incidence of heart failure and 
LVSD and determine the fate of those with heart failure or LVSD from the original cohort. 
The aim was also to examine the role of NP testing in screening for heart failure and LVSD in 
a community population. The study started in 2008 and received funding from the National 
Institute for Health Research School of Primary Care, the NHS Research and Development 
Support for Science and Roche Diagnostics. Full ethical approval was gained from the South 
Birmingham Research Ethics Committee. 
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7.4 Methods in the ECHOES-X Study 
7.4.1 ECHOES-X Study Population 
All participants involved in the original ECHOES study had their medical record ‘flagged’ to 
enable the Office for National Statistics to report all deaths to the study team. 2754 
participants of the original ECHOES study had died prior to recruitment to the ECHOES-X 
study. All 3408 surviving participants were eligible to take part in the ECHOES-X study. The 
16 practices included in the original ECHOES study were all invited, and agreed, to take part 
in the follow-up study.  
 
7.4.2 Screening Assessment 
All participants underwent clinical assessment by a general practitioner with an interest in 
cardiovascular disease, or a trained research nurse. ECG and echocardiography was carried 
out and reported by an echocardiographer accredited by the British Society of 
Echocardiography (BSE). In addition, participants had blood tested for natriuretic peptide 
using a near patient testing device (NT-proBNP point of care system, Roche Diagnostics, UK). 
All participants were also invited to complete a quality of life questionnaire. Data collection 
was carried out between October 2008 and June 2011.  
 
7.4.3 European Heart Failure Diagnostic Criteria  
The ECHOES-X protocol was written in 2007-8, however the diagnostic criteria for heart 
failure, according to the ESC, changed twice between the study start date and final 
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reporting. In 2008, the ESC guideline on chronic heart failure suggested that the presence of 
symptoms, signs and objective evidence were all required at assessment to confirm a 
diagnosis of heart failure as shown in Table 2 in Chapter 1. However in the revised 2012 ESC 
chronic heart failure management guideline, the society recognised that signs may not 
always be present, and that two distinct diagnostic categories of heart failure are now in use 
as shown in Table 17.7 In light of this revised position, the data analysis plan needed to be re-
written to ensure that the latest definition of heart failure was used.  
 
The diagnosis of HF-REF requires three conditions to be satisfied: 
1. Symptoms typical of heart failure 
2. Signs typical of heart failure* 
3. Reduced left ventricular ejection fraction 
The diagnosis of HF-PEF requires four conditions to be satisfied: 
1. Symptoms typical of heart failure 
2. Signs typical of heart failure* 
3. Normal or only mildly reduced left ventricular ejection fraction and left ventricle not 
dilated 
4. Relevant structural heart disease (left ventricular hypertrophy/left atrial 
enlargement) and/or diastolic dysfunction. 
*Signs may not be present in the early stages of heart failure (especially in HF-PEF) and in 
patients treated with diuretics. 
 
Table 17: European Society of Cardiology guideline 2012: Diagnosis of heart failure 
 
Heart failure with reduced ejection fraction (HFREF) has been the most prevalent and well-
researched type of heart failure to date. Traditionally a normal ejection fraction was 
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associated with a presumption that cardiac function was adequate and many of the early 
heart failure treatment studies only recruited patients with a reduced ejection fraction.92 
However in recent years, heart failure with preserved ejection fraction (HFPEF) has emerged 
as an important diagnostic concept and now may account for up to half of all heart failure 
cases.177  It appears to be pathologically distinct from HFREF and is associated with left 
ventricular stiffness and reduced diastolic filling but an overall preserved ejection fraction.12 
The treatments known to be beneficial in HFREF have largely failed to improve outcome for 
patients with HFPEF in studies to date.32  
 
The original ECHOES study required a reduced ejection fraction, or other structural or 
functional abnormality such as valve disease or arrhythmia, for a diagnosis of heart failure. 
Participants with heart failure due to atrial fibrillation (AF) may have partly captured the 
HFPEF group but it is likely that the original ECHOES study under-reported the incidence of 
heart failure overall according to the definitions in use today.18  
 
7.4.4 ECHOES-X Heart Failure Diagnostic Criteria   
Given the changes to the European definitions for heart failure, the diagnostic criteria for the 
ECHOES-X study were reviewed and revised. Proposals were circulated to the clinicians and 
the BSE accredited echocardiographer on the study team for agreement. The final criteria for 












Ejection fraction 41-50% HFREF 
Diastolic dysfunction  Diastolic dysfunction defined as E:E’ >13 or 
E:E’ 8 to13 with LV hypertrophy (IVS 
>1.2cm) or LA enlargement (>4cm (males); 




Moderate to severe (grade 2-3) HFPEF 
Atrial fibrillation Diagnosed on ECG HFPEF 
 
LA=left atrium, IVS=interventricular septum, ECG=electrocardiogram 
 
Table 18: ECHOES-X criteria for objective evidence of heart failure 
 
All data from the clinical record form were input to the study database. An algorithm was 
designed which allowed the database to be interrogated to classify participants with heart 
failure to be consistent with the ESC definition 2012. In the algorithm, the presence of 
symptoms was vital for a diagnosis of heart failure, absence of signs did not exclude a 
diagnosis of heart failure and one or more objective evidence from the agreed list was 
required.  Of note, we did not include the natriuretic peptide (NP) level in the diagnostic 
algorithm to allow subsequent calculation of sensitivity and specificity of NP testing. The 





Symptoms = Shortness of breath alone or with tiredness and/or ankle swelling 
Shortness of breath: ‘Do you get short of breath when you walk?’ or ‘Do you get shortness 
of breath’. 
AND/OR 
Tiredness: ‘Do you get tired easily’ 
AND/OR 
Ankle swelling: ‘Do your ankles/feet swell’ 
 
Signs = May be no signs if early or treated HF as per ESC definition 2012 so removed 




Left ventricular systolic 
dysfunction 
Ejection fraction 40% or below 
Borderline left ventricular systolic 
dysfunction 
Ejection fraction 41-50% 
Diastolic dysfunction  Diastolic dysfunction defined as E:E’ >13 or E:E’ 8 
to13 with LV hypertrophy (IVS >1.2cm) or LA 
enlargement (>4cm (males); >3.8cm (females)).     
Significant valvular disease  Moderate to severe (grade 2-3) 
Atrial fibrillation Diagnosed on ECG 
 
NT-proBNP not included in diagnosis at this stage to allow for calculation of PPV and NPV 
 




7.4.5 ECHOES-X Consensus Panel 
The consensus panel comprised three clinicians: Dr Russell Davis (a Consultant Cardiologist 
and previous research fellow on the original ECHOES study), Professor Richard Hobbs (a 
General Practitioner and Professor with a research interest in heart failure) and I. Three 
meetings took place between December 2012 and February 2013. The panel reviewed the 
clinical notes and echocardiograms or reports of the following groups: 
 Symptoms and no echo abnormality but objective evidence based on abnormal ECG. 
 Symptoms, ejection fraction >50% and report of subjective left ventricular impairment 
recorded by echocardiographer, diastolic dysfunction or significant valve disease. 
 All cases with a recorded ejection fraction of 50% but subjective record of left ventricular 
impairment by echocardiographer. 
A total of 210 participant notes were reviewed. The result of the consensus panel was 
agreed to supersede the diagnosis assigned by the algorithm if this was different. The panel 
agreed that HFREF was given as a primary diagnosis in cases where ejection fraction was less 
than 50% in the presence of diastolic dysfunction, valve disease or AF.  
 
7.4.6 Final Classification of Heart Failure Diagnosis 
Following this process, a summary table was generated to allow analysis. The key headings 
are shown in Table 20. Each participant was assigned a case definition (heart failure or not 
heart failure). For each case, the type and cause of heart failure was recorded. Objective 




















         
 
Table 20: ECHOES-X classification summary table headings 
 
7.4.7 Analysis Plan and Statistical Methods 
There were several ways to analyse and present the data in order to answer the original 
research questions. The two ECHOES studies are similar in format and both had recruitment 
and diagnostic groups which made the analysis complex. It was important to draw out 
clinically relevant data and present the results in a useful, understandable way which would 
address the main research questions.  
 
The overall prevalence rate of heart failure, subdivided into HFREF and HFPEF, was 
calculated for the ECHOES-X cohort. Prevalence of objective abnormalities for participants 
with and without heart failure was also calculated. The prevalence of heart failure by original 
diagnostic group was also determined. The general population subgroup was considered 
alone to determine the progress to new heart failure at re-screening. Finally, the median 
values of NT-proBNP were calculated for participants with and without heart failure, and 
performance characteristics for diagnosing heart failure, including sensitivity, specificity, 
positive and negative predictive values, were calculated for NT-proBNP thresholds of 150 
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and 400pg/ml. No data were available for those who did not attend for re-screening. 
Confidence intervals were calculated using the binomial exact method. Statistical analyses 
were undertaken using SAS V.9.2 and Stata V.10 and 12. 
 
7.5 Results of the ECHOES-X Study 
1618 of 3408 participants who were still alive at the start of the study underwent screening 
which represented 47% of survivors and 26% of the original ECHOES cohort. Figure 13 
provides a summary showing flow and numbers of participants in the ECHOES and ECHOES-X 
studies. 
 
The baseline characteristics of the ECHOES and ECHOES-X cohort are given in Table 21. 
Average age was 64 years in ECHOES and 71 years in ECHOES-X with an equal gender mix in 
both studies. The mean time between screenings was 13.4 years (SD 1.3, range 10.2-15.5 
years). 
 
The numbers of participants who were re-screened, did not respond or had died are shown 
in Table 22, grouped according to their original ECHOES recruitment subgroup. 80% of those 
in the ‘previous label of heart failure’ group in the original study had died. Those in the ‘on 
diuretics’ group also had a higher proportion of deaths (59%) than the general population 
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7.5.1 Prevalence of Heart Failure in ECHOES-X 
A total of 176 (11%) participants from all four original recruitment groups were classified as 
having heart failure at re-screening; 103 (58.5%) participants had symptoms and an ejection 
fraction less than 50% and could therefore be classified as HFREF. The remaining 73 (41.4%) 
participants with heart failure had an ejection fraction above 50% with evidence of diastolic 
dysfunction, atrial fibrillation or significant valve disease and were classified as HFPEF. 84 of 
176 (47.7%) participants with heart failure had more than one objective abnormality. 
Significant valve disease or atrial fibrillation was present in over 33% of heart failure cases 
and diastolic dysfunction was found in over 30%. In the general population group alone, 
there were 73 cases of heart failure out of 1242 participants re-screened giving a prevalence 
of 5.9% (95% CI 4.6% to 7.3%) in this group.  
 
1442 participants did not have a diagnosis of heart failure according to the ESC definition but 
a significant number of this group had one or more objective abnormality of cardiac 
function. 105 (7%) participants had significant valvular disease and 37 (2.6%) participants 
had an ejection fraction of 41 to 50%, without heart failure. Diastolic dysfunction was 
present in 30 (2%) participants in the no heart failure group. 62 of 176 (35%) participants in 
the heart failure group had atrial fibrillation compared to 36 of 1442 (2.5%) in the 
comparator group without heart failure. Overall the prevalence of atrial fibrillation in the 




7.5.2 Outcome of Participants from the Original ECHOES Cohort 
Participants in the original ECHOES study were categorised into 4 diagnostic groups following 
screening; no heart failure and no LVSD, heart failure and no LVSD, no heart failure and 
LVSD, and heart failure and LVSD. Table 23 shows the ECHOES-X outcome for each group. 
184 of 219 (84%) participants with heart failure and LVSD, 194 of 230 (84%) participants with 
heart failure and no LVSD and 80 of 109 (73%) participants with no heart failure and LVSD 
had died. The largest group from the original ECHOES study was participants with no heart 
failure and no LVSD and of these, 144 of 1579 (9.1%) participants re-screened now had a 






Died HF on re-
screen 




No HF + no LVSD 5604 2296 144 1435 1729 
HF + no LVSD 230 194 12 1 23 
No HF + LVSD 109 80 7 6 16 
HF + LVSD 219 184 13 0 22 
Total 6162 2754 176 1442 1790 
 




7.5.3 Progression to Heart Failure 
When the original ECHOES study was reported, 5604 participants were assessed and found 
not to have heart failure or LVSD however ECHOES-X included some participants particularly 
at high risk of heart failure so to have a true baseline group to calculate heart failure 
progression, the general population group should be considered alone (Table 24). Data 
collection for the original ECHOES study took place between 1995 and 1999 and for the 
ECHOES-X study between 2008 and 2011. On completion of the ECHOES-X study, of the 3834 
participants from the general population cohort in the no heart failure, no LVSD group in the 
original study, 1323 participants had died, 1279 did not respond and 1232 attended for re-
screening; of those re-screened, 68 (5.5%, 95% CI 4.3% to 6.9%) were found to have 






Died HF on re-
screen 




No HF + no LVSD 3834 1323 68 1164 1279 
HF + no LVSD 54 43 2 1 8 
No HF + LVSD 34 19 2 4 9 
HF + LVSD 38 34 1 0 3 
Total 3960 1419 73 1169 1299 
 




A breakdown of progression to heart failure (including cause) according to original ECHOES 
recruitment subgroup is shown in Table 25. Of those recruited to the original study from the 
general population over the age of 45, 73 of 1242 (5.9%, 95% CI 4.6% to 7.3%) re-screened 
participants had a diagnosis of heart failure in ECHOES-X. Forty seven of 214 (22%, 85% CI 
16.6% to 28.1%) participants with risk factors at the time of the original study (hypertension, 
diabetes, angina or history of myocardial infarction) had heart failure at re-screening. Heart 









Heart failure (% of re-screened group) 
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7.5.4 NT-proBNP levels in those with heart failure 
All participants in ECHOES-X were invited to have a blood test to assess NT-proBNP. Two 
attempts were made to take blood in those who provided consent. NT-proBNP level was 
available for 1511 (93%) participants. The median NT-proBNP level was 772pg/ml (IQR 
454pg/ml to 1338pg/ml) in those with heart failure and 135pg/ml (IQR 72pg/ml to 
255pg/ml) in those without heart failure.  
 
The receiver operator characteristic (ROC) curve for NT-proBNP is shown in Figure 14. The 





Figure 14: Receiver operating characteristics curve to show effectiveness of NT-proBNP in 
predicting a diagnosis of heart failure at screening 
 
Thirty three of 176 (18.8%) participants with heart failure had an NT-proBNP level less than 
400pg/ml, the current threshold suggested by the National Institute for Health and Care 
Excellence (NICE) in England for ruling out a diagnosis of heart failure. A cut-off of 400pg/ml 
had sensitivity for the diagnosis of heart failure of 79.5% (95% CI 72.4% to 85.5%), specificity 
of 87% (95% CI 85.1% to 88.8%), positive predictive value of 42.2% (95% CI 36.6% to 48.0%) 
and negative predictive value of 97.3% (95% CI 96.2% to 98.1%). A lower cut off of NT-
proBNP less than 150pg/ml had a sensitivity of 95.7% (95% CI 91.2% to 98.2%), specificity of 
54.4% (95% CI 51.7% to 57.1%), positive predictive value of 20% (95% CI 17.2% to 23.0%) and 
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7.6 Discussion of the ECHOES-X Study Findings 
Most patients with heart failure and/or LVSD in the original ECHOES cohort had died in the 
decade before re-screening commenced. At re-screening, those with cardiovascular risk 
factors in the original cohort were more likely to have heart failure on re-screening than 
those from the general population group. HFPEF was not recorded at the time of the original 
ECHOES study but accounted for 47% of heart failure cases in the ECHOES-X cohort. This 
would be expected to have been partially captured in the heart failure, no LVSD group of 
ECHOES. Multiple objective abnormalities were found in patients with heart failure in 
ECHOES-X suggesting a complex and multifactorial disease. NT-proBNP levels were generally 
higher in patients with heart failure yet almost 20% had levels below a 400pg/ml cut-off for 
heart failure, suggesting that this cut-off may be inappropriate for screening in a community 
setting.  
 
7.6.1 Strengths and Limitations 
The ECHOES study provided one of the largest community heart failure screening cohorts in 
the world. The ECHOES-X study followed up those still alive with a comprehensive clinical 
assessment to establish or rule out a diagnosis of heart failure of the time of re-screening. 
Progression to heart failure according to baseline group and the prevalence of HFREF vs 
HFPEF within the cohort are important epidemiological findings which advance our 
understanding of heart failure in community populations. The presence of multiple 
echocardiographic abnormalities and the performance of natriuretic peptide testing are 
important considerations for future studies screening for heart failure in the community.  
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Diagnosis was determined according to the latest guidance from the European Society of 
Cardiology which was agreed by a large expert panel of specialists in the field.7 However, the 
definition requires symptoms to be present for a diagnosis of heart failure to be made yet 
patients on known effective treatments such as angiotensin converting enzyme inhibitors, 
beta-blockers or diuretics may have been rendered asymptomatic by therapy. The estimate 
of heart failure prevalence is therefore likely to be a conservative one in both the ECHOES 
and ECHOES-X studies.  
 
The ECHOES and ECHOES-X studies were carried out a decade apart during which time there 
are likely to have been incident cases of heart failure who subsequently died or did not 
attend for re-screening. These results therefore give an estimate only for those who survived 
and attended for re-screening. Screening in itself requires high attendance rates to confer 
benefit and this is a consideration for any future screening programme. 
 
A range of ethnic groups and social classes were represented in the ECHOES cohort to 
ensure that the study was generalisable to community populations in Europe.18 The 
proportion of White participants in ECHOES-X was greater than the UK average and Black 
participants were under-represented; however the E-ECHOES study, which specifically 
included South Asian and Black participants, found that rates of heart failure were similar to 




The original ECHOES study required a reduced ejection fraction, or other structural or 
functional abnormality such as valve disease or arrhythmia, for a diagnosis of heart failure to 
be made and did not attempt to phenotype HFPEF.177 Including participants with heart 
failure due to AF may have partly captured the HFPEF group but it is likely that the original 
ECHOES study under-reported the prevalence of heart failure overall according to today’s 
definitions.  Echocardiography technology has also improved significantly since the original 
study, for example tissue Doppler, which is used to diagnose diastolic dysfunction, was not 
available in 1995 when the original ECHOES study began. 
 
7.6.2 Comparison with Existing Literature 
Several registries document the characteristics of patients admitted to hospital with heart 
failure179 and community-based studies, such as the Framingham and Olmsted County 
studies in the US or the Rotterdam study in the Netherlands, have followed up patients over 
a number of decades to describe the epidemiology of cardiovascular diseases, including 
heart failure.1 34 180  However, the ECHOES-X study represents the first follow-up study of a 
large UK cohort previously screened for heart failure. In particular, patients selected from 
the general population and found not to have heart failure a decade ago were re-screened 
to ascertain how many had developed the disease.  
 
At the time of the original ECHOES study, HFPEF was not identified as a separate diagnostic 
category12 but the follow-up study used the latest echocardiographic definition to identify 
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participants with HFPEF. In ECHOES-X, 73 of 176 (41%) participants found to have heart 
failure were classified as HFPEF. Pooled estimates from international community-based 
studies found an average HFPEF prevalence of 54% (range 40-71%) amongst those with 
heart failure.181 The presence of multiple echocardiographic abnormalities was also found in 
ECHOES-X and in previous screening studies has been shown to be associated with a 
significant increase in all-cause mortality.35 
 
Both HFREF and HFPEF were found to be more common in participants with cardiovascular 
risk factors at baseline, compared to the general population, which is consistent with recent 
findings from Framingham.4  However, the onset of heart failure timing in Framingham was 
determined according to outpatient and hospital records. In ECHOES-X, patients were fully 
screened, including echocardiography and NT-proBNP testing, to actively seek out new heart 
failure cases. The ECHOES-X results therefore represent findings from an actively screened 
community population. 
 
7.6.3 Implications for Practice and Further Research 
Screening identified a significant number of patients with previously undiagnosed heart 
failure in a population age 55 and over and therefore may provide a window of opportunity 
to intervene early and prevent heart failure progression, ultimately improving quality of life 
and survival. Screening of high-risk groups, in whom the prevalence of heart failure is 
highest, would seem the most effective strategy. Indeed data from the high-risk groups in 
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the original ECHOES study helped inform the UK Cardiovascular Disease National Service 
Framework182 and other guidelines183 recommending that echocardiography be undertaken 
in all patients following myocardial infarction; how frequently these patients should be re-
screened remains unknown.  
Other structural and functional abnormalities can also be discovered in asymptomatic 
patients which may provide further opportunities to provide timely treatment. For example, 
operating on patients with significant valvular disease who are well at the time of surgery 
substantially reduces their perioperative risk.184 Further investigation into the clinical and 
cost-effectiveness of optimal intervention for LVSD is also warranted. The level of natriuretic 
peptide currently used to rule out heart failure may be too high for a screened population. 
Nearly 20% of participants in the heart failure group had an NT-proBNP level less than the 
current threshold used in national guidelines.26  
 
Prospective studies are required to formally assess the value of screening - in particular to 
assess if and when patients with heart failure may benefit from earlier diagnosis and 
intervention. Patients at high risk of developing heart failure, such as those with a history of 
myocardial infarction, may benefit most from a targeted screening programme. 
 
7.7 Summary of the Chapter 
This chapter presented the findings of the ECHOES-X study which re-screened patients from 
the original ECHOES cohort. Progression to heart failure was more common in high-risk 
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groups but even in the general population was significant over time and screening provided 
an opportunity to identify new cases. The results of the natriuretic peptide sub-study 
showed that the cut-off level for ruling out heart failure must be low enough to ensure that 





8.1 Chapter Overview 
This chapter gives a summary of the key findings in this thesis. The strengths and limitations 
of the methodologies used are considered then the implications for practice, key 
recommendations and areas for further research are considered.  
 
8.2 Summary of Key Results 
Heart failure is an important disease associated with troublesome symptoms and reduced 
life expectancy for patients and high costs for healthcare systems.1 3 This thesis examined 
the clinical pathway for patients diagnosed with heart failure in primary care as illustrated in 
Figure 1. In Chapter 2, trends in the incidence of heart failure in the community were 
explored using records from a large general practice database. In Chapters 3-5, the patient 
experience from the development of symptoms to receiving a diagnosis of heart failure was 
considered and in Chapter 6, the survival rates of patients following a diagnosis of heart 
failure were determined from the same dataset. Finally in Chapter 7, the role of screening a 
community population to identify patients with heart failure was explored.  
 
In Chapter 2, The Health Improvement Network (THIN) database was used to examine 
patterns of a first diagnostic label of heart failure within general practice records. Overall, 
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incidence of heart failure increased with age and was more common in men than women. 
The incidence of a first diagnostic label of heart failure fell from 5.36 (95%CI 5.17 to 5.55) per 
1,000 person-years in year 2000 to 2.41 (95%CI 2.33 to 2.49) per 1,000 person-years in 2007 
and remained around 2.3 per 1,000 person-years until 2012. A moderate sized practice with, 
for example, 5,000 patients over the age of 45 years could therefore expect 10-12 new cases 
of heart failure per year.  
 
The qualitative interview study in Chapters 3-5 explored the patient experience of the 
diagnostic pathway. Patients with heart failure were asked to describe key points in their 
journey from the time they first noticed symptoms to when they received a formal diagnosis. 
Analysis using the Framework Method found that three key themes emerged: Heart Failure 
Onset, Interactions with Healthcare and Heart Failure Diagnosis - Delivery and Impact.  
 
In the Heart Failure Onset theme, participants experienced shortness of breath, ankle 
swelling and fatigue but initially ‘normalised’ their symptoms by putting them down to 
ageing, other co-morbidities, lack of physical fitness or a side effect of medications. 
Participants only sought medical help once their symptoms affected activities of daily living.   
 
In the Interactions with Healthcare theme, participants entered the healthcare system 
through primary care and were referred for further testing in secondary care. Patients 
valued the longitudinal relationship they had with their GP and practice and GPs were 
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usually quick to consider a diagnosis of heart failure, although not in all cases; two 
participants had a ‘delayed’ diagnosis where treatment for a different condition was 
initiated but failed to improve symptoms. Most participants in the study who could recall the 
sequence of consultations in detail were usually referred by their third or fourth GP 
appointment. Some participants described interactions with healthcare professionals in 
secondary care as impersonal or rushed. Logistical frustrations such as GP access and 
hospital waiting times for procedures added to patient burden. 
  
Finally, the Heart Failure Diagnosis - Delivery and Impact theme highlighted that the term 
‘heart failure’ was unhelpful for participants as they found it confusing. The impact of a 
heart failure diagnosis depended on the presence of other conditions, which may have 
caused more debilitating symptoms than the heart failure itself. Patient adaptability - ability 
and willingness to adapt to new circumstances – was important in determining the impact 
that the diagnosis had on patients’ lives.  
 
The findings of this qualitative interview study on the diagnostic pathway for heart failure 
highlighted areas where the patient experience could be improved. Greater public 
awareness of heart failure symptoms, improved access to primary care, a generalist patient-
centred approach in secondary care and adequate explanation of ‘heart failure’ as a term are 




THIN was used again in Chapter 6 to determine the survival rates in patients following a first 
diagnostic label of heart failure. The study found overall survival rates for cases with heart 
failure were 81.5%, 51.6% and 29.5% at one, five and ten years, respectively although 
survival changed little between 2000 and 2012. Confirmed evidence of heart failure was 
associated with improved survival. 
 
In Chapter 7, the results of the ECHOES-X study, which re-screened the participants of the 
original ECHOES study, were reported. 1618 of 3408 participants underwent screening which 
represented 47% of survivors and 26% of the original ECHOES cohort. A total of 176 (11%, 
95% CI 9.4% to 12.5%) participants were classified as having heart failure at re-screening; 
103 (58.5%) had heart failure with reduced ejection fraction (HFREF) and 73 (41.5%) had 
heart failure with preserved ejection fraction (HFPEF). 68 of 1232 (5.5%, 95% CI 4.3% to 
6.9%) participants who had been recruited from the general population over the age of 45 
and did not have heart failure in the original study, were found to have developed heart 
failure on re-screening. An NT-proBNP cut-off of 400pg/ml had sensitivity of 79.5% (95% CI 
72.4% to 85.5%) and specificity of 87% (95% CI 85.1% to 88.8%) for the diagnosis of heart 
failure, so one in five of those with heart failure would be missed at this threshold. Re-
screening provided an opportunity to identify new cases of heart failure and participants 
with cardiovascular risk factors, particularly a history of myocardial infarction, were most 




8.3 Strengths and Limitations of Methodologies 
This thesis used both quantitative and qualitative methods to answer the research questions 
posed at the beginning. The strengths and limitations of these methods were considered in 
the discussion of each study and are summarised here. 
 
8.3.1 The Health Improvement Network – Incidence and Survival Analysis 
General practice databases such as THIN provide a large amount of data taken directly from 
the records of patients presenting to their GP with a wide variety of symptoms.86 The NHS is 
free at the point of access and nearly everyone in the population is registered at a general 
practice allowing a denominator – the number of people in the population – to be 
generated.  The number of patients in the dataset is far greater than prospective studies 
and, unlike some research cohorts, provides a snapshot of the activity in ‘real-life’ general 
practice.87 The results of the incidence and survival analyses are therefore likely to be 
generalizable to the community population of the UK.97  
 
The main limitation of THIN database is the reliability on accurate clinical coding.39 Heart 
failure is a chronic condition which is often insidious in onset and can masquerade as other 
conditions making early and accurate diagnosis difficult.21 All records within the database 
are anonymised so researchers are unable to see individual patient records. The quality of 
the data therefore depends on the accuracy of the clinical codes input by clinicians, usually 
GPs, who use the system during routine consultations. Reliability of coding has improved 
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over time, particularly for some conditions where payment for performance through the 
Quality and Outcomes Framework (QOF) relies on the use of certain clinical codes to identify 
work which has an associated financial incentive; a QOF heart failure indicator was 
introduced in 2006. 90 90 The observed fall in incidence between 2000 and 2007 may partly 
reflect more robust clinical coding methods, in addition to any true reduction in new heart 
failure cases.98  
 
The definition of heart failure has also altered over time so a code for heart failure in an 
individual’s medical record may be based on different criteria depending on the accepted 
definition at the time of diagnosis.7 29 30  In addition, two distinct types of heart failure have 
recently been recognised: heart failure with reduced ejection fraction (HFREF) and heart 
failure with preserved ejection fraction (HFPEF).7 The emergence of this new classification 
has meant that the clinical picture of heart failure is changing and, from a recent search we 
undertook for these codes in THIN database, coding in the general practice record has not, 
until very recently, started to capture this.  
 
The survival analysis did not explore cause of death, or other factors associated with 
outcome. THIN database does not record death certificate information although this is being 
introduced. More broadly the cause of death on certificates may not always be accurate.185 
This may be particularly true for heart failure which is associated with symptoms such as 




8.3.2 Qualitative Study 
The qualitative interview study examined the experience of the diagnostic pathway for 16 
patients referred from primary care to a large heart failure clinic at a teaching hospital in 
central Birmingham. The findings suggest that there are areas at both an individual patient 
and system level where patient experience and healthcare processes could be improved. As 
well as improved access to primary care, increased provision of generalist services and 
improved communication, the study highlighted a need to raise awareness of heart failure 
symptoms amongst the community population, particularly amongst those most at risk.  
 
The study recruited participants from a single outpatient clinic which may have introduced a 
selection bias and could limit the generalisability to other heart failure services; however the 
findings are unlikely to be isolated to patients attending this clinic, particularly the 
observation that participants normalise their heart failure symptoms until they have an 
impact on daily life, a phenomenon which has been well described for other chronic 
conditions.126 127 128 There was also the potential for researcher bias, as a GP conducting the 
interviews and carrying out analysis myself, although attempts were made to minimise this 
effect, as described in detail in Chapter 5. The study was carried out according to a detailed 
protocol and robust analysis using the Framework method and crosschecked by experienced 




8.3.3 Screening for Heart Failure 
The ECHOES-X study re-screened those still alive and willing to participate from the original 
ECHOES study. Participants underwent detailed clinical assessment which ensured a reliable 
diagnosis of heart failure could be made. The ECHOES cohort represents one of the largest 
groups of participants screened for heart failure in the world. The epidemiological 
information from the original ECHOES study, and related work on the five and ten year 
prognosis of the cohort, has advanced knowledge in the area of heart failure epidemiology in 
the community population. ECHOES-X provides a further understanding of the progression 
to heart failure more than a decade after the original study, and also provides a new 
baseline for further prognostic research. 
 
Prospective research studies rely on volunteers and so may not be as representative of the 
general population as databases of routinely collected GP records. The interval between the 
original and follow-up studies also meant that participants could have developed heart 
failure and subsequently died in the intervening period. The relatively low response rate may 
have introduced bias and the rates of progression to heart failure may have been different in 




8.4 Implications for Practice, Recommendations and Further Research 
8.4.1 New Heart Failure Cases 
The incidence study found that new cases of heart failure are occurring at a consistent rate 
(2.3 per 1,000 person-years). This figure, stratified for age, sex and ethnicity of the 
population, could be used by commissioners to predict the likely number of new heart 
failure cases that will occur in the community they serve in any given year. This has 
implications for both diagnostic services and also provision of heart failure management 
including heart failure nurses, general practitioners and other community services.   
 
The reasons why incidence has remained static need further exploration. Is it because more 
patients survive myocardial infarction but with a damaged heart and subsequently develop 
heart failure? Or is it that risk factor modification at a population level has been successful in 
some areas (e.g. reduced smoking rates) but not in others (e.g. rising obesity rates)? A better 
understanding of the trends in disease pattern could highlight areas where intervention may 
be best targeted. The effectiveness of any intervention could then be explored through 
prospective research particularly randomised controlled trials.   
 
It is also important to explore the trends in incidence in other datasets so a similar analysis is 
planned in Clinical Practice Research Database (CPRD) to see if the number of new cases and 
pattern over time is similar. International comparison may also be valuable; Australia and 
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Canada have healthcare systems with a strong primary care base and so opportunities for 
epidemiological studies in these countries are being explored.  
 
8.4.2 Awareness of Heart Failure Symptoms 
The qualitative interview study revealed that patients developed plausible and complex 
explanations for their symptoms which delayed their presentation to primary care. Increased 
awareness of heart failure symptoms is vital for patients, carers and the public to recognise 
the condition. Campaigns by government and charities have raised awareness of the 
symptoms of several different cancers with the hope of earlier diagnosis leading to better 
outcomes. A similar campaign at a national level, or a more targeted campaign aimed at 
those with a previous history of myocardial infarction, may help encourage patients with 
possible heart failure to access healthcare earlier. This would have a large associated cost so 
further research in this area to consider effectiveness is warranted. 
 
Patients who are at increased risk of heart failure such as those with a history of myocardial 
infarction, come into contact with the healthcare system frequently. Initially following a 
cardiac event, patients are invited to attend cardiac rehabilitation programmes. Yet none of 
the participants in the qualitative study with a history of MI had initially considered heart 
failure as a possible cause for their symptoms. Education about the symptoms of heart 
failure may be considered although further research would be required to assess the 
acceptability and usefulness of this approach. In addition, patients are seen annually by their 
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GP as part of the QOF coronary artery disease indicator. It should be feasible to include 
screening questions such as ‘Do you get breathless, tired or swollen ankles’ and/or arrange a 
natriuretic peptide test to effectively ‘screen’ for heart failure in this high-risk group. 
 
8.4.3 Improving Patient Experience 
Interviews with patients revealed some difficulty in accessing general practice which is a key 
entry point in the diagnostic pathway. Improved access to general practice through 
increasing the number of GP appointments would help to allow patients to be seen more 
easily and quickly. When the patient was able to see the GP, the care was good overall. In a 
small number of cases, a different diagnosis was considered before heart failure. Availability 
of point of care testing to measure natriuretic peptide level within the practice may have 
helped differentiate the cause of symptoms in those patients, although further research is 
required to assess the cost-effectiveness of this option. 
 
There is a need for a compassionate, patient-centred approach in secondary care. The 
‘Hellomynameis…’ campaign in hospitals is helping to improve communication skills of 
secondary care staff and help patients feel more at ease by knowing the name of the person 
responsible for their care.149 Clinicians should explain key parts of the diagnostic pathway, 
including what tests are required and why, and patients should have the time and 




The delivery of the diagnosis of heart failure needs to be done in an empathic way. Patients 
wanted more information about heart failure and often sought this out after being told 
about their condition. Appropriate written information should be given to all patients 
following a diagnosis of heart failure. Further opportunities to discuss the diagnosis and its 
implications and to ask any questions, should be agreed for a future date a short time after 
the initial diagnosis. Facilitating physical and psychological adaptation following the 
diagnosis should be an important part of any heart failure management plan; more research 
is required to establish how to achieve this in the most effective way. 
 
Patients with heart failure are often managing multiple conditions and taking many 
medications so need generalist (managing the whole person rather than just one system) as 
well as specialist care. More emphasis on the benefits of generalism and training in 
generalist skills within secondary care are needed. 
 
8.4.4 Outcome of Patients with Heart Failure 
The survival rates presented in Chapter 6 provide estimates of prognosis by age and sex at a 
population level. Discussions with patients about their individual outlook should be done in a 
sensitive manner, if and when they wish to discuss the issue. More tailored and reliable 




The outlook for patients with heart failure at one, five and ten years following diagnosis 
were better than reported for some hospital populations169 but survival had not changed for 
more than a decade. More research is needed to examine this trend in greater detail and a 
similar analysis in a different UK dataset (CPRD) is planned. Has survival improved in some 
subgroups but declined in others resulting in no overall change in prognosis? What factors at 
an individual patient level are most important in determining prognosis? How can 
interventions at a population and individual patient level improve outlook for patients 
following a diagnosis of heart failure? International comparison is also planned to establish if 
this trend in survival rates is seen in other primary care settings, particularly Canada and 
Australia.   
 
8.4.5 Could Screening for Heart Failure be a Solution? 
Screening provides an alternative diagnostic pathway to identify patients with heart failure 
in primary care. The screening study in Chapter 7 identified participants with a new diagnosis 
of heart failure. Those with risk factors such as previous MI were particularly at risk of 
subsequently developing heart failure. However this thesis does not recommend screening 
as a diagnostic strategy and more research is required to evaluate the benefit. Table 4 sets 
out the criteria required by the UK National Screening Committee before recommending a 




Firstly, the condition must be important and well understood, and primary prevention 
should have been implemented. Heart failure is often the end result of a sustained insult to 
the heart. Primary prevention of cardiovascular disease is a priority in the NHS but remains 
suboptimal.186 Opportunities to modify risk factors associated with the development of heart 
disease are often missed. More emphasis on identifying and treating conditions which are 
the precursors to heart failure, such as hypertension and diabetes, could reduce the number 
of people diagnosed with the condition over time.187 
 
Secondly, the screening test needs to be simple, precise and validated. Natriuretic peptide 
testing is a possible screening test for heart failure although the cut-off values remain 
controversial. As described in Chapter 7, the threshold level would need to be low enough to 
ensure cases of heart failure are not missed. In particular, in a screened population the levels 
of natriuretic peptide may be lower than in patients presenting with symptoms at a 
potentially more advanced stage of the disease. Further work on optimal cut-off levels in 
screening is planned.  
 
Thirdly, effective interventions which improve outcomes need to be established for patients 
identified earlier in the disease process through screening. It is currently unclear if treatment 
for heart failure at an early, asymptomatic stage improves quality or quantity of life for 




Finally, the benefits, harms and opportunity cost of any screening programme need to be 
considered. Screening is expensive and can cause unnecessary psychological burden. More 
research is required to establish if screening for heart failure leads to improved outcomes for 
patients. Can an earlier diagnosis of heart failure improve patient outcomes such as quality 
of life and survival? Would a targeted screening programme, inviting those most at risk such 
as heart attack survivors, effectively identify patients with heart failure and be a cost-
effective option to reduce morbidity, mortality and the high healthcare costs currently 
associated with the disease? Until all of the questions are addressed, the value of screening 
for heart failure remains uncertain. 
 
8.5 Summary of the Chapter 
This chapter summarised the key findings of the thesis, explored the strengths and 
limitations of the methodologies used and presented key recommendations and areas of 
further research. 
 
8.6 Conclusion of the Thesis 
The research questions in this thesis arose from real-life clinical and teaching scenarios in 
which I realised that there was not a current evidence-base to answer the questions posed 
by my patients and students.  Through the four studies in this thesis, I have provided 
evidence to answer these questions and identified new areas in which further research is 
needed. Primary care remains an important part of the clinical pathway for patients with 
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heart failure and strategies to reduce the number of new cases, enhance patient experience 







9.1 My Contribution 
 
GP Database Incidence and Survival Studies: I conceived the idea, gained ethical approval 
through the Scientific Review Board at THIN, drafted the protocol, generated coding lists, 
carried out statistical analysis using Stata 10 and 11, interpreted the findings and presented 
the results at the NIHR School for Primary Care Research Showcase in Oxford, September 
2014 as a plenary lecture (abstract ranked joint top). 
Dr Ronan Ryan (research fellow) and Linda Nichols (data analyst) extracted the data from 
THIN and transferred into Stata. Linda Nichols provided statistical support at the early part of 
the study. Sayeed Haque (statistician) provided statistical advice at the end of the study. 
Professor Tom Marshall (supervisor) provided comment on data extraction, analysis plan and 
draft manuscripts throughout.  
 
Qualitative Interview Study: I conceived the idea, drafted the protocol, obtained ethical 
approval through the National Research Ethics Service, conducted all 16 interviews, 
transcribed the first 4 transcripts, generated the coding framework, coded all transcripts, 
summarised the data into the analytical framework, developed the analytical memo for each 
category, identified emerging themes and concepts, reviewed the literature and presented 
the findings at the Society for Academic Primary Care conference in Oxford, July 2015. 
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Professor Francisco Leyva-Leon and team facilitated recruitment. Sonal Shah (research 
fellow) commented on the coding framework. Dr Nicola Gale (qualitative researcher and 
supervisor) oversaw each stage of data collection and analysis.  
 
ECHOES-X Study: I have been part of the ECHOES-X study team since 2008. I carried out the 
data collection, along with a trained echocardiographer, for the first nine months of the 
study. I also trained research nurses to complete data collection. I provided clinical input and 
advice to the team throughout the study. Once data collection was completed, I worked with 
the study statistician to determine an analysis plan and I was one of three clinicians on the 
consensus panel to determine the diagnosis where it was equivocal. 
The recognised definition of heart failure changed twice during the study so all cases of 
heart failure needed to be reclassified clinically based on the new criteria at the end of the 
study. I developed a diagnostic algorithm to allow a diagnosis to be allocated along with a 
plan for analysis and presented it to the team in 2012 and again, following further 
refinement, at a team meeting in February 2013. The study statistician calculated the final 
numbers according to this agreed analysis plan. I presented the final set of results at a team 
meeting in May 2013. I wrote the first draft of the manuscript and subsequent revisions 
prior to its publication in BMJ Open.  
Professor FD Richard Hobbs was Principal Investigator for the study and Dr Russell Davis 
provided clinical cardiology expertise. Andrea Roalfe, senior lecturer and statistician for the 
heart failure team, undertook the statistical analysis using SAS. Dr Lynda Tait was project 
manager and Mrs Rachel Iles was research fellow. 
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The work submitted in this thesis has been presented at two national and one international 
meeting and published in two peer-reviewed journals to date: 
Conference Abstracts 
- Taylor CJ, Ryan R, Nichols L, Gale G, Hobbs FDR, Marshall T. Incidence and Survival of 
Patients with a First Diagnostic Label of Heart Failure in General Practice. Plenary 
Presentation (top scoring abstract), NIHR School for Primary Care Research showcase, 
University of Oxford, September 2014. 
 
- Hobbs FDR and Taylor CJ. Incidence and survival of patients with a first diagnostic label of 
heart failure in primary care. North American Primary Care Research Group Annual 
Meeting, New York, NY, November 2014. 
 
- Taylor CJ. Heart Failure – A Primary Care Problem. Yvonne Carter Outstanding New 
Researcher Prize Presentation, Society for Academic Primary Care Annual Scientific 
Meeting, University of Oxford, July 2015. 
 
- Taylor CJ, Hobbs FDR, Marshall T, Leyva-Leon F, Gale N. Patient experience of the clinical 
pathway for diagnosing heart failure in primary care. Society for Academic Primary Care 




- Taylor CJ and Hobbs FDR. Heart failure therapy in patients with coronary artery disease. 
Curr Opin Pharmacol 2013; 13:205-209. 
 
- Taylor CJ, Roalfe AK, Tait L, Davis RC, Iles R, Derit M, Hobbs FDR. Observational 
longitudinal cohort study to determine progression to heart failure in a screened 
community population: the Echocardiographic Heart of England Screening Extension 
(ECHOES-X) study. BMJ Open 2014; 4:e005256. doi:10.1136/bmjopen-2014-005256 
 




Taylor CJ, Ryan R, Nichol L, Gale N, Marshall TP*, Hobbs FDR*. Incidence and survival of 
patients with a first diagnostic label of heart failure in general practice:  a UK retrospective 
cohort study (*joint senior author) 
Taylor CJ, Marshall TP, Hobbs FDR, Leyva-Leon F and Gale N. Patient experience of heart 





9.2 Patient Information Sheet 
 
Patient Information Sheet 
 
Patient Experiences of Diagnosis of Heart Failure in Primary Care 
Principal investigator: Dr Clare J Taylor 
 
You are invited to take part in a study looking into heart failure diagnosis in primary care. 
This information sheet explains the reasons we are doing the study and what will be 
involved if you decide to take part. Please read the information in your own time and 
discuss with friends and family if you want to. Please contact us if you have any queries 
or would like to be involved. Thank you for taking the time to read this. 
 
What is the purpose of the study? 
The study is designed to find out about patients experience of seeing their doctor and 
being diagnosed with heart failure. 
 
Why have I been chosen? 
You have been invited to take part in the study because you have recently been 
diagnosed with heart failure. 
 
Do I have to take part? 
It is your choice whether to take part or not. If you do want to be part of the study, you 
will be asked to sign a consent form and you will be given a copy of this for your records. 
A letter will also be sent to your GP to let them know you are in the study. You can 
withdraw from the study at any time and you do not have to give a reason. 
 
What will happen to me if I take part? 
The study will involve being interviewed for approximately 1 hour by a training 
researcher. Interviews will take place in your own home or at an alternative location 
convenient to you. We will ask you to describe your experiences from when you first 
noticed symptoms to when you received the diagnosis of heart failure in the clinic. The 
interview will be recorded on a tape player and then analysed along with recording from 
interviews with other patients who have the same condition. 
 
Will my taking part in this study be kept confidential? 
The interview will be confidential and the data we gather will be recorded anonymously. 
The recordings will be transferred into a written document called a transcript. This will 
be securely stored at the University of Birmingham according to the university’s ‘Code of 
Conduct for Research’. According to this code, transcripts have to be kept securely for 10 
years after the study has been reported. We may use some direct quotes in the final 
report but these will be anonymous so no one will know who said them. 
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What will happen to the results of the study? 
The results will be published in a scientific journal which will allow doctors and other 
medical professionals to understand more about the patient experience of being 
diagnosed with heart failure. 
 
Who is organising and funding the study? 
The University of Birmingham is organising the study and it is funded by the National 
Institute for Health Research.   
 
What indemnity arrangements are in place? 
The University of Birmingham has an insurance policy which covers research studies. 
 
How can I get further information? 
Please contact Dr Clare Taylor   if you would like to find out more about 
the study or would be willing to take part. 
 
 










Version 1.1 – 7th August 2013 
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I confirm that I have read and understood the patient information sheet for this 
study and have had the opportunity to ask questions. 
 
 
I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my legal rights being affected. 
 
 












I confirm that I give permission to use direct quotations. I understand that any 





Name of Interviewee [please print]__________________________ 
 
 




Name of Researcher [please print]__________________________ 
 
 
Signature _________________________   Date _____(day)/_____(month)/____(year) 
 
Version 1.1 – 7th August 2013  
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9.4 Interview Topic Guide 




Dr Clare J Taylor, GP and Clinical Research Fellow 
 
 
Introduction (5 mins) 
Thank you for taking part in this research. 
 
Introduce self – Clare Taylor doing PhD at University of Birmingham. 
 
Duration – interview will last about an hour. Please let me know at any time if you would like 
to take a break. 
 
Purpose of study – To get a better understanding of the experiences of patients affected by 
heart problems.  
 
Confidentiality – As I mentioned before, I will be recording the interview using this tape 
machine if that’s ok with you? All discussions are confidential and data will be safely stored.  
 
Questions – We want to hear about your experience so there are no right answers. Please 
feel you can be open and tell us what you really think and feel.  
 
Respondent introduction (10 mins) 
Tell me a bit about yourself: 
- Age 
- Family 
- Social situation 
 
Research topics (40 mins) 
Tell me about when you first noticed there might be something wrong? 
- What symptoms did you experience? 
- What did you think might be happening? 
 
Tell me about your thinking around going to see the doctor for the first time. 
- Was there anything that prompted you to go? 
- Was there anything that stopped you from going? 
 
Tell me what happened after that. 
- Did you have any tests? 
- Tell me about your symptoms during that time? 
- How did you feel during this time? 
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Tell me about your diagnosis. 
- What have you been told about your diagnosis? 
- What does that mean to you? 
- Is there anything you don’t understand? 
 
Are there are part of the process which you feel could be changed or improved? 
 
Close (5 mins) 
Summarise key topics discussed. 
Are there any further questions? 








Role of age Influence of age in treatment decisions, 
lifestyle, outlook on life. As explanation for 
symptoms. 
Retirement Duration, daily activities, advantages. 
Occupation Influence on interpretation of symptoms, 
understanding of diagnosis. Manual or 
professional. 
Social life Sports, hobbies, going out, enjoyment. 
Religion Role in sense-making. Impact on decision-
making. 
Independence Importance of maintaining independence. 
Independent thought and decision-making. 
Autonomy. 
Role of Family  
Spouse/partner Marriage. Co-dependence. Spouse fitness. 
Spouse illness. Bereavement. 
Children Jobs, location, offspring. No children. 
Relationships Generations, positive relationships, conflict. 
Practical help Support with daily activities, socialising. 
Geographical location Role of geography on relationship, help, 
involvement. 
Interactions with healthcare professionals Call ambulance. Speaking to doctor. Hospital 
appointments. 
Role in decision-making Support. Asking questions. Respect patients 
autonomy. 
Time 
Symptom onset Gradual. Sudden.  
Delay in seeking medical advice Reasons for delay. Lack of delay.  
Progression of symptoms Got worse. Got better.  
Recall of events Clear. Can’t remember. Conflicting accounts.  
Temporal sequence of events What happened first, how did events link, 
emergency, planned. 
Prompt to seek medical advice Factors which influence help-seeking. 
Emergency.  
Waiting Length of wait. Consequences of wait. Cause 
of wait. 
Symptoms 
Shortness of breath Breathlessness, on exertion, at rest, in bed 
(orthopnoea). Onset.  
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Swollen ankles When noticed. How often. Action. 
Chest pain Dizziness 
Dizziness When. Where. Severity. Cause. 
Pain Onset, duration, management, cause. 
Lack of symptoms Absence of expected symptoms. Symptoms 
resolved.  
Patient understanding of symptoms Put down to age, prior medical knowledge, 
media influence. 
Symptom improvement Following treatment, procedure, with time. 
Medical Interactions – logistical 
GP appointments Number of appts. Ease of obtaining appt. 
Same/different GP. 
Telephone consultations Role of telephone consultation. Acceptability 
to pt.  
Home visits Availability. HCP doing visit. Reason for visits.  
Delay/prompt action in primary care Were there delays, if so where and why? 
Was action prompt. 
Ambulance What prompted call. Who called ambulance. 
Speed of arrival. Role of ambulance crew. 
Hospital appointments Number. Where. Difficulties.  
Hospital stay Duration. Experience. Discharge. 
Emergency or elective Presentation, appropriateness of care. Speed 
of action. Effect of other emergencies. 
Delay/prompt action in secondary care Were there any delays or prompt action in 
secondary care. What caused 
delay/facilitated prompt action. Waiting 
lists. Cancellations. Consequences. 
GP role in co-ordinating care Request tests, referral. Expedite hospital 
appointments. Follow-up care.  
Patient safety Role of patient safety within primary and 
secondary care. Protocols and processes to 
ensure pt safety. 
Patient empowerment Knowledge of services. How to access care. 
Understanding of system. 
Healthcare costs  Cost of care received. Amount in private 
sector. Foreign healthcare system costs. 
Value of health. 
Medical Interactions – decision-making 
Initial GP appointment When. Action agreed. Explanation. 
Referral To whom. When. Problems.  
GP-patient relationship Duration, positive, conflict, trust. 
Primary/secondary care interface Interaction between GP and specialists.  
Consultant(s) Actions – e.g. arrange tests. Explanation. 
Conflicting advice. Responsibilities.  
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Heart failure nurses Actions. Role in care. Follow-up. 
Responsibilities. 
Other healthcare professionals Echo tech, nurses, porters. Effect on 
experience. 
Shared decision making Patient involvement in decisions. Patient 
ability to challenge medical opinion.  
Alternative treatment options Second opinion, all options, pros and cons.  
Resources/rationing Availability of expertise, beds. Role of 
waiting times. Equity, fairness. Competing 
pressures. 
Explanation of Symptoms 
Patient explanation of symptoms Patient’s own explanation. Lack of 
explanation.  
GP explanation of symptoms Patient’s recall and understanding of GP 
explanation. 
Specialist (consultant/HF nurse) explanation 
of symptoms 
Patient’s recall and understanding of 
specialist explanation. 
Previous health state 
Premorbid state Prior to developing symptoms of HF. 
Primary prevention Strategies to keep well – done in past or 
wish had done. 
Prior health beliefs Ideas around cause of illness and protective 
factors.  
Multimorbidity/co-morbidities 
Cardiovascular co-morbidities Heart attack, stroke, arrhythmias. 
Contribution to heart failure. 
Arthritis When. Effect on life. Treatment.  
Mental Health Impact of mental health on physical health. 
Treatments. Quality of life. 
Other conditions Number of conditions. Treatment burden.  
Ageing process Role of the ageing process in symptoms and 
diagnosis. Impact of ageing on lifestyle. 
Diagnostic Tests 
Electrocardiogram When, how many, where, purpose of test. 
Heart scan When, how many, where, purpose of test. 
Blood test When, how many, where, purpose of test. 
Specialised tests e.g. angiogram Reason for the test, done by whom. 
Patient understanding of tests Reasons for tests, process involved, risks, 
what hope to find out. 
Explanation of Diagnosis (and Causes) 
Patient’s own explanation of HF Patient’s own understanding, meaning, 
theory about cause. 




Specialist explanation Patient’s recall and understanding of 
specialist explanation. 
HF nurse explanation Patient’s recall and understanding of HF 
nurse explanation. 
Causation Cause of heart failure. Relationship to 
symptoms. 
Heart failure terminology Meaning of the term ‘heart failure’. 
Emotional response. Use of the term. 
Impact on Life 
Activities of daily living Limitations, what able to do, aids, support. 
Physical activities Limitations, adaptations, support. 
Socialising Events, relationships with friends, positives. 
Driving Role of driving. Limitations. Safety. 
Travel Concerns. Feasibility. Insurance. 
Patient adaptability Ability, willingness to adapt to new 
circumstances/limitations. Capacity to adapt 
– enablers and barriers. 
Treatment 
Purpose of treatment Why on tablets. What hope to achieve. 
Initiation When, by whom, any problems, timely, 
patient understanding. 
Monitoring What involved. Done by whom. Role of 
patient e.g. self-monitoring. Follow-up. 
Side effects What side effects. Explanation. Impact on 
lifestyle. 
Polypharmacy Multiple medications. Interactions. 
Treatment burden. 
Delay in treatment Cause of delay. Consequence of delay, 
avoidable/unavoidable factors. 
Patient understanding and knowledge of 
treatments and side effects 
What patient knows about medications. 
Ability to recognise causal link between 
medications and their side effects. 
Cardiac surgery When, where, duration, operative risks. 
Cardiological intervention Stents, angioplasty. Why, when, outcome. 
Implantable cardiac defibrillator Why needed, how inserted, what it does. 
Effect of treatment on symptoms Improve, worsen, no effect. How soon. 
Treatment for other co-morbidities Conflicting treatments, suboptimal 
treatment due to other conditions. 
Current health state 
Wellness Feeling well. Sense of wellbeing. 
Age Expectation for age. Comparison with age 
cohort. 




Psychological adaptation Acceptance of diagnosis, coping with illness. 
Uncertainty Unanswered questions, worries. 
Research and teaching Assist in training doctors, medical students. 
‘Give something back’.  
Outlook 
Death Possibility of death during diagnostic 
pathway or treatment procedures.  
Survival rates Discussion with whom. Patient perception. 
Want/not want to know. Initiated by whom. 
Long term planning Residential care. Palliative care. End of life 
care. 
Do Not Attempt Resuscitation (DNAR) Had discussion? Outcome? 
Quality of Care 
Failure in care Breakdown of care. Failure to manage 
appropriately. Effect on patient.  
Good experience Positive experiences within care – who/what 
were these down to. 
Continuity of care GP, primary/secondary care interface, 
consultant, HF nurses, discharge. 
Relationships with healthcare professionals 
(HCPs)  
Patient relationship with GP, consultant, 
nurses, other HCPs. 
General practice care Overall quality of care provided by practice 
team 
Hospital care Overall quality of care provided by hospital 
Communication skills All HCPs. Listening, breaking bad news, 
dealing with conflict, checking 
understanding. 
Patient satisfaction Satisfied, frustrated, happy, recommend to 
others, dissatisfaction. 
Complaints Patients approach to raising 
concerns/complaint. Enablers and barriers. 
Reluctance to criticise. 
Suggestions for change Areas for improvement, complaints, conflict, 
unresolved issues.  
Value of NHS Importance of NHS in patient’s lives. What it 
means to them. 
Patient’s Emotions 
Grateful Gratitude, thankful to people and/or health 
services. 
Relief Sense of relief. Following period of worry. 
Positive outlook Feeling of happiness. Optimism about the 
future. 
Fear Scared, frightened, fearful during process or 
about the future. 
241 
 
Anxiety Anxious, worry before, during or after 
diagnosis. 
Trust Trust or lack of trust in individuals, 
healthcare service, spiritual figure. 
Anger Angry with medical care, disease process, 
hospital logistics. 
Burden and guilt ‘Being a burden’. Feeling of over-reliance 
and dependence (e.g. on family) leading to 








9.6 An Example of Charted Data in Framework Matrix 
Extract from Explanation of diagnosis (and causes) category 
 
 Patients own 
explanation of HF 
GP explanation Specialist explanation HF nurse explanation Causation HF terminology 
P1 "I’ve got heart failure 
and [er] me heart is 
only [er] function, 
functioning at 20%. All 
the rest is [er] they say 
is dead you know 
soluble…" 
 Breaking bad news: 
"...she was a registrar. 
She was good, no 
doubt about it, she 
knew her job. And [er] 
[pause] she came out 
with the [er] not very 
nice words, you realise 
you could drop down 
dead at any time and 
[er] it shook me to the 
core, and me wife, and 
me daughter."  
   
P2 "Well I mean heart 
failure means, when 
they heart failure it 
means your heart’s 
going to, it’s wearing 
out or whatever, it’s 
going to stop. It could 
stop. It’s failing. And I 
know you’ve only got 
one so I mean let’s face 
it that’s not a good 
thing." 
 "Well, they told me my 
heart’s not working 
properly". Need for 
more detailed specialist 
explanation: "I’ve 
looked up on the 
computer...so I’ve I’ve a 
pretty good 
understanding I 
suppose of what 
happens but [erm] 
[pause] I don’t know 
about me and that’s 
  "It was worrying I mean 
you know when they 
tell you that your 
hearts not working 
properly and they call it 
‘heart failure’, 
whatever’s wrong with 
your heart they call it 
heart failure don’t they 
which I think is horrible 
because failure means 
[laughs] it could stop 
you know. That’s 
243 
 
what I want to know 
about me." Suggestion 
for more time and 
explanation as felt 
rushed: " I think 
appointments telling 
you more about your 
particular problem. I 
realise their hurry and 
it seems like they want 
to get you out because 
the next person’s 
waiting to come in, I 
mean but [erm] I don’t 
think age should, 
should, should be a 
factor in that. I think 
they should, you know, 
give you just as much 
time and explanation as 
they do with a young 
person [pause] but they 
don’t."  
worrying but [erm] the 
longer you live with it, 
the more you get used 
to it". 




 "...he said to me that I 
could have, the heart 
wasn’t pumping the 
blood, round the body 
sufficiently and I could 
have developed a 
cardiac arrest." Seen 
for tests at one stop 
clinic and cardiologist 
explanation at the end: 
"he says all this, that 
[um] me heart wasn’t 
pumping the blood 
around the body but 
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[pause] that’s what 
causes it."  
P4 Engineer uses 
background to explain 
HF: "because [er] 
having been an 
engineer, it’s a pump 
system isn’t it that’s all 
it is, it’s a pump 
system. You’ve got the 
[er] power of the 
pump, you’ve got the 
pipework going round, 
and the various sizes of 
the pipework. And if 
you [er] increase the 
size of the pipework, 
the pump will bang it 
round very easily but if 
the pipework gets [er] 
constricted in any way 
then the pressure will 
go up. There’s an easy 
hydraulic relationship 
with that, the viscosity 
of the blood is the 
other thing." 
GP had provisionally 
diagnosed cause of 
swelling. "as my doctor 
had diagnosed, it was 
this [er] blood not 
getting circulated 
round." "the doctors 
described what [er] 
what he thought was 
going on with respect 
to the [erm] the 
swelling up. And really 
that was the only 
diagnosis I had ‘cause I 
was satisfied that that 
was what was going on 
‘cause I understood the 
basics with regard to 
plumbing system shall 
we say." 
Specialist did drawing 
to show damaged bit of 
heart at bottom, ", as 
my doctor had 
diagnosed, it was this 
[er] blood not getting 
circulated round. And it 
was then that [er] I was 
given the information 
that I could be having a 
development of heart 
failure. And that was it 
really they couldn’t say 
what the heart failure 
was." 
 Pt description 
(engineer): "as any 
other machine is, being 
static until it’s asked to 
do something. It can’t 
tell you what bits are 
are wearing out. They 
could tell you if you had 
a valve going or 
something like that. I 
know that the bottom 
end of my heart has 
been damaged slightly. 
So there really is not 
much other other that 
can be done. But they 
can’t switch the power 
off and you can see the, 
your heart there. You 
only know what the 
physical effect of it is." 
 
P5 Not aware has HF. Only explanation pt has 
received was from GP: 
"Nobody mentioned 
anything about 
problems with my 
heart. It was only the 
one occasion when I 
was… Before I went to 
the hospital, I went to 
Limited explanation 
from specialist: "But 
I’ve asked since, and 
they’ve said, at that 
particular time, my 
heart was like, you 
know, it’s a bit iffy."  
Not aware has heart 
failure, HF nurses not 
explained and 
reassured: "Of course I 
asked her that and she 
said, “We’re perfectly 
happy. Your heart is 
giving no problems. 
Your blood is okay, and 
 "Have they mentioned 
the diagnosis of heart 
failure to you 
specifically?  
Respondent: Sorry? 
Interviewer: Have they 
mentioned a diagnosis 




my GP and he gave me 
a good examination 
and he explained to me 
about this. I’ve got the 
leaflets in there." Use 
of humour: "So he 
knows all about it and 
all that. As a matter of 
fact, he’s got a model 
of his heart on his desk. 
I said to him, “Can I 
have that? It looks a 
good one.” (Laughter)" 
everything is okay.” Respondent: No." 
P6 "I know I’ve got a weak 
heart." 
 Poor explanation and 
communication: "I 
don’t know what he 
was actually. He didn’t 
give a name. He didn’t 
say, “I’m a so and so”. 
All he said was that I’ve 
got a weak heart. I said, 
“What would happen if 
something... I needed 
to come in, what 
treatments?” He said 
none. There’d be no 
treatment if I came in. 
So I thought “Well, 
what a happy day!” 
Lacking in feelings of 
any sorts. They were so 
impersonal." "Just how 
impersonal the 
personnel were when I 
went in for my heart 
examination. That 
could be improved 
 No clear cause: "No. I 
just think I gradually 




immensely. It wouldn’t 
have hurt them to have 
become a little human 
and thought a little bit 
about the... just the 
diagnosis and “There 
you are. [bump]”. 
There’s a better way of 
dealing with somebody 
than that. Not difficult 
to do."  
P7 "I was having a job 
going up and down 
stairs and I was saying, 
because I’m not getting 
enough oxygen in my 
blood, to have the 
energy to push myself."  
 "from what they tell 
me, the blood is 
coming in and the 
heart, the walls are 
weak and they’re not 
squeezing it enough for 
it to go out as quick. So 
the heart goes into a 
wobble."  
Faith in HF nurses: 
"They’re clever, they 
are. They know all 
about it. They’ve got 
the little heart there 
and they explained to 
me how it all goes 
through and 
everything. They’ve 
been ever so good. 
They know what 
they’re doing. They 
know all about 
everything." 
"I think this is one of 
the reasons I’ve, over 
the years, probably just 
wore myself out...I’m 
just like an engine, just 
blowing up, you know." 
But also MI as reason: 
"They did find that my 
heart was scarred over 
from the previous heart 
attack 19 years ago". 
But overall is unclear 
on exact cause: "I don’t 
know why I had that 
first heart attack, 
because I was fit when I 
had that. But I think, 
just like an idiot, I blew 
it up and went too fast. 
That’s my theory. They 
never found out. I’ve 
got no heart disease of 
any sort, you see." 
Ejection fraction 
causing confusion and 
worry: "25%. She 
worried me for a 
minute. We both 
looked at each other, 
because she said, “Your 
heart is only working at 
25%. That’s why you’ve 
got classed as serious 
heart failure.” God, I 
thought, that’s not very 
good, is it? But she 
said, “It’s 25% of…” 
Basically she said, “It’s 
50, because the rest of 
it doesn’t really come 
into it.” So that would 
be what she said, 
wouldn’t it? It’s not 
really just 25% 
basically, it’s 25% of a 
certain amount, like. 
It’s bad, like, but not so 
bad as what it sounds." 
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9.7 Example of Analytical Memo 
MEMO: ‘Explanation of diagnosis and cause’ category 
Definition 
This category examines the explanation of HF diagnosis from patients own perspective and 
what they recall being told by GP and specialists. Also explores causes of HF. 
Codes 
Pt’s own explanation of HF; GP explanation; specialist explanation; HF nurse explanation; 
causation; HF terminology. 
Summary of data 
Pt own explanation 
Pt explanations were varied in complexity and depth. Some simply described having a ‘weak 
heart’ or ‘not getting enough oxygen in my blood to have the energy to push myself’ while 
others had a detailed description in their mind. 
Pt education and background influenced their understanding and sense-making of the 
diagnosis. Several pts were engineers by background and thought of it in mechanical terms. 
P4: "…it’s a pump system isn’t it that’s all it is, it’s a pump system. You’ve got the [er] 
power of the pump, you’ve got the pipework going round, and the various sizes of the 
pipework. And if you [er] increase the size of the pipework, the pump will bang it round 
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very easily but if the pipework gets [er] constricted in any way then the pressure will go up. 
There an easy hydraulic relationship with that…” 
Some pts actively sought extra knowledge about the diagnosis by looking online or in 
textbooks whilst others preferred to avoid knowing too much. 
P8: "I didn’t bother to go too deeply into it, you know knowledge can kill you, the wrong 
kind of knowledge, or half knowledge" 
One pt still working and finds needs an explanation to tell work colleagues to account for 
why she gets so tired. 
P13: I just tell them it’s a heredity thing, I’ve got a bit of heart failure and I get more tired 
than what you do. As I said it’s probably being twice as tired and working twice as hard as 
what they do". 
Fear associated with the term heart failure whilst for others an understanding of the 
problem in the heart led to a greater awareness of symptoms. 
P2: "Well I mean heart failure means, when they heart failure it means your heart’s going 
to, it’s wearing out or whatever, it’s going to stop. It could stop. It’s failing. And I know 
you’ve only got one so I mean let’s face it that’s not a good thing." 
P15: "I’d been told that the valves were not operating properly and they told me the result 
was a reflux and I was… I would often wake up very conscious of this going on in my chest. 
Knowing what it was I could imagine blood not just going through and then shutting off 
but coming back again and sort of regurgitating inside the heart." 
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Medical professional explanation 
Secondary care specialists, usually cardiologists, were responsible for giving the diagnosis to 
most pts. GPs were involved in initial investigation of the problem and referral for a 
definitive diagnosis but did not explain in detail what HF was etc as diagnosis not confirmed. 
Breaking bad news was not handled well in some cases. Lack of ascertainment of what pt 
knew already, signposting or empathic delivery. Several examples of pts left shocked by 
mode of delivery as well as diagnosis itself. Need for more time and space to explore and 
understand problem. 
P2: I think appointments telling you more about your particular problem. I realise their 
hurry and it seems like they want to get you out because the next person’s waiting to come 
in… 
P6: "Just how impersonal the personnel were when I went in for my heart examination. 
That could be improved immensely. It wouldn’t have hurt them to have become a little 
human and thought a little bit about the... just the diagnosis and “There you are. [bump]”.  
There’s a better way of dealing with somebody than that. Not difficult to do." 
For others explanation was proportionate and appropriate, delivering the news of HF 
gradually and initially avoiding use of the term. 
P13: "It was very good, I mean he says, it’s just a degree of heart failure. They actually 
didn’t use those words for a long time to me, he just said… he told me it was a left valve 
that wasn’t pumping properly. It should pump at so much percentage and it was pumping 
at a lesser percentage and that’s why you’re feeling tired because it’s having to work 
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harder. You’re working twice as hard as you should be, he says, that’s why you feel tired. 
He explained to me quite well..." 
P15: "No it was all explained to me very well and I had visions of valves going like this so I 
got a clear picture of what was going on inside my heart". 
Explanations clear for some ‘heart not pumping blood around the body’ or similar but for 
others medical jargon led to lack of understanding although some pts prefer to take stance 
of not wanting to know too much. 
P9: "They tried, but they used so much jargon, I didn’t understand. I didn’t want to know 
too much, anyway. But I saw what was written down and was able to translate that…They 
say my left ventricle is not working fully. They don’t say why...The last thing I do is worry. 
There’s a hospital full of doctors. Let them do it." 
Causation 
Pts had developed their own, sometimes detailed, reasons why they had developed HF, for 
others they recalled being told by the specialists e.g. heart damaged due to heart attack.  
P10: "But a part of my heart is damaged, he says, which is caused by a heart attack I 
suppose". 
One pt blamed himself for ‘over doing it’. 
P7: "I think this is one of the reasons I’ve, over the years, probably just wore myself 





As above. Many different ways to describe HF used by pts and specialists. The term itself was 
often associated with fear and a concern that heart may stop or that outlook was poor. Pts 
developed strategies to cope with this as time went on. 
P2: "It was worrying I mean you know when they tell you that your hearts not working 
properly and they call it ‘heart failure’, whatever’s wrong with your heart they call it heart 
failure don’t they which I think is horrible because failure means [laughs] it could stop you 
know. That’s worrying but [erm] the longer you live with it, the more you get used to it". 
Some confusion over ejection fraction terminology and what that meant – if ejection fraction 
20% pts assumed that meant only 20% of heart was working – not aware that normal 
ejection fraction is 50% or above.  
Deviant cases 
One pt (P5) had been to heart failure clinic and had volunteered to be part of the study 
which gave full details of what hoping to explore around HF but did not realise/acknowledge 
he had HF. 
Points for further consideration 
Delivery of diagnosis important. Breaking bad news needs to be improved in some cases. 
Provision of more information. Opportunity to ask questions. ?change in terminology of HF 
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